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Abstract 
Given the complexity of medicines use in elderly patients, structures and 
processes of medicines management are key to deriving best outcomes. This 
research was conducted in hospitals in the United Arab Emirates (UAE) and 
focused on the patient journey from admission to discharge.  
 
The overall aim was to explore the structures and processes of medicines 
management in elderly hospitalised patients in the UAE, conducted in three 
phases. 
 
Phase 1 
Following a review of systematic reviews of aspects of medicines management 
(e.g. reconciliation), this phase focused on a specific, emerging tool (the Drug 
Burden Index (DBI)) relating to anticholinergic/sedative agents, which are 
problematic in the elderly. The aim was to critically appraise, synthesize and 
present evidence of DBI use. The review protocol was registered with the 
Joanna Briggs Institute and conducted according to best accepted practice. The 
key finding was the lack of evidence of DBI use prospectively to identify 
potentially inappropriate prescribing.  
 
Phase 2 
Phase 2 employed a qualitative phenomenological design to explore health 
professionals’ views and experiences of medicines management. Semi-
structured interviews were conducted with 27 professionals and analysed using 
Normalization Process Theory (NPT) and the Theoretical Domains Framework 
(TDF). Findings revealed little evidence of coherence, cognitive participation, 
collective action and reflexive monitoring (NPT). TDF domains dominant were: 
professional role, identity; beliefs about capabilities; beliefs about 
consequences; environmental context, resources; and knowledge.  
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Phase 3 
The Delphi technique in phase 3 aimed to determine consensus around 
medicines management using an expert panel of policy makers, educators and 
lead health professionals. Phase 1 and 2 findings were used in construction of 
validated statements. A high level of consensus (≥70% strongly agree/agree) 
was obtained for statements other than those for targeting medicines 
management (rather than all elderly admissions) and tasks linked to professions 
(rather than trained staff).  
 
Overall, this research has generated original findings focused on the entire 
inpatient hospital journey, particularly the need to more clearly define, refine 
and agree on healthcare structures and processes across the entire patient 
journey from admission to discharge. The use of the NPT and TDF has 
highlighted those individual practitioners and organisational issues which require 
consideration. 
 
Keywords: Medicines management, structures, processes, Drug Burden Index, 
qualitative interview, TDF, NPT, Delphi study 
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CHAPTER 1: Medicines Management in Elderly Patients  
 
This chapter commences with an overview of medicines management in terms 
of definitions and scope, while highlighting the lack of a global definition. The 
medicines management model to be studied in this doctoral research is 
presented. Attention is then paid to aspects of medicines management in the 
elderly, such as medicines review and medicines adherence, describing relevant, 
published systematic reviews. There is specific focus on tools and approaches to 
identify and eliminate potentially inappropriate prescribing in elderly patients. 
The doctoral research is then considered within the context of the United Arab 
Emirates (UAE). The chapter ends with defining the overall aim and the aims of 
the phases of the doctoral research.  
 
1.1 Medicines management  
Given the multiplicity of issues relating to medicines in the elderly (which are 
described throughout this thesis), the structures and processes of medicines 
management should be defined and described clearly to optimise patient 
outcomes.  
 
However, a search of several literature databases (Medline, Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), International Pharmaceutical 
Abstracts (IPA) and Google Scholar) and grey literature sources (Google) 
highlighted the lack of a globally accepted definition of the term, ‘medicines 
management’. There are, however, several more commonly cited definitions.  
 
The United Kingdom (UK) Audit Commission in 2001 stated that, ‘medicines 
management in hospitals encompasses the entire way that medicines are 
selected, procured, delivered, prescribed, administered and reviewed to 
optimise the contribution that medicines make to producing informed and 
desired outcomes of patient care’. (Audit Commission 2001)  
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In 2002, the National Prescribing Centre (NPC) in England (now part of the 
National Institute for Health and Care Excellence, NICE) added that medicines 
management ‘considers the systems of processes and behaviours determining 
how medicines are used by patients and the [National Health Service] NHS. 
Medicines management has primarily been led by pharmacy teams and is the 
term that has been used historically in the NHS for managing people’s 
medicines'. (National Prescribing Centre 2002) This was a comprehensive 
document which included details of specific objectives, and health professionals’ 
key roles and actions. The following objectives were suggested for medicines 
management: 
 
 to maintain good health,  
 to improve the health status of people, 
 to enable people to care for themselves,  
 to improve choice and enable access to better health services and 
 to reduce waste and save money. 
 
The concept of medicines management should allow healthcare professionals 
and patients to ‘maximise benefits from the use of medicines and reduce 
associated risks’. (National Prescribing Centre  2002) A wide range of practices 
such as prescribing, dispensing, administering and monitoring as well as 
promoting patient adherence to medicines are encompassed within the scope of 
medicines management. Key roles of healthcare professionals (particularly 
pharmacists and others) comprise: developing medicines related care plans to 
promote appropriate choice of drug therapy; monitoring outcomes of 
effectiveness and safety; and educating patients, families and carers to promote 
medicines adherence. (National Prescribing Centre  2002) 
 
In 2004, the Medicines and Healthcare Products Regulatory Agency (MHRA) in 
the UK stated that ‘medicine management is the clinical, cost-effective and safe 
use of medicines to ensure patients get the maximum benefit from the 
medicines they need, while at the same time minimising potential harm’. 
(Medicines Healthcare products and Regulatory Agency  2004) 
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Very recently, NICE suggested the term ‘medicines optimisation’ which ‘requires 
evidence-informed decision making about medicines, involving effective patient 
engagement and professional collaboration to provide individualised, patient-
centred approach to medicines use, within available resources’. (NICE Medicines 
and Prescribing Centre  2015) 
 
Whatever the definition, medicines management in the elderly is complex, 
requiring clarity around healthcare structures and processes in order to achieve 
the best possible outcomes.  
 
The medicines management model being studied in this thesis focuses on 
healthcare structures and processes throughout the patient journey while in the 
hospital, as depicted in Figure 1.1. 
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Figure 1.1: The medicines management model for patients while in hospital 
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1.2 Medicines in elderly 
This research focused on medicines management in the elderly. While the 
United Nations (UN) refers to those aged 60 years and over as ‘older people’, 
most developed countries have accepted the chronological age of 65 years as 
the definition of an ‘older person’. (WHO 2015) The age of 65 years is used as a 
reference point for older persons as this is often the age at which persons 
become eligible for old-age social security benefits; Medicare in the United 
Statues of America (USA) also adopts this age as the cut-off for older people. 
The UN report on World Population Ageing states that the global share of older 
people (aged 60 years and over) increased from 9.2% in 1990 to 11.7% in 
2013 and will continue to grow as a proportion of the world population, reaching 
21.1% by 2050. (WHO 2015) This trend is said to have a serious impact on 
healthcare considerations for the elderly. 
 
There are many issues to consider in relation to medicines and their 
management in this target group. These are described in relation to the 
components of the medicines management model described in Figure 1.1. 
 
1.2.1 Physiological changes and chronic conditions 
As people age, they become more susceptible to disease and disability. The 
process of aging is a continuum of changes in parameters of biology, 
functionality, psychology and social status that vary from individual to 
individual. This variation depends on many factors such as genetics, age-related 
vulnerability, and differences in organ functioning. Chronic conditions, such as 
type 2 diabetes mellitus, rheumatoid arthritis, hypertension, and chronic 
obstructive pulmonary disease compromise the quality of life of older people. 
According to the USA National Council of Aging, almost all (91%) older people 
have at least one chronic condition, and 73% have at least two. (Lee, Cigolle 
and Blaum 2009) 
 
Multimorbidity is defined by the World Health Organisation as ‘the co-occurrence 
of two or more chronic medical conditions in one person’. (World Health 
Organization  2014) Epidemiological data indicate that multimorbidity increases 
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markedly with age, being prevalent in almost two thirds of individuals aged 80 
years and over.  (Barnett et al. 2012, Ornstein et al. 2013) A systematic review 
reported by Violan et al. aimed to review studies of the patterns, prevalence 
and determinants of multimorbidity in primary care. The search was conducted 
in databases (CINAHL, PsychINFO, Medline and Embase) for the period of 1961 
to 2013. The review identified 5665 titles, which were reduced to 39 papers by 
screening of titles, abstracts, papers and critical appraisal. Synthesis of the 
findings highlighted that multimorbidity is associated consistently with age 
(odds ratio 1.26-227.46), lower socioeconomic status (odds ratio 1.20-1.91) 
and presence of mental health problems (odds ratio 2.90-3.00). The authors 
concluded that, almost regardless of study approaches and methods employed, 
multimorbidity is the norm in those aged 65 and older. (Violan et al. 2014) 
 
A further consideration in terms of the elderly and chronic conditions is that 
certain conditions or syndromes, termed ’geriatric syndromes’ are very common 
among older adults. Delirium (a form of temporary confusion) and dementia (an 
illness, such as Alzheimer's disease, characterized by on-going confusion and 
memory loss) are key examples of such syndromes. Others which are prevalent 
include urinary incontinence (or other bladder problems), dizziness, a tendency 
to falls, and deterioration in vision and hearing. (Blanco-Reina et al. 2014) 
 
1.2.2 Pharmacokinetics, pharmacodynamics  
Two basic concepts that are important considerations to pharmacotherapy in the 
elderly are pharmacokinetics and pharmacodynamics. Pharmacokinetics 
describes how medicines are absorbed, distributed, metabolized and eliminated 
from the body (i.e. the effect of physiological processes on drugs). 
Pharmacodynamics is the study of the biochemical and physiological effects of 
drugs (i.e. the effect of drugs on the body) which are effected through specific 
mechanisms of action, including therapeutic, intended effects and adverse, 
unwanted effects. (Hammerlein, Derendorf and Lowenthal 1998) 
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Age-related physiological changes influence drug absorption. These changes 
include increased gastric pH, decreased gastric emptying, decreased intestinal 
motility, and reduced splanchnic blood flow. Of the four pharmacokinetic 
considerations (drug distribution etc.), absorption is the least affected by age. 
(Kinirons and Crome 1997) 
 
Drug distribution depends on a variety of factors including body composition, 
plasma protein binding and organ blood flow. The first factor, body composition, 
changes significantly with age. (Kinirons and Crome 1997) The elderly have 
lower total body water and lean muscle mass, with an increased percentage of 
fat tissue. (Woodhouse 1994) The significance of these changes on distribution 
depends on the physiochemical properties of the drug in question. For example, 
a fat-soluble drug taken by an elderly patient will be distributed more to the 
adipose tissue, reducing the amount of the drug available to the systemic 
circulation.  (Woodhouse 1994) In contrast, a water-soluble drug taken by the 
same elderly patient will be more available in circulation due to decreased water 
composition. (Woodhouse 1994) Body composition is not the only factor that 
influences distribution of a drug in the body. Many drugs bind to plasma 
proteins circulating in the bloodstream. Acidic drugs bind primarily to albumin, 
which may be decreased in the elderly, especially if malnutrition or serious 
illness is present. Factors that influence binding and therefore drug distribution 
include the protein concentration, the presence of comorbid diseases and 
concurrent drugs, and the nutritional status of the patient. (Kinirons and Crome 
1997) These factors are all relevant in the elderly. 
 
Drug metabolism impacts how the drug in turn affects the body. Drug clearance 
through the liver is dependent on biotransformation through enzyme systems 
and hepatic blood flow. (Ritschel and Kearns 2004) Some of these enzyme 
systems are reduced considerably in the elderly, while others are not altered to 
any significant extent. The liver itself decreases in total mass with age, but its 
function is not impaired. Of much more importance is the decrease in hepatic 
blood flow with advancing age. (Ritschel and Kearns 2004) It is estimated that 
blood flow to the liver is reduced by as much as 45% in those over 65 years. 
(Woodhouse 1994) This decrease in blood flow may increase bioavailability of 
drugs that have a high extraction rate by the liver. 
26 
 
 
Probably the most significant change in the elderly relates to the renal 
elimination of drugs. Renal anatomical and functional changes are associated 
with aging. The kidney decreases in size, with renal tubular and vascular 
changes. (Ritschel and Kearns 2004) The number of glomeruli also decrease. 
Functional changes include a decrease in the glomerular filtration rate (GFR) 
and mean creatinine clearance.(Ritschel and Kearns 2004) The decrease in GFR, 
renal plasma flow and tubular secretion contribute to a significant decrease in 
elimination of renally excreted drugs, in some cases, by a factor of 50% or 
greater. (Ritschel and Kearns 2004) The important consideration of the changes 
in renal function in relation to selection of medicines, dosing, route, and 
monitoring required is highlighted by the number of texts which intend to 
support practitioners. For example the British National Formulary (BNF) guides 
prescribers to: only use a medicine when there is a definite indication; select a 
medicine with minimal or no nephrotoxicity; monitor the patient carefully for 
evidence of toxicity of drugs and clinical effectiveness; and use a dosage 
regimen recommended for renal impairment. (British National Formulary 2013) 
 
Pharmacodynamic effects involve the positive or negative effects of drugs on 
the body. Pharmacodynamic effects are influenced by changes in receptor 
binding, the number of receptors or events that occur after binding. The 
consequences of these changes include increased sensitivity to a drug or a 
decreased response from other drugs. Receptor binding is a major factor in the 
occurrence of adverse reactions.(Swift 1990) 
 
Pharmacokinetic and pharmacodynamic considerations are therefore extremely 
important as part of medicines management in the elderly. 
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1.2.3 Polypharmacy  
Given the worldwide expansion in pharmacotherapy and an ever expanding 
emphasis on evidence based therapeutics, elderly patients are likely to be 
prescribed numerous medicines. Polypharmacy is considered to be ‘one of the 
greatest prescribing challenges’, increasing the likelihood of adverse drug 
reactions (ADRs), drug interactions and contributing to patient non-adherence 
to their medicines regimen. (Payne and Avery 2011) While traditionally 
polypharmacy has been classified in terms of the number of medicines 
(Woodward  2003, McLean and Le Couteur 2004) (usually defined as the use of 
five or more medicines), Patterson et al. suggested, as part of a Cochrane 
review in 2012 (later updated in 2014), that there should be a change in 
emphasis from inappropriate polypharmacy (prescribing of many medicines 
which are either inappropriate or no longer indicated) to appropriate or optimal 
polypharmacy (appropriate prescribing of many medicines). (Patterson et al. 
2014) 
 
There is a wealth of recent evidence on prevalence of polypharmacy in the 
elderly. UK data published in 2014 highlighted that 20.8% of patients with two 
clinical conditions were prescribed four to nine medicines, and 1.1% of patients 
ten or more medicines; in patients with six or more comorbidities, values were 
47.7% and 41.7% respectively. (Payne et al. 2014) Similar statistics have been 
published for elderly residents of nursing homes in the USA.(Dwyer et al. 2010) 
 
It is therefore evident that inappropriate polypharmacy is a major concern in 
the elderly and hence should be a focus of medicines management. Efforts are 
required to review medicines regimens to promote appropriate polypharmacy 
and indeed prevent potentially inappropriate prescribing at the point of 
medicines initiation. A systematic review reported by Patterson et al. aimed to 
determine which interventions, alone or in combination, were effective in 
improving the appropriate use of polypharmacy and reducing medication-related 
problems in older people. The search was conducted in databases (Database of 
Abstracts of Reviews of Effectiveness (DARE), Medline and Embase) for the 
period of 2009 to 2013. The review identified 2657 titles, which were reduced to 
ten papers by screening of titles, abstracts, papers and critical appraisal. 
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Despite its limitations, the review suggested that pharmaceutical care appears 
to improve prescribing for older patients receiving polypharmacy, especially 
when a multi-disciplinary element is included in the provision of care. The 
authors concluded that there is uncertainty about the elements of intervention 
that impact positively appropriate polypharmacy and thus further research is 
recommended. (Patterson et al. 2014) 
 
Promoting appropriate polypharmacy at the initiation of medicines or during 
review of prescribed medicines is therefore a key aim of medicines 
management. 
 
1.2.4 Adverse drug reactions (ADR) 
The World Health Organisation (WHO) in 1972 defined an ADR as ‘a response to 
a drug which is noxious and unintended, and which occurs at doses normally 
used in man for the prophylaxis, diagnosis, or therapy of disease, or for the 
modifications of physiological function'. (World Health Organization  1972)  
 
According to the Medicines and Healthcare Products Regulatory Agency (MHRA), 
an ADR is defined as ‘an unwanted or harmful reaction which occurs after 
administration of a drug or drugs and is suspected or known to be due to the 
drug(s)'. (Medicines Healthcare products and Regulatory Agency  2004) 
 
As described earlier, older people are likely to have multimorbidities and hence 
are likely to be prescribed a number of different medicines.  
 
The concurrent use of multiple medicines increases the potential for ADRs and 
drug-drug interactions. Many studies from around the world demonstrate the 
correlation between increasing age and the incidence of ADRs.  (Beijer and De 
Blaey 2002, Routledge, O'Mahony and Woodhouse 2004, Kongkaew, Noyce and 
Ashcroft 2008, Brahma et al. 2013) More than 80% of ADRs resulting in 
admission to hospital or occurring during stay in hospital are classified as being 
type A (dose-related) in nature, and thus are predictable from the known 
pharmacology of the drug. Such ADRs are therefore potentially avoidable, hence 
of relevance to medicines management.  (Routledge, O'Mahony and Woodhouse 
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2004) In a systematic review, Wiffen et al. aimed to estimate the burden of 
ADRs in the UK. The search was conducted in databases (Medline, Embase and 
International Pharmaceutical Abstract). The review identified 138 titles, which 
were reduced to 69 papers by screening of titles, abstracts and papers. Findings 
of the review were that the incidence (cause of death) of ADRs in studies 
conducted in the UK was double that reported in the USA.  (Wiffen et al. 2002)  
 
The association of advanced age and vulnerability is well known. In 1991, 
Gurwitz and Avorn concluded that ‘patient-specific physiological and functional 
characteristics are probably more important than any chronological measure in 
predicting both adverse and beneficial outcomes associated with specific drug 
therapies’. (Gurwitz and Avorn 1991) 
 
Prescribing medicines with less likelihood of ADRs and monitoring regularly 
prescribed medicine in the elderly for the occurrence of ADRs (as well as 
effectiveness) is therefore a key focus of medicines management. 
 
1.2.5 Medicines review  
The need for cautious prescribing of medicines in the elderly is emphasised in 
standard texts. For example the BNF has a specific section on prescribing for the 
elderly. Key issues highlighted are:  
 
 appropriate prescribing - medicines should be reviewed regularly and 
medicines which are not of benefit should be stopped, 
 form of medicines - patients should always be encouraged to take 
medicines with enough fluid, 
 manifestations of ageing - for example, age related muscle weakness and 
difficulty in maintaining balance should not be confused with neurological 
disease and 
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 sensitivity - the nervous system of elderly patients is more sensitive to 
commonly used medicines, such as opioid analgesics, benzodiazepines, 
antipsychotics, and antiparkinsonian medicines, all of which must be used 
with caution. (Joint Formulary Committee and Royal Pharmaceutical 
Society of Great Britain  2012) 
 
There is also a need to review regularly the medicines prescribed in the elderly 
(and indeed all patients) to ensure that they continue to be indicated, are 
effective and not resulting in ADRs. The NPC defines a ‘medicines review’ as a 
‘structured and critical examination of individual patients’ medicines by a 
qualified healthcare provider with the objective of reaching an agreement with 
the patient about the continued appropriateness and effectiveness of the 
treatment, optimising the impact of medicines, minimising the number of 
medicines related problems and reducing waste’. (Room for Review 2002) 
 
NPC describes three types of medicines review namely:  
 
 prescription review – addresses issues related to the prescription and the 
medicines and may be conducted in the absence of the patient, 
 concordance and compliance review – addresses issues related to the 
patients’ medicines taking behaviours and 
 clinical medicines review – addresses issues relating to the use of 
medicines being taken in accordance with the patients’ clinical condition. 
(Clyne, Blenkinsopp and Seal 2008) 
 
A guide for the UK NHS published in 2008 aimed to advise those providing and 
commissioning medicines reviews in a wide range of care settings.  (Clyne, 
Blenkinsopp and Seal 2008) The medicines pathway and medicines review 
services are illustrated in Figure 1.2.          
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Figure 1.2: The medicines pathway and medicines review services 
 
The authors proposed that the guide could support medicines review for safe, 
effective patient centred care.  (Clyne, Blenkinsopp and Seal 2008, Violan et al. 
2014) Regular, effective and efficient medicines reviews are therefore important 
aspects of medicines management in elderly patients. 
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1.2.6 Medicines reconciliation  
A key process of medicines management for all patients (and not just the 
elderly) in the hospital setting is medicines reconciliation.  
 
Medicines reconciliation has been defined by the Institute for Healthcare 
Improvement (an independent not-for-profit organisation based in UK) as ‘the 
process of identifying the most accurate list of a patient’s current medicines – 
including the name, dosage, frequency and route – and comparing them to the 
current list in use, recognizing any discrepancies, and documenting any 
changes, thus resulting in a complete list of medications, accurately 
communicated’. 
 
Another definition by the Joint Commission (an independent, not-for-profit group 
in the US that gives voluntary accreditation to programs such as patient care, 
medicine safety for hospitals and other healthcare organisations) of medicines 
reconciliation is ‘the process of comparing a patient's medicines orders to all of 
the medicines that the patient has been taking.  This reconciliation is done to 
avoid medicines errors such as omissions, duplications, dosing errors, or drug 
interactions. It should be done at every transition of care in which new 
medicines are ordered or existing orders are rewritten. Transitions in care 
include changes in setting, service, practitioner, or level of care’. (Joint 
Commission  2010) 
 
According to the Joint Commission, medicines reconciliation comprises five 
steps:  
 
 developing a list of current medicines,  
 developing a list of medicines to be prescribed,  
 comparing the medicines on the two lists,  
 making clinical decisions based on the comparison and  
 communicating the new list to appropriate caregivers and to the patient. 
(Joint Commission  2010) 
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Across many countries, medicines discrepancies demanding reconciliation have 
been found at the points of patient admission and discharge, and in a range of 
situations, including emergency units (De Winter et al. 2010, Caglar et al. 2011, 
Mazer et al. 2011, Soler-Giner et al. 2011), mental health/psychiatry (Nelson et 
al. 2011, Paton et al. 2011), kidney dialysis (Peter  2010) and the elderly. (Gizzi 
et al. 2010, Steurbaut et al. 2010, Stitt, Elliott and Thompson 2011, Villanyi, 
Fok and Wong 2011, Pérennes et al. 2012) 
 
Medicines reconciliation has been improved by a number of approaches.  
Various electronic reconciliation tools have been shown to be effective 
(Schnipper et al. 2009, Manzorro et al. 2011) and such tools have been 
reviewed.  (Bassi, Lau and Bardal 2010) Reducing discrepancies have also been 
achieved by using an automated filtering process. (Hasan, Duncan, et al. 2008) 
 
The use of standardised documentation has also been shown to have a positive 
impact,  (Bédard et al. 2011) as has standardised list of questions.  (De Winter 
et al. 2011) Standard processes for nurses to document medicines have been 
implemented in both home (Green, Burgul and Armstrong 2010) and hospital 
(Bedouch et al. 2012) settings. 
 
A systematic review reported by Kwan et al. aimed to summarise the evidence 
of effectiveness of hospital-based medicines reconciliation interventions. The 
search was conducted in databases (Medline, EMBASE and the Cochrane 
Library) for the period of 1980 to 2012. The review identified 1845 titles which 
were reduced to 18 papers by screening of titles, abstracts, papers and critical 
appraisal. The review included 20 interventions (delivered largely by 
pharmacists, n=17; several studies had >1 intervention) at the point transitions 
in care. Review findings identified no clinical significance associated with the 
unintentional discrepancies identified. The authors concluded that medicines 
reconciliation alone probably does not reduce post discharge hospital utilization 
but it is recommended to avoid unintentional discrepancies between patients' 
medicines across transitions in care. (Kwan et al. 2013) 
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A further systematic review, published in the same year, by Mueller et al. aimed 
to summarize the available evidence on medicines reconciliation interventions in 
the hospital setting, and to identify the most effective practices. The search was 
conducted only in Medline for the period 1966 to 2012. The review identified 
1632 titles, which were reduced to 26 controlled studies by screening of titles, 
abstracts, papers and critical appraisal. Findings of the review identified 15 
studies of pharmacist-related interventions, 6 studies of IT interventions and 5 
other interventions. These studies gave a reduction in medicines discrepancies 
(17 studies), potential adverse drug events (5 studies), actual adverse drug 
events (2 studies) and post-discharge health care utilization (2 studies). The 
authors concluded that the involvement of pharmacists or pharmacy staff in all 
medicines reconciliation related processes lead to better patient outcomes. 
(Mueller et al. 2012) 
 
Medicines reconciliation is therefore an extremely important aspect of medicines 
management during transition points (admission, transfer between wards and 
discharge), particularly in the elderly.  
 
1.2.7 Adherence  
While the UK NHS spent around £10.6billion on medicines in 2006-2007, it was 
estimated that up to half of all medicines prescribed for long term conditions 
were not taken as recommended.  (Horne et al. 2005) Furthermore, the 
estimated cost of unused or unwanted medicines in the NHS is around 
£100million annually. (Department of Health  2008) 
 
While there are many definitions of the term adherence, this was redefined 
recently as ‘the process by which patients take their medicines as prescribed, 
composed of initiation, implementation and discontinuation’.  (Vrijens et al. 
2012) Adherence comprises three components of initiation, implementation and 
discontinuation as illustrated in Figure 1.3. 
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Figure 1.3: The process of adherence to medicines (light blue) and the process 
of management of adherence (dark blue), adapted from Vrijens et al. 2012) 
 
Initiation is defined as ‘the moment at which the patient takes the first dose of a 
prescribed medication; the implementation of the dosing regimen, being the 
extent to which a patient's actual dosing corresponds to the prescribed dosing 
regimen from initiation until the last dose taken; and discontinuation, being the 
end of therapy, when the next dose to be taken is omitted and no more doses 
are taken thereafter’. (Vrijens et al. 2012) 
 
Medicines non-adherence is a major concern as only approximately 50% of 
patients have been estimated to adhere to their medicines (McDonald, Garg and 
Haynes 2002), and this percentage ranges from 47% to 100% in older adults.  
(Vik, Maxwell and Hogan 2004) In a recent narrative review of 51 systematic 
reviews covering 19 different disease categories, exclusively assessing non-
adherence to chronic therapies, 771 individual factor items were identified. 
Factors with an unambiguous effect on adherence were further grouped (see 
Table 1.1) into 8 clusters of socio-economic-related factors, 6 of healthcare 
team- and system-related factors, 6 of condition-related factors, 6 of therapy-
related factors, and 14 of patient-related factors. (Kardas, Lewek and 
Matyjaszczyk 2013)  
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Table 1.1: Summaries for all factors affecting medicines adherence (adapted 
from Kardas, Lewek and Matyjaszczyk 2013) 
Clusters Domains 
Socio-economic-related factors 1. Family support  
2. Family/Caregiver factors 
3. Social support 
4. Social stigma of disease  
5. Cost of medicines and/or disease  
6. Prescription coverage  
7. Socioeconomic status  
8. Employment status  
Healthcare team- and system-
related factors 
1. Barrier to healthcare  
2. Medicines supply 
3. Prescription by specialist 
4. Information about drug administration 
5. Healthcare provider-patient 
communication  
6. Follow-up 
Condition-related factors 1. Presence of symptoms 
2. Disease severity 
3. Clinical improvement 
4. Psychiatric condition 
5. Certain diagnoses/indications 
6. Duration of the disease  
Therapy-related factors 1. Adverse effect 
2. Patient friendliness of the regimen 
3. Medicines effectiveness 
4. Duration of treatment 
5. Medicines type 
6. Well organised treatment 
Patient-related factors 1. Age 
2. Gender 
3. Marital status 
4. Education 
5. Ethnicity 
6. Housing 
7. Cognitive function 
8. Forgetfulness and reminders 
9. Knowledge 
10. Health beliefs 
11. Psychological profile 
12. Comorbidities and patient history 
13. Alcohol or substance abuse 
14. Patient-related barriers to compliance 
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This extensive retrospective literature review provides clear evidence that 
medicines non-adherence is affected by multiple determinants, many of which 
are modifiable and hence need to be considered as part of medicines 
management.  
 
A systematic review by Haynes et al. aimed to review studies which assisted 
patients to adhere to medicines, excluding addictions. The search was 
conducted in databases (The Cochrane Library, MEDLINE, EMBASE, CINAHL, 
PsycINFO and International Pharmaceutical Abstracts) for the period 1993 to 
2007. The review identified 5806 titles, which were reduced to 78 RCTs by 
screening of titles, abstracts, papers and critical appraisal. Findings from this 
review indicated that interventions (such as information, reminders, self-
monitoring, reinforcement, counseling, family therapy, psychological therapy, 
crisis intervention, manual telephone follow-up, and supportive care) were 
effective on both adherence and clinical outcomes for short-term treatments, 
while those interventions showed less improvement on both adherence and 
clinical outcome for long-term treatments. The authors concluded that, 
improving medicines taking might have a far greater impact on clinical 
outcomes than an improvement in treatments. (Haynes et al. 2008) 
 
A systematic review by George et al. identify interventions which improved 
adherence of community-living elderly patients prescribed at least three or 
more long-term medicines. The search was conducted in databases (Medline, 
Embase, CINAHL, PsycINFO and IPA. The review identified 1427 titles, which 
were reduced to eight controlled studies by screening of titles, abstracts, papers 
and critical appraisal. Findings from this review revealed a slight change in 
adherence among the intervention groups. The interventions comprised: regular 
scheduled patient follow-up along with a multi-compartment compliance aid; 
group education combined with individualised medicines cards; and medicines 
review by pharmacists with a focus on regimen simplification. The authors 
concluded that combinations of educational and behavioural strategies should 
be used to improve medicines adherence in the elderly. (George, Elliott and 
Stewart 2008) 
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Aiming to maximise medicines adherence in elderly patients is an important 
aspect of medicines management. 
 
1.3 Criteria/tools to encourage optimising prescribing 
Due to the factors described, the elderly are considered a high-risk population in 
terms of medicines selection and use. The Audit Commission in 2001 highlighted 
that the concepts of medicines management were particularly relevant in terms 
of paying prudent attention to processes of medicines choice, dosing, and 
monitoring for effectiveness and toxicity. (Audit Commission  2001) 
 
A systematic review by Kaufmann et al. aimed to create a comprehensive and 
structured overview of existing tools to assess potentially inappropriate 
prescribing. The search was conducted in PubMed for the period 1991 to 2013. 
The review identified 716 titles, which were reduced to 46 papers by screening 
of titles, abstracts and full papers. Findings from this review identified 46 
different tools to assess potentially inappropriate prescribing, showing a large 
variety in methodological aspects and any validation in a clinical setting. While 
many might serve as useful aids to improve prescribing, each tool has its 
limitations, strengths and weaknesses. Most were specific to the region in which 
they were developed. These tools were categorised as explicit, implicit or mixed 
tools. Implicit and explicit criteria promoting appropriate medicines selection are 
considered both essential and supportive tools for practitioners caring for the 
elderly. While implicit criteria focus on clinician interpretation and are time 
consuming, explicit criteria are designed to be easily and effectively interpreted.  
(Levy, Marcus and Christen 2010) They provide details of categories of drugs 
and associated prescribing indicators to enhance reliable treatment evaluation. 
Kaufmann et al. concluded that this review identified 46 assessment tools which 
could serve as a summary to assist readers in choosing a tool, either for 
research purposes or for daily practice.(Kaufmann et al. 2014) 
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Two criteria most commonly described are the ‘Beers Criteria’ and the ‘STOPP 
START criteria’. 
 
1.3.1 Beers Criteria  
Beers Criteria were originally conceived in 1991 by Mark Beers (a geriatrician) 
in the USA. The criteria were developed by an expert panel of geriatric health 
care providers who identified medicines that should be avoided in the elderly. 
The main goal of the criteria was to improve care of older adults by reducing 
exposure to potentially inappropriate medicines (PIMs). The intended uses were 
to identify medicines that posed potential risk outweighing potential benefits for 
people ≥65 years, inform clinical decision-making concerning the prescribing of 
medicines for elderly and improve medicines safety and quality of care. (Beers 
et al. 1991) 
 
The Beers Criteria were published in 1991 and consisted of two drug lists to be 
avoided in the elderly. The first included medicines considered inappropriate 
regardless of clinical condition whereas the second comprised inappropriate 
medicines in relation to specific medical conditions.  (Beers et al. 1991) Beers 
criteria were updated in 1997 to incorporate the ambulatory elderly. The list 
classifies inappropriate medicines, inappropriate combinations of medicines, 
inappropriate (exceeded) duration of treatment, and excessive doses all with 
questionable efficacy or undesirable risk/benefit.  (Beers  1997) Beers Criteria 
were updated again in 2003.  (Fick et al. 2003) In 2011 the American Geriatrics 
Society (AGS) funded and undertook an update of the criteria by putting 
together a team of experts who used an advanced, evidence-based 
methodology to come up with the American Geriatrics Society (AGS) 2012 Beers 
criteria. (American Geriatrics Society  2012) The updated criteria aimed to 
incorporate new evidence related to PIMs and new medicines and conditions 
that were not covered in the 2003 update. The strength and quality of each PIM 
statement was rated on the basis of the level of evidence and strength of 
recommendation grading. 
 
The AGS 2012 Beers criteria are intended for use in ambulatory or institutional 
settings of care of populations aged 65 and above in the United States. The 
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primary target audience is the practicing clinician, but researchers, pharmacy 
benefit managers, regulators, and policy-makers also use the criteria widely. 
(American Geriatrics Society  2012) The intentions of the criteria include: 
 
 improving the selection of medicines by clinicians and patients,  
 evaluating patterns of medicine use within populations, 
 educating clinicians and patients on proper medicine usage and 
 evaluating health-outcome, quality of care, cost, and utilization data. 
 
A Delphi technique was employed with a 13 member interdisciplinary panel of 
experts in geriatric care and pharmacotherapy, with the aim of updating the 
2012 AGS Beers criteria. (American Geriatrics Society 2015) Two major 
components incorporated into the updated AGS 2015 Beers criteria were: 
 
 drugs for which dose adjustment was required based on kidney function 
and  
 drug-drug interactions. 
 
Although the Beers criteria have been the standard for documenting and 
identifying potentially inappropriate prescribing, several limitations have been 
highlighted: confinement to the USA as some indicators do not concur with 
guidelines in other regions/countries; and the need for regular updating. (Levy, 
Marcus and Christen 2010) 
 
1.3.2 STOPP/START 
A consensus panel of 18 experts (covering geriatric medicine and clinical 
pharmacology, clinical pharmacy, old age psychiatry and primary care) in 
Ireland and the UK defined and validated criteria the ‘‘screening tool of older 
persons’’ prescriptions (STOPP) and “screening tool to alert right treatment” 
(START). The criteria were developed in 2008 using a Delphi technique 
approach.  (Gallagher et al. 2008) The final list of STOPP medicines comprised 
65 items describing drug-drug and drug-disease interactions, therapeutic 
duplication, and increased risk of cognitive deterioration. START provided 22 
rules related to common instances of prescribing omissions in older people.  
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Version 2 of STOPP/START was launched in 2015, with a 31% increase in the 
number of criteria compared to the original version, giving a total of 114. 
(O'Mahony et al. 2015) 
 
The main goal of the STOPP/START criteria is to ‘provide explicit, evidence-
based rules of avoidance of commonly encountered instances of potentially 
inappropriate prescribing and potential prescribing omissions’. (O'Mahony et al. 
2015)  The aims are to: improve medicines appropriateness; prevent adverse 
drug events; and reduce drug costs. 
 
A systematic review by Hill-Taylor et al. aimed to inform researchers, clinicians 
and policy makers about the quality and extent of evidence relating to the 
STOPP/START criteria.  (Hill-Taylor et al. 2013) The search was conducted in 
databases (Cochrane Library, Database of Abstracts of Reviews of Effectiveness 
(DARE), PubMed, Embase, CINAHL, ISI Web of Science, IPA, Google Scholar, 
TRIP Database, ClinicalTrials.gov, metaRegister of Controlled Trials (mRCT), 
ProQuest Dissertation and Theses Database) for the period 2007 to 2012. The 
review identified 133 titles, which were reduced to 13 papers by screening of 
titles, abstracts, papers and critical appraisal. Of these 13, of which 12 were 
observational studies and one RCT. Due to the lack of homogeneity, a narrative 
analysis was carried out. Findings were that STOPP/START was more sensitive 
than Beers criteria, while less sensitive from tools developed in Australia. 
Medicines identified as potentially inappropriate were higher using 
STOPP/START compared to the 2002 version of Beers criteria. The authors 
concluded that despite the limited evidence application of STOPP/START, the 
criteria had been used for medicine review for community-dwelling, acute care 
and long-term care older patients in Europe, Asia and North America. (Hill-
Taylor et al. 2013) 
 
1.3.3 Medicines appropriateness index (MAI)  
The MAI is a further tool which promoted appropriate use of medicines. It is 
designed to allow rating of ten explicit criteria to determine whether a given 
medicine is appropriate for an individual patient. The ten criteria are: an 
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indication for the medicines effectiveness for the patient’s condition; correct 
dosage and directions; practical directions; drug-drug interactions; drug-disease 
interaction; unnecessary duplication; duration of therapy; and cost-
effectiveness. Each criterion is rated on a three-point Likert scale, depending on 
whether the drug is ‘appropriate’, ‘marginally appropriate’, or ‘inappropriate’. 
For each criterion a rating of 1 represents appropriate medicines use, a rating of 
2 represents marginally appropriate use and a rating of 3 represents 
inappropriate medicines use. (Samsa et al. 1994, Burnett et al. 2009) 
 
While the MAI was developed initially as an item-analysis tool, it was modified 
to derive a summated MAI score per medicines based on a weighting scheme. A 
weight of three is given for indication and effectiveness. A weight of two is 
assigned to dosage, correct directions, practical directions and drug-drug 
interactions. A weight of one is assigned to drug-disease interactions, expense, 
duplication and duration. This therefore results in a total combined score of 0 to 
18 (0 meaning the drug is appropriate and 18 representing maximal 
inappropriateness). (Samsa et al. 1994, Burnett et al. 2009) 
 
The MAI has several advantages for potentially inappropriate prescribing 
assessment: it focuses on the patient holistically, rather than on the medicine; 
it is comprehensive and therefore potentially sensitive to detect meaningful 
inappropriate prescribing or disease; it addresses multiple components of 
prescribing appropriateness, and can be applied to every medicines in the 
context of patient specific characteristics. (Burnett et al. 2009) 
 
However, it has been noted that, while rather comprehensive, the MAI is time-
consuming to use, and it requires a well-trained health professional. (Burnett et 
al. 2009) 
 
1.4 Anticholinergic prescribing in the elderly  
There were several reasons for the specific focus on anticholinergic agents as 
part of medicines management in the elderly. These agents are particularly 
problematic in the elderly and there is limited coverage within generic 
potentially inappropriate prescribing scales (e.g. STOPP/START, Beers criteria). 
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(Kay et al. 2005, Chew et al. 2008, Rudolph et al. 2008) A systematic review by 
Duran, Azermai and Vender (2013) identified a list of 100 drugs (47 graded as 
high anticholinergic potency and 53 as low anticholinergic potency), which may 
be problematic in the elderly, highlighting potentially a need for more specific 
tools.  (Durán, Azermai and Vander Stichele 2013)  
 
There is emerging evidence the most recent scale developed to assess 
anticholinergic (and sedative) burden, the Drug Burden Index (DBI), may have 
advantages over existing scales. (Kouladjian et al. 2014) The development and 
use of this scale is the subject of the systematic review which is presented in 
Chapter 3. 
 
1.5 Healthcare in the United Arab Emirates 
1.5.1 History and Demographics 
This research on medicines management was conducted in the United Arab 
Emirates (UAE), which comprises seven emirates: Abu Dhabi, Dubai, Ajman, 
Fujairah, Sharjah, Ras Al Khaimah, and Umm Al Quwain. It borders Oman in the 
southeast and north, and Saudi Arabia in the west and south (See Figure 1.4). 
Currently, these emirates have one of the highest human development indices 
(a composite statistic of life expectancy, education, and per capita income 
indicators) in Asia. The region has remained inhabited since at least 5500 B.C. 
The emirates saw the arrival of Islam in the seventh century A.D. During the 
sixteenth century, it fell under the influence of the European colonial powers, 
settling finally under the mastering of the British. After the end of the 
protectorate of the UK in December 1971, six Sheikhs formed the union by 
signing the Constitution of 1971, in which Ras al-Khaimah joined two months 
later. (Shihab  2001) 
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Figure 1.4: Map of the United Arab Emirates 
 
According to the WHO in 2013, the population of the UAE is around 9,346,000.  
(WORLD HEALTH Organisation 2013) A recent report of the UAE National 
Bureau of Statistics notes that the UAE nationals account for only around 20% 
of the total population. (National Bureau of Statistics2014) The remainder are 
expatriates, predominantly from south and southeast Asia (around 60% of the 
UAE population), and western Europe (around 10%) While Arabic is the official 
language, English is spoken widely, particularly within professional settings. 
(WORLD HEALTH Organisation 2013) 
 
1.5.2 Health Status in the UAE 
Life expectancy is defined by World Bank as ‘the average number of years a 
newborn is expected to live with current mortality patterns remaining the 
same’.  (The World Bank Group2013) According to figures published by the 
World Bank in 2013, the life expectancy in the UAE is 77.13 years in 2013 
compared to UK (80.96), USA (78.84) and Saudi Arabia (75.7) (See Figure 1.5). 
The UAE ranks highest among Arab countries in terms of life expectancy. (The 
World Bank Group2013) 
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Figure 1.5: Life expectancy of the UAE compared to other countries (adapted 
from World Bank, 2013) 
 
According to the UAE Ministry of Health, the percentage of Emiratis above the 
age of 60 years was 5.1% in 2000 and is expected to reach 11% in 2032 and 
19% in 2050.  (The UAE Ministry of Health. 2013) These statistics show that life 
expectancy has increased from around 74 years in 2000 reaching around 78 
years in 2013.  (The UAE Ministry of Health. 2013) This could be attributed to 
the improvements in the standards of living, health care facilities and 
management of many non-communicable diseases. 
 
According to WHO, in 2013 ischaemic heart disease was the leading cause of 
death in the UAE, responsible for the death of 1,700 people.  (WORLD HEALTH 
Organisation 2013) Table 1.2 illustrates the top ten causes of death in the UAE. 
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Table 1.2: The top ten causes of death in the UAE (adapted from WHO, 2013) 
Number of deaths (n) 2012 Change in rank 2000-2012 
Ischaemic heart disease (1700)  
Road injury (900)  
Stroke (700)  
Congenital anomalies (400)  
Preterm birth complications (400)  
Diabetes mellitus (300)  
Self-harm (300)  
Lower respiratory infections (200)  
Endocrine, blood, immune disorders (200)  
Interpersonal violence (200)  
RankIncreased  No Change  
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1.5.3 Healthcare Regulation in the UAE 
Public healthcare services are administered and regulated by different 
authorities at both the federal and local level. Figure 1.6 illustrates the principal 
regulatory authorities in the UAE. 
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Ministry of 
Health
Health 
Authority Abu 
Dhabi (HAAD)
Dubai Health 
Authority 
(DHA)
Dubai 
Healthcare 
City Authority 
(DHC)
Federal Local Local Local
-Licenses 
companies and 
individuals 
providing 
healthcare services
-Builds and 
manages health 
facilities
-Regulates the 
various areas of 
healthcare including 
medicines, 
dentistry, nursing 
and 
pharmaceuticals
-Oversees the 
Northen Emirates 
healthcare system 
(Ras Al Khaimah, 
Ajman, Umm Al 
Quwain, Sharjah 
and Fujairah)
-Aims to enhance 
quality, control, 
transparency and 
access to healthcare 
in Abu Dhabi
-Ensure the 
provision of the 
highest levels of 
medical and health 
insurance services
-Enhances 
stakeholder 
alignment among 
the regulator, 
healthcare 
providers, 
professionals, 
patients and 
insurance services
-Plans and 
promotes 
healthcare 
investment in Dubai
-Improves 
healthcare quality 
through information 
systems and 
standards
-Regulates 
healthcare services 
in Dubai
-Develops 
healthcare funding 
and insurance 
policy
-Develops medical 
education and 
research 
-Owns and 
operates healthcare 
facilities in Dubai
-Establishes and 
manages Dubai 
Healthcare City’s 
infrastructure and 
administrative 
framework
-Establishes and 
licenses hospital, 
medical institutions 
and companies
-Exercises 
monitoring and 
inspection 
prerogatives  
Emirates 
Health 
Authority 
(EHA)
Abu Dhabi 
Health 
Services 
Company 
(SEHA)
Medical 
Practice 
Committee
Centre for 
Healthcare 
Planning and 
Quality (CPQ)
Federal Local Local Local
-Encourages 
cooperation 
between the federal 
and local health 
authorities
-Facilitates 
cooperation 
between the 
authorities and the 
private sector 
-Owns and 
manages public 
health facilities 
-Impalements 
policies, projects 
and strategies 
approved by HAAD 
to develop the 
healthcare industry 
in Abu Dhabi
-Operates local 
hospital facilities, 
ambulatory and 
primary healthcare 
centres 
-Proposes and 
revises the rules, 
conditions and 
criteria for the 
practice of health-
related professions 
in Dubai
-Impelements 
standards for 
healthcare delivery 
and patient care 
with DHC
-Manages 
registration & 
commercial 
licensing of entitles 
doing business in 
the Free Zone
 
Figure 1.6: Principal Regulatory Authorities (adapted from SEHA annual report 
2012) 
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According to a recent report of the UAE Ministry of Health, public healthcare in 
the UAE is planned, delivered and regulated through three geographical zones 
(Figure 1.7), each of which operate independently.  (LATHAM & WATKINS2011) 
These are: 
  
 the southern zone comprising Abu Dhabi. The Health Authority of Abu 
Dhabi (HAAD) is the regulatory body while the Abu Dhabi Health Service 
Company (SEHA [‘health’ in Arabic]) is manages public hospitals, 
  
 the central zone of Dubai, under the auspices of the Dubai Health 
Authority (DHA) and 
  
 the north Emirates or the northern zone under the Ministry of Health 
(MoH). 
 
These three zones differ in terms of geographical and population estimates, 
governance systems and healthcare expenditure. Data from a 2014 national 
census gives Abu Dhabi the highest population at around 2.3 million. (National 
Bureau of Statistics2014) 
  
 
Figure 1.7: The UAE Healthcare Zones, 2014, National Bureau of Statistics 
(millions) 
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This research focuses on aspects of medicines management of elderly, 
hospitalised patients in the UAE. At the time of commencement of this research, 
there were no guidelines at country or emirate level to support medicines 
management and there was an absence of standard operating procedures. 
There was therefore the potential to generate original data to support the 
development of such guidelines and procedures. 
 
1.6 Medical Research Council (MRC) Framework  
The development and implementation of guidelines to support medicines 
management of elderly, hospitalised patients in the UAE should be considered a 
complex intervention. Complex interventions are described by MRC framework 
as ‘interventions that contain several interacting components’. (Craig et al. 
2008) There are many possible dimensions of complexity. For example, it could 
be the range of possible outcomes, or the variability in the target population, 
rather than the number of elements in the intervention itself.  
 
The key elements of the development and evaluation process are illustrated in 
Figure 1.8 
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Figure 1.8: Elements of the development and evaluation process (adapted from 
Craig et al. 2008) 
 
This doctoral research focuses on the initial stages of the development of a 
complex intervention. Developing interventions systematically to achieve a good 
practice requires consideration of the following: 
 
 identifying the evidence base, through published systematic reviews or 
may necessitate conducting a systematic review, 
 
 Identiying and applying appropriate cognitive, behavioural or 
organisational theory to understand better how to implement and sustain 
interventions, and understand better why interventions do (or do not) 
work and   
 
 modelling processes and outcomes. 
Feasibility/ piloting 
1. Testing procedures 
2. Estimating recruitment/ retention 
3. Determining sample size 
Evaluation 
1. Assessing effectiveness 
2. Understanding change process 
3. Assessing cost-effectiveness 
Development 
1. Identifying the evidence base 
2. Identifying/ developing theory 
3. Modelling process and outcomes 
Implementation 
1. Dissemination 
2. Surveillance and monitoring 
3. Long term follow-up 
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1.7 Overall study aim, review questions and objectives  
Research aim 
The overall aim was to explore the structures and processes of medicines 
management in elderly hospitalised patients in the United Arab Emirates.  
 
This would form part of the initial phase of developing and implementing 
guidelines to support medicines management. The research was conducted in 
three phases. 
 
Phase 1 
The review of the literature in chapter 1 identified a wealth of evidence around 
aspects of medicines management in terms of medicines reconciliation, 
medicines adherence and potentially inappropriate prescribing.  
 
While there are generic tools to support medicines selection and identify 
potentially inappropriate prescribing in the elderly, there is less evidence around 
specific tools which relate to anticholinergic agents. The first phase therefore 
was a systematic review of an emerging tool, the Drug Burden Index (DBI). 
 
The aim of this phase was to critically appraise, synthesize and present 
evidence of the use of the Drug Burden Index (DBI) to identify potentially 
inappropriate prescribing of anticholinergic and sedative agents in elderly 
patients in institutionalised care. 
This phase sought to answer the following review questions: 
 
 in which specific settings and patient groups had the DBI been applied? 
 
 what outcomes had been studied? (e.g. occurrence and incidence of 
adverse drug reactions, physical functioning, mental functioning, cause of 
admission to hospital etc.) 
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 had the use of DBI impacted prescribing of anticholinergic and sedative 
agents in elderly patients in institutionalised care? (e.g. cessation of 
therapy, prescribing altered to other agents, reduction in adverse drug 
reactions etc.) 
 
Phase 2 
The aim of this phase of the research was to explore the views, experiences and 
perceptions of health professionals in Abu Dhabi in terms of the medicine 
management healthcare structures, processes and outcomes for elderly, 
hospitalised patients.  
 
The detailed objectives were to explore health professionals’ views, experiences 
and perceptions of the following: 
 
 medicines related issues (e.g. drug selection, adverse drug reactions, 
adherence) 
 
 current healthcare structures (e.g. personnel, resources) and processes 
(e.g. training, documentation, communication) of medicines management 
 
 potential to optimise patient outcomes (e.g. clinical, economic) 
 
 changes to structures and processes (e.g. personal, professional, 
organisational etc.) required to optimise patient outcomes. 
 
Phase 3 
The aim of this phase of the research was to determine consensus in relation to 
strategic and operational approaches around medicines management for elderly, 
hospitalised patients in the UAE. 
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Objectives: 
The detailed primary objectives were: 
 
 to develop and validate a series of statements in relation to the 
structures, processes and outcomes in relation to strategic and 
operational approaches around medicines management,  
 
 to determine the levels of consensus of key stakeholders (the expert 
panel members) around these statements, 
 
 to determine any additional statements derived from key stakeholder 
feedback and 
 
 to determine any reasons for not achieving consensus. 
 
The secondary objectives were: 
 
 to determine key stakeholders’ views on the potential for the findings to 
aid the development of policies, quality indicators and professional norms  
 
 determine key stakeholders’ views of their involvement in the consensus 
approach, and its potential for future healthcare developments. 
 
By combining the findings of these three phases (Figure 1.9), original data 
would be generated which could potentially impact the development of 
guidelines of aspects of medicines management in elderly, hospitalised patients.  
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Figure 1.9: An overview of the doctoral research phases 
 
The next chapter provides a discussion and justification for the research 
paradigms, methodologies, methods and underpinning theories employed 
throughout the research.  
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CHAPTER 2: Methodology 
 
This chapter reviews and justifies the research philosophies, methodologies and 
methods which underpinned the doctoral research. Specific aspects of data 
sampling, collection and generation, analysis, and quality assurance are 
discussed with justification for the chosen approaches. The following definitions 
are applied throughout this chapter (Bowling 2009): 
 
 ‘research’ is derived from the French ‘recherche’, meaning ‘to go about 
seeking’, 
 
 ‘methodology’ is defined as ‘the systematic, theoretical analysis of the 
methods applied to a field of study’. This should not be confused with the 
research method and 
 
 ‘method’ is defined as ‘procedure’, ‘technique’ or ‘planned way of doing 
something’. 
 
2.1 Theoretical perspectives:  Philosophical paradigms 
Johnson and Onwuegbuzie (2004), Bowling (2009) and Creswell (2013) 
describe that the term ‘paradigm’ refers to ‘the progress of scientific practice 
based on people’s philosophies and assumptions about the world and the nature 
of knowledge’.  (Johnson and Onwuegbuzie 2004, Bowling  2009, 
Creswell  2013) These paradigms have three elements of 
 
 ontology is the ‘“reality” that researchers investigate’, 
 epistemology is the ‘relationship between reality and the researcher’ and 
 methodology . 
According to accepted scientific frameworks, research paradigms are classified 
into four as illustrated in Table 2.1.  
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Table 2.1: Features of Research Paradigms (adapted from Johnson and 
Onwuegbuzie 2004, Bowling  2009, Creswell  2013) 
Paradigm Features 
Positivist A positivist paradigm will maintain that reality is concrete and 
objectivity is achievable through rigorous methodologies and 
methods, assuming that reality is constant. 
Constructivist A constructivist paradigm will maintain that meaning does not 
exist in its own right but is constructed by people as they 
interact and engage in interpretation. Truth is said to be 
relative and that it is subjective to one’s perspective. 
Transformative A transformative paradigm is generally applied to those 
marginalised in society or issues of power and social justice, 
discrimination and oppression.  
Pragmatic A pragmatic paradigm is not committed explicitly to any one 
philosophy; truth is what works at that time. Many mixed 
methods researchers subscribe to this paradigm.  
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2.1.2 Overall philosophical paradigm in current research 
The research design must map to the research paradigms. 
 
Phase 1 
While the primary research considered within a systematic review could relate 
to either (or all) of the paradigms, depending on the review aim and questions, 
the DBI systematic review focused on quantitative research only and hence 
aligns to the positivist paradigm.  
 
Phase 2 
A constructivist paradigm was appropriate for phase 2, which sought to describe 
and understand health professionals’ perspectives of aspects of medicines 
management structures and processes. Meaning was therefore constructed by 
the participants in the research.  
 
Phase 3 
The consensus research also maps to the positivist paradigm in that the views 
of the experts were quantified around a set of statements which were derived 
from the systematic reviews of aspects of medicines management (positivist) 
and phase 2 findings (constructivist). 
 
2.2 Qualitative versus quantitative methodologies  
Research methodologies are described as qualitative, quantitative and mixed 
qualitative/quantitative approaches. Table 2.2 provides a comparison of key 
characteristics of qualitative and quantitative methodologies.  
 
 
 
 
 
 
 
 
   
59 
Table 2.2: Qualitative versus Quantitative methodologies (adapted from 
Johnson and Onwuegbuzie 2004, Bowling  2009, Creswell  2013) 
Qualitative Quantitative 
The aim of qualitative analysis focuses 
on providing a complete, detailed and 
rich description of the research topic 
 
The aim of quantitative research is to 
quantify, classify, count, construct and 
test statistical models in an attempt to 
explain what is observed 
The design may be planned or emerge 
as the study unfolds 
All aspects of the study are carefully 
designed before data is collected 
The researcher is the data-gathering 
instrument 
The researcher uses tools (e.g. 
questionnaires, equipment) to collect 
data 
Data are in the form of words 
(interviews), pictures (videos) or 
objects (artifacts)  
Data are in the form of numbers and 
statistics 
Qualitative data are more richer, time 
consuming, and should not be 
generalized  
Quantitative data are more efficient, 
able to test hypotheses, but may miss 
contextual data 
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The research methodologies for each of the three phases are described.  
 
Phase 1 
The DBI systematic review in this case was quantitative research, including 
studies of cohort and cross-sectional survey based methodologies.  
 
Phase 2 
Phase 2 was qualitative, employing a phenomenological design with the 
phenomenon being aspects of medicines management. 
 
Phase 3 
A survey based methodology of consensus research was employed quantifying 
key stakeholders’ levels of agreement with a series of statements derived 
through the previous research phases. 
 
These quantitative and qualitative methodologies and methods are described 
and justified in greater detail.  
 
2.3 Quantitative methodologies 
Evidence based medicine was defined by Sackett et al. ‘the conscientious, 
explicit and judicious use of current best evidence in making decisions about the 
care of individual patients’.  (Sackett et al. 1996) Within evidence based 
medicine and the various approaches to investigation in quantitative research, 
there is an accepted hierarchy of evidence that ranks the relative strengths of 
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evidence between different methodologies as illustrated in Figure 2.1. 
 
 
Figure 2.1: Hierarchy of evidence (adopted from Markman and Callanan 1984, 
Greenhalgh  1997) 
 
At the very top are systematic reviews (and meta-analyses) of well constructed 
randomised controlled trials. These allow pooling of data from studies which are 
homogenous in terms of the populations studied, settings and outcome 
measures.  (Hunter and Schmidt  2004) Methodologies such as randomised 
controlled trials offer results with greater predictive power, demonstrate causal 
relationships between variables, and control for extraneous variables, hence are 
rated as providing stronger evidence. However, this methodology is not always 
feasible, due to issues such as: availability of resources and time; opportunities 
available to conduct the research; and ethical issues. Methodologies with less 
explanatory power can still be useful in circumstances where more rigorous 
approaches are not practical. (Markman and Callanan 1984, Greenhalgh  1997) 
Table 2.3 provides a description of the different quantitative methodologies and 
outlines their key advantages and disadvantages.  
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Table 2.3: Hierarchy of evidence in quantitative methodologies (adopted from 
Markman and Callanan 1984, Greenhalgh  1997) 
 Description Advantages Disadvantages 
Systematic 
reviews 
Synthesising results 
from multiple studies. 
If homogenous, meta-
analyses may be 
conducted. 
Can detect patterns of 
effects rather than 
isolated 
unrepresentative 
results. 
Sometimes produces 
equivocal results. 
Randomised 
controlled 
trials 
Manipulating 
independent variable 
and measuring a 
dependent variable. 
Participants randomly 
assigned to 
experimental/ control 
groups and 
performances 
compared. 
Can make causal 
inferences between 
variables. Confounding 
factors can be 
controlled for, so that 
specific effects can be 
isolated.  
Controlled conditions 
are not always reflective 
of everyday reality, so it 
can be difficult to 
generalise results. Can 
be resource intensive. 
Cohort 
studies 
A longitudinal study 
with a sample sharing 
a common 
characteristic, like 
age. Subgroups can be 
compared. 
Efficient way to study 
variables over time. 
Difficult to make causal 
inferences, as there is 
no true control group or 
random assignment. 
Case Control 
Studies 
Comparison between 
groups that are 
similar, except for one 
factor, such as 
presence of a disease. 
Used often in 
epidemiology.  
Cheaper than 
randomised controlled 
studies. 
Less evidence for causal 
relationships, as 
participants are not 
randomly assigned to 
groups. 
Survey based 
approaches 
(including 
consensus 
approaches) 
Administering 
questions to a group, 
either in writing or 
verbally.  
Inexpensive, useful to 
describe characteristics 
of a group. 
Cannot make causal 
inferences, although 
correlations may be 
possible. 
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2.3.1 Systematic reviews 
A systematic review uses systematic, explicit methods to gather and synthesise 
findings from research to produce a review. (Gough, Oliver and 
Thomas  2012)There are three stages in producing a systematic review: 
retrieving and describing all relevant research; evaluating the studies; and 
synthesising data to develop general conclusions about the body of evidence. 
The robust methods used in these reviews allow for more confident use of 
evidence than would be possible when relying on individual studies. (Gough, 
Oliver and Thomas  2012) 
  
2.3.1.1 Narrative versus systematic review  
Narrative reviews are commonly reported in the literature, and while these must 
be conducted using a systematic approach, there are key differences between a 
narrative review undertaken systematically and a systematic review. Narrative 
reviews are a more traditional approach to providing an overview of research 
methodologies, methods, data and findings within a field of study. They may be 
produced by experts using their knowledge and experience of the field to select 
and assess the studies, which can introduce biases into the review. Unlike a 
narrative review, a systematic review attempts to cover all known literature 
relating to a particular research question and provides its approach and 
methods for the reader, so that the quality of the review can be assessed.  
(Mulrow  1987) Table 2.4 gives a comparison between narrative and systematic 
reviews. 
 
 
 
 
 
 
 
 
 
64 
 
Table 2.4: Comparing narrative versus systematic reviews (adapted from 
Mulrow  1987, Bowling  2009, Creswell  2013) 
 Narrative Review Systematic Review 
Review question Often absent; if given is 
broad, exploratory 
Focused 
Method Often omitted Made explicit, with: 
detailed inclusion 
criteria; (PICO); 
exclusions; search 
strategies and sources 
Quality assessment  Not a key feature Must be robust, with 
specified criteria 
Synthesis of research Usually a qualitative 
discussion 
A quantitative summary 
(e.g. meta-analysis or 
narrative synthesis) 
Inferences from research Sometimes evidence-
based 
Usually based on 
evidence 
Updated with new 
research 
Rarely Often 
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2.3.1.2 Systematic review bodies 
There are several bodies or organisations which have been established with the 
specific aim of supporting systematic reviews.  
 
A Cochrane systematic review is a particular type of systematic review that 
specialises in the fields of medicine, healthcare and related policies. Cochrane 
reviews are published in the Cochrane Database of Systematic Reviews and are 
categorised as intervention, diagnostic test accuracy, methodology, qualitative 
or prognosis reviews. Review protocols and reports must meet certain quality 
standards, which include: using studies from a variety of databases; clear, 
predefined exclusion and inclusion criteria; and robust collection and 
appropriate data synthesis. Authors of reviews are also expected to update their 
reviews when new data becomes available to ensure they reflect the current 
body of evidence. (Cochrane Library 2015) 
 
CRD reviews are produced at the University of York’s Centre for Reviews and 
Dissemination, a research department that focuses on healthcare topics. This 
organisation synthesises data from a wide range of research for applications in 
policy development and decision-making relating to medicine, health, and well-
being. (Centre for Reviews and Dissemination 2015) In other respects, CRD 
reviews are very similar to Cochrane reviews. 
 
The Joanna Briggs Institute is based at the University of Adelaide in South 
Australia and specialises in evidence-based healthcare and related research. 
This organisation produces systematic reviews of healthcare practices with an 
interest in improving healthcare internationally. (Joanna Briggs Institute 2015) 
 
As an extension of its global focus, the JBI has numerous collaborations with 
other groups and institutions around the world, including affiliates such as the 
Scottish Centre for Evidence-based Multi-professional Practice (SEMP 2015), 
based at Robert Gordon University. The SEMP’s activities include training in 
conducting systematic reviews, reviewing research and identifying best 
practices in healthcare, using evidence to identify audit criteria, and assessing 
the impact of introducing evidence-based approaches into healthcare 
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organisations. (The Scottish Centre for Evidence-based Multi-professional 
Practice 2015) Given the link to the JBI at RGU, the doctoral student (principal 
investigator) undertook training with JBI; the principal supervisor is also an 
accredited trainer with the JBI. The systematic review conducted in phase one 
of the research was therefore registered with the JBI. While the systematic 
review of the DBI focused on quantitative research only, it should be noted that 
systematic reviews are also conducted for qualitative studies (or mixed 
methodology reviews) where appropriate, with specific qualitative approaches to 
data synthesis. In this case, systematic reviews can also be considered 
qualitative and the hierarchy of evidence does not apply.  
 
2.3.2 Consensus approaches   
Consensus, or ‘collective agreement’, involves collaboration between different 
key stakeholders (experts), and while it is regarded as relatively low evidence 
compared to randomised controlled trials, its approaches are justified many 
situations. These include: where unanimity of opinion does not exist and is 
sought in view of a lack of scientific evidence; where there is contradictory 
evidence; and to develop guidelines.  (Nair, Aggarwal, et al. 2011) This 
approach was employed in phase 3 to determine consensus around issues 
relating to medicines management.  
 
It is worth noting that there is some debate to the classification of consensus 
approaches with some classifying as purely qualitative, some mixed qualitative 
and quantitative and some purely quantitative.  (Bowling  2009, Nair, Aggarwal, 
et al. 2011, Creswell  2013) In this doctoral research, the consensus statements 
(see later) were derived through previous research phases and then consensus 
determined and quantified, hence in this research the consensus approach is 
more correctly described as a positivist paradigm and quantitative methodology. 
The specific methodology in this case was a form of survey methodology.  
 
The three most common consensus development methods are the Delphi 
technique, Nominal Group Technique (NGT) and RAND/UCLA Appropriateness 
Method (RAM).  (Bowling  2009, Nair, Aggarwal, et al. 2011, Creswell  2013) 
Each method is particularly suited for obtaining specific types of data.  
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In the 1960s, the Delphi Technique was originated and developed at the 
Research and Development (RAND) Corporation to obtain the most reliable 
consensus of opinion of experts on a particular area in a systematic manner. A 
series of well-defined questionnaires were circulated to experts based on survey 
and feedback.  (Nair, Aggarwal, et al. 2011)  
 
In the 1960s, the Nominal Group Technique (NGT) was derived from social-
psychological studies of decision conferences and management sciences studies. 
It is mostly used in the government, social services and education and is based 
on a face-to-face, structured group meeting of experts led by an experienced 
moderator. (Nair, Aggarwal, et al. 2011) 
 
In the 1980s RAND (research and development) Corporation and UCLA 
(University of California-Los Angeles) developed RAND-UCLA Appropriateness 
Method (RAM). This method is based on using current scientific evidence in 
conjunction with expert opinion to evaluate the overuse/underuse of medical or 
surgical procedures. (Nair, Aggarwal, et al. 2011) 
 
Strengths and weaknesses of each of these three methods are compared in 
Table 2.5 
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Table 2.5: Strengths and weaknesses of the three consensus development 
methods (adapted from Bowling  2009, Nair, Aggarwal, et al. 2011, 
Creswell  2013) 
Method Strengths  Weaknesses 
Delphi Technique  Large number of participants 
possible 
 Each participant expresses their 
opinion freely and impersonally 
 Limits dominance by eminent, 
eloquent, or highly opinionated 
individuals in the field 
 Less likely that the moderator of 
the panel may bias the group 
 Substantial amount of time to 
express ideas, reflect on 
answers, and make changes 
 Cheap, convenient, and no 
geographical constraints 
 Easy to understand, flexible, 
and can be applied to broad 
range of topics 
 Can be used preceding NGT 
meeting for initial item 
generation 
 Generalisability of the study 
findings (external validity) 
 Dependent on questionnaire 
design 
 Vulnerability with respect to who 
is an “expert” 
 Obliviousness to reliability 
measurement and scientific 
validation of findings 
 Potential for bias exists in 
participant selection 
 Consensus panel judgments 
influenced by panel composition 
and by feedback given during the 
panel process 
 Coordinating large groups and 
several rounds can be 
complicated and costly 
 Delphi does not allow any 
personal contact between the 
experts 
Nominal Group 
Technique 
 Participants meet face-to-face 
 All participants have an 
opportunity to voice opinions 
 Personal contact between 
experts 
 Design of NGT does not allow 
any individual to dominate 
 Group voting can occur if 
desired in later rounds 
 
 Certain members of the panel 
can take over discussion and 
drive results—experienced 
moderator required 
 Limited by time—only a few 
questions can be discussed and 
agreed upon 
 Economic and time costs 
associated with face-to-face 
meeting 
 Limited to providing a solution to 
a few problems limits its 
applicability to multiple scenarios 
RAND/UCLA 
Appropriateness 
Method (RAM)  
 Synthesis of published literature 
prior to consensus techniques 
incorporated 
 Allows for both confidential 
ratings as well as group 
discussion 
 Multidisciplinary panel 
encourage consensus from a 
wider group 
 Reproducibility of RAM ranges 
from moderate to excellent as 
determined by different 
panelists for “appropriate” and 
“inappropriate” care 
 Acceptable predictive validity for 
a recommendation supported by 
RCTs 
 Misclassification is expected 
 Takes great deal of time from 
gathering of the evidence to 
multiple rounds of consensus 
 Face-to-face, which can add 
cost/time delay and lead to 
highly opinionated individuals in 
the field dominating the 
discussion 
 Requires third party (core panel) 
to construct clinical indications 
for an intervention and 
analyse/interpret the results 
from the expert panel meeting 
 9-point Likert scale can be 
cumbersome 
 Requires voting on multiple case 
scenarios  
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In this doctoral research, the Delphi technique was employed in phase 3 using 
an expert panel of key stakeholders in the UAE. This approach was selected 
over the other approaches for a number of reasons as described in Table 2.5, 
primarily logistics for the principal researcher (can use Internet as medium for 
data collection), participants (no travel, less time consuming), and cost. The 
Delphi technique is also characterised by anonymity of Delphi participants, with 
the advantage that it prevents the possibility of a group of participants 
dominating over others. 
 
2.4 Qualitative methodologies 
Table 2.6 provides a comparison of the five methodologies most commonly 
employed in the qualitative, namely narrative, phenomenology, grounded 
theory, ethnography and case study methodologies.  
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Table 2.6: Comparison of five methodologies in the qualitative (adapted from 
Johnson and Onwuegbuzie 2004, Bowling  2009, Creswell  2013) 
Dimension Narrative Phenomenology Grounded 
Theory 
Ethnography Case Study 
Focus Exploring 
the life of 
an 
individual 
 
Understanding 
the essence of 
experiences 
about a 
phenomenon 
Developing 
a theory 
grounded 
from data 
in the field 
Describing 
and 
interpreting a 
cultural or 
social group 
Developing 
an in-depth 
analysis of a 
single case 
or multiple 
cases 
Main 
methods of 
data 
Generation 
Interviews 
and 
analysis of 
documents 
 
Interviews and 
focus groups 
 
Interviews 
and focus 
groups  
Observations 
and 
interviews 
with 
additional 
artefacts 
during 
extended 
time in the 
field  
Multiple 
sources  
including  
documents, 
archival 
records, 
interviews, 
focus groups 
observations 
Approaches 
to data 
analysis 
Stories, 
historical 
content 
Statements, 
meanings, 
themes, general 
description of 
the experience 
Open 
coding, 
axial 
coding, 
selective 
coding, 
conditional 
matrix 
Description, 
analysis, 
interpretation 
Description, 
themes, 
assertions 
Narrative 
Form 
Detailed 
picture of 
an 
individual’s 
life 
 
Description of 
the “essence” of 
the experience 
 
Theory or 
theoretical 
model 
Description 
of the 
cultural 
behaviour of 
a group or an 
individual 
In-depth 
study of a 
“case” or 
“cases”  
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A qualitative, phenomenological approach was employed in phase 2 of this 
doctoral research. This was consider most appropriate to allow generation of in-
depth, rich data to describe and understand participants’ experience of the 
phenomenon under investigation (medicines management structures and 
processes). There was no attempt to generate theory, hence grounded theory 
was rejected and existing theories (see later) applied.  
 
2.4.1 Participant observation versus Focus groups versus interview  
The three most common qualitative methods are the use of participant 
observation, focus group discussions and in-depth interviews.  (Bowling  2009, 
Creswell  2013) Each method is particularly suited for obtaining specific types of 
data. Strengths and weaknesses of each of these three methods are given in 
Table 2.7.  
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Table 2.7: Strengths and weaknesses of the three qualitative methods (adapted 
from Mack et al. 2005, Bowling  2009, Creswell  2013) 
Method Strengths  Weaknesses 
Participant 
observation 
 Allows the researcher to directly 
see what participants actually do 
without having to rely on what 
they say they do  
 The researcher can determine 
what does not occur 
 The researcher may observe 
events and happenings that 
escape the awareness of the 
participants in the setting 
 May provide information on 
things participants would 
otherwise be unwilling to talk 
about  
 May move beyond the selective 
perceptions of participants   
 
 Sampling of settings and 
participants may be problematic 
and hence limited  
 Some settings and content of 
interest cannot be observed  
 Collection of unimportant material 
may be moderately high  
 Researcher effects (e.g. personal 
biases and selective perception) 
may limit the usefulness of the 
data 
 Reactive effects may occur when 
participants know they are being 
observed 
 May generate vast amount of 
data and analysis can be time 
consuming 
 May place researcher at risk 
 
Focus 
groups 
 Useful for exploring ideas and 
concepts 
 Provides an opportunity for 
participants to discuss issues 
amongst each other 
 Researcher can assess how 
participants react to each other  
 Allows researcher probing. 
 Most content can be recorded  
 
 May be difficult to find a focus 
group moderator with good 
facilitative and rapport building 
skills  
 Reactive and researcher effects 
may occur if participants feel they 
are being watched or studied 
 Recruitment may be difficult in 
certain groups, resulting in 
results if small, unrepresentative 
samples of participants    
 Data analysis can be time 
consuming 
 Data trustworthiness may be low 
 
In-depth 
interviews  
 Suited to discussion of views, 
attitudes and experiences  
 Allows probing and posing of 
follow-up questions by the 
researcher 
 Can provide in-depth information 
and rich textual data 
 Closed-ended interviews can 
provide exact information needed 
by researcher  
 Moderately high credibility for 
well constructed and tested 
interview protocols  
 Useful for exploration as well as 
confirmation  
 
 One to one, face to face 
interviews can be expensive and 
time consuming 
 Researcher effects may occur 
(e.g., untrained interviewers may 
distort data because of personal 
biases and poor interviewing 
skills)  
 Participants may not recall 
important information and may 
lack self-awareness  
 Data analysis can be time 
consuming for open-ended items  
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In-depth, face to face interviews were undertaken in phase 2. This approach 
was considered to be the most appropriate method of data generation to allow 
participants from a range of backgrounds, professions and experiences to talk 
about their personal views and perceptions without potentially being inhibited 
when openly discussing and sharing information with others. For example less 
experienced nurses or pharmacists may not have fully discussed issues of poor 
prescribing practice in the presence of high grade medical staff in a focus group 
setting, with implications for data trustworthiness.  
 
2.4.2 Qualitative method data collection: use of interview 
The most common types of interview used in qualitative research are 
structured, semi-structured and unstructured. Bowling (2009) describes these 
and highlights similarities and differences, which are summarised in Table 2.8 
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Table 2.8: Features of structured, semi-structured and unstructured interviews  
Structured Semi structured Unstructured  
Set of questions 
that are asked in a 
standard way across 
all participants.  
Specific topic areas and a 
general set of questions 
but the interview flows like 
a conversation and topics 
are covered as they come 
up.  
Topic area to be explored 
but what gets covered is 
left up to the participant. 
An opening question might 
introduce the topic. 
Fixed questions with 
fixed order.  
Open questions, order can 
vary. 
Non-directive in-depth 
interview. 
Control lies with 
researcher. 
Control lies with both 
researcher and participant.  
Control lies with 
participant. 
Data will be 
probably coded in 
advance. 
Data will be probably 
coded and analysed after 
each interview (iterative 
development).  
Data will probably be 
coded and analysed after 
interview (iterative 
development). 
Data generation 
tool: questionnaire.  
Data generation tool: 
interview schedule.  
Data generation tool: 
interview guide.  
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In phase 2, a semi-structured face-to-face approach was employed. This 
approach allowed for collaborative (researcher and participant) designing and 
contributing to the content of the interviews. Core questions were offered so as 
to stimulate response among the respondents. Holmes (2012) noted that 
standardisation of at least some of the questions would increase credibility 
during data generation. (Holmes  2012) 
 
2.4.3 Approaches to analysis of qualitative data  
Bowling (2009) highlights that qualitative research can result in large amounts 
of richly detailed data and that a very transparent approach to data analysis 
needs to be employed to avoid claims that the findings are highly subjective and 
open to interpretation. Bowling (2009) and Braun and Clarke (2006) suggest 
that qualitative data analysis should consist of identifying, coding with reference 
to relevant theoretical frameworks, and categorising themes.  (Braun and 
Clarke 2006) Boyatzis (1998) defines a theme as ‘a pattern in the information 
that at minimum describes and organises the possible observations and at 
maximum interprets aspects of the phenomenon’.  (Boyatzis  1998) Braun and 
Clarke (2006) describe six phases of thematic analysis (see Table 2.9) for 
qualitative research.  
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Table 2.9: Phases of thematic analysis (adapted from Braun and Clarke 2006) 
1. Familiarisation  Transcribing data, reading and re-reading the data, 
noting down initial ideas. 
2. Generating initial 
codes 
Coding interesting features of the data in a systematic 
fashion across the entire data set, collating data 
relevant to each code. 
3. Searching for 
themes 
Collating codes into potential themes, gathering all 
data relevant to each potential theme. 
4. Reviewing 
themes 
Checking if themes work in relation to the coded 
extracts (Level 1), and the entire data set (Level 2), 
generating a thematic ‘map’ of the analysis. 
5. Defining and 
naming themes 
Ongoing analysis to refine the specifics of each theme, 
and the overall story the analysis tells, generating clear 
definitions and names for each theme. 
6. Producing the 
report 
The final opportunity for analysis. Selection of vivid, 
compelling extract examples, final analysis of selected 
extracts, relating back of the analysis to the question 
and literature, producing a scholarly report of the 
analysis. 
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This approach is very similar to the Framework Approach developed by Ritchie 
and Spencer (2002), which is increasingly and frequently used in healthcare 
research where the research objectives are well defined in advance of any 
fieldwork. Lacey and Luff (2007) describe the Framework Approach in five 
phases of data analysis as illustrated in Table 2.10.  
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Table 2.10: Phases of Framework Approach (adapted from Lacey and Luff 2007) 
1. Familiarisation  Whole or partial transcription and reading of the data. 
2. Identifying a 
thematic 
framework 
This is the initial coding framework which is developed 
both from a priori issues and from issues emerging from 
the familiarisation stage. This thematic framework 
should be developed and refined during subsequent 
stages. 
3. Indexing The process of applying the thematic framework to the 
data, using textual codes to identify specific pieces of 
data which correspond to differing themes. 
4. Charting Using headings from the thematic framework to create 
charts of data to be read easily across the whole dataset. 
Charts can be either “thematic” for each theme across all 
respondents (cases) or by “case” for each respondent 
across all themes. 
5. Mapping and 
interpretation 
Searching for patterns, associations, concepts, and 
explanations in data, aided by visual displays and plots. 
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This approach to coding and thematic analysis was considered more appropriate 
than other approaches (e.g. grounded theory) as the research objectives and 
theoretical frameworks were well described and there was no intention to derive 
new theories.  (Lacey and Luff 2007) These approaches are therefore much 
more appropriate for phenomenological methodologies. 
 
2.5 Sampling in quantitative and qualitative research 
The approaches to sampling in quantitative and qualitative research are key 
issues which merit further consideration. Garson (2012) describes sampling as 
the process of selection of a particular group of participants for a study, noting 
that collecting or generating data from a target population does not necessitate 
researching all members of that population. Oversampling has implications for 
study duration, resources and most importantly ethics. (Garson  2012) 
 
Sampling techniques can be categorised as probability or non-probability 
techniques. Probability techniques are most commonly employed in quantitative 
research and use some form of randomisation to select participants. Random 
sampling is generally considered to produce a sample that closely reflects the 
larger population from which it is drawn. As a result, random sampling is 
regarded as the ideal approach to produce results with high internal and 
external reality. In contrast, non-probability sampling is commonly employed in 
qualitative research and uses non-random techniques to select participants. As 
a result, these approaches may not be representative of the broader population, 
but sometimes are necessary when more rigorous sampling is not practical or 
possible.  (Black  1999) Table 2.11 illustrates comparison of different sampling 
techniques. 
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Table 2.11: Comparison of different sampling techniques  
 Procedure Common 
Usage 
Advantages Disadvantages 
Probability Sampling (adapted from Morgan  2008) 
Simple 
random 
Selected from 
population 
according to 
chance. Each 
member has 
same probability 
of being 
selected. 
Randomising 
algorithms often 
used to select 
sample. 
Large, easily 
accessible 
populations. 
 
High chance of 
being 
representative. 
Not much 
information about 
population 
required. 
Can be 
inefficient, 
expensive. 
Systematic Similar to simple 
random 
sampling, but 
participants are 
chosen at 
specific intervals 
Large, 
homogenous 
populations. 
High chance of 
being 
representative. 
Underlying 
patterns or non-
random 
variations in the 
population can 
cause a 
sampling bias. 
Stratified  Population is 
divided into 
homogenous 
subgroups, 
based on prior 
knowledge of 
the population, 
before randomly 
sampling from 
each subgroup. 
Each subsample 
is proportional 
to the size of its 
population 
subgroup. 
Large, well-
known 
populations. 
More 
representative of 
population than 
simple random 
sampling, data 
can be more 
manageable, can 
control for 
regional 
differences in 
population size. 
Requires 
accurate 
knowledge of 
sub-group sizes 
and/or 
proportions. 
Cluster Similar to 
stratified 
sampling, but a 
sample of 
subgroups is 
first taken, and 
then samples 
within each 
selected 
subgroup are 
taken. Data is 
grouped 
according to 
subgroups, or 
‘clusters’. 
 
 
 
Very large 
populations 
with known 
subgroups. 
Often cheaper and 
more efficient 
than other 
techniques. 
High chance of 
sampling error, 
a systematic 
bias in a 
particular 
cluster can 
influence the 
impression of 
the larger 
population. 
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Non-probability Sampling (adapted from Morgan  2008) 
Purposive Researcher 
selects 
participants 
based on their 
perceived 
relevance to 
study. 
Small, 
specific 
populations. 
Often cheap and 
efficient; useful 
for qualitative 
research. 
Vulnerable to 
selection bias 
on the part of 
the researcher, 
therefore high 
risk of sampling 
error. 
Snowball Current 
participants 
recruit new 
participants 
from their 
acquaintances. 
Small, 
difficult to 
access 
populations. 
Low cost, easier 
to find otherwise 
hidden 
participants, can 
promote trust 
when 
investigating 
sensitive topics. 
High chance of 
sampling error, 
potentially 
subject to 
confounding 
variables and 
participant 
biases. 
Convenience Participants 
selected 
according to 
availability to 
researcher. 
Pilot studies. Easy to recruit, 
efficient. 
High chance of 
sampling error, 
subject to 
confounding 
variables that 
influence ease 
of access. 
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All sampling approaches should be undertaken with reference to the study aim, 
objectives and characteristics, which in turn should determine the number of 
participants required.  
 
Mack et al. (2005), Bowling (2009) and Garson (2012) describe the two most 
common methods in qualitative research sampling as convenience and 
purposive sampling.  (Mack et al. 2005, Bowling  2009, Garson  2012) In 
convenience sampling, participants are selected mainly on the basis of 
convenient access to the researcher and they are generally the easiest to recruit 
to the study and are not necessarily representative of the population.  
 
Purposive sampling is a common strategy in qualitative research and is used 
when the researcher has preselected criteria considered relevant to the study. 
This involves filtering the selected population according to these criteria or 
strata which may include, for example, age, place of residence, gender, social 
class and profession and aim to allow researching those individuals most likely 
to experience, or have insights into the research topic. With purposive 
sampling, the number of participants is more of a target than a steadfast 
requirement; with sample size determined by saturation of data and is 
considered to be most effective when review and analysis of data is done 
together with the generation. (Bowling  2009, Garson  2012, Creswell  2013) 
 
There are several variations of purposive sampling including quota and snowball 
sampling. Quota sampling is specific in respect to sizes and proportions of 
subsamples, with these subgroups chosen to reflect corresponding proportions 
in the population. Snowball (or chain referral) sampling is a type of purposive 
sampling which relies on past participants making contact with new ones 
through their network (e.g. relatives, friends, colleagues etc.). Snowballing is 
used to recruit participants who are difficult to find or not easily accessible to 
researchers through other sampling strategies. (Bowling  2009, Garson  2012, 
Creswell  2013) 
 
In phase 2, a purposive sampling approach was employed for the face to face 
interviews. Sampling was undertaken purposively to explore a range of views, 
experiences and perceptions of medicines management in elderly, hospitalised 
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patients, according to the research aim. This approach was considered most 
likely to generate rich and complex data arising from diversity in views, 
experiences and perceptions, and offering further insight into factors that might 
not have been considered before.  
 
In phase 3, a snowball sampling approach was employed for the Delphi 
technique. This is considered to be more appropriate in qualitative studies to 
recruit participants who are difficult to find or not easily accessible to 
researchers. While the Delphi study in phase 3 is described as quantitative, thee 
was no readily list of potential participants hence snowball sampling was used.  
 
2.6 Robustness and rigour in research  
Promoting validity and reliability are principal constructs to be considered in 
relation to the robustness of quantitative research. Validity has been defined as 
‘the accuracy and truth of the data being produced in terms of the concepts 
being investigated, the people and objects being studied and the methods of 
data collection and analysis being used’.  (Sines et al. 2013) There are several 
aspects of validity to be considered.  
 
Internal validity relates to the degree to which the results relate to the 
operationalised constructs (i.e. the cause and effect relationship). External 
validity is the extent to which the results can be generalised to contexts and 
settings outside of the study.(Black  1999) 
 
There are specific approaches to determining internal validity: 
 
 Content validity assesses if a tool (domains and items) covers the topic 
(aims and objectives) under investigation, 
 Face validity assesses whether from the appearance of items, the tool 
measures what it claims to measure, 
 Construct validity, the theoretical understanding of the item being 
measured and assesses how well a construct is understood and 
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 Criterion-related validity assesses the correlation between the tool and 
findings and an established standard. 
 
In terms of the Delphi technique, attempts were made to promote the face and 
content validity and various theories were considered during construction of the 
research tool.  
 
Reliability (consistency) refers to the likelihood that the findings from a 
particular study can be replicated with the same methodology, method and 
sample at a later time. It can also refer to the likelihood that the scores 
obtained on a particular measure can be repeated at a later stage. One 
approach to assessing the reliability of results is to replicate a study and 
compare the results with the original. (Black  1999) 
 
Qualitative research is often criticised from a quantitative perspective on the 
basis that it is thought to lack rigour and is difficult to assess the quality of the 
research. (Horsburgh  2003, Shenton  2004) Essentially, by definition, 
qualitative research is not measurable in terms of constructs such as validity or 
reliability. Shenton (2004) discusses four constructs to ensure and assess 
trustworthiness in qualitative research, which are summarised here. 
(Shenton  2004) 
 
Credibility is similar to internal validity in quantitative research and is an 
approach to ensuring that findings are an accurate reflection of a wider reality. 
There are numerous ways to promote credibility. Researchers can employ well-
established methodologies and methods that have been used successfully in 
prior research. Where possible, research findings should be compared with 
published research and assessed for similarities or deviations. Researchers 
should provide detailed description of the researched phenomenon under 
investigation and should familiarise themselves with the population being 
studied. Triangulation of research data is also encouraged to promote credibility. 
Researchers can examine different aspects of the phenomenon by using multiple 
groups, organisations, or settings. Researchers should also encourage 
participant honesty through direct instructions, developing rapport, and giving 
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opportunities for withdrawing from the study.  (Shenton  2004) Researchers 
should meet with team members frequently for debriefing sessions and peer 
review of all aspects of the research. Researchers can also use the participants 
to check the data interpretation. (Shenton  2004) 
 
Transferability is similar to external validity (generalisability) and is described as 
the extent to which the findings can be applied to other contexts and settings. 
Qualitative research also tends to use small sample sizes, which can make 
establishing transferability difficult. Many researchers agree that a limited form 
of transferability is possible and advise providing detailed information so that 
readers can judge the applicability of the study. This detail should include: the 
number of organisations participating and their locations; participant inclusion 
and exclusion criteria; participants numbers; data generation approaches; 
duration and frequency of data generation sessions; and the overall duration of 
the data generation period. (Shenton  2004) 
 
Dependability is similar to reliability, and is described as the extent to which 
similar findings would be generated if the study was repeated with the same 
methods, participants, etc. To promote dependability, detailed account should 
be provided of the overall research design, as well as a self-reflective 
examination of the effectiveness of the data-gathering process. (Shenton  2004) 
 
Confirmability relates to the basis of the findings, and the extent to which they 
have arisen from data gathered rather than the biases and preconceived notions 
of the researcher. Techniques for promoting confirmability also apply to 
confirmability: triangulation; self-reflection; and audit trail of steps taken from 
the beginning to the end of the research process. (Shenton  2004) 
 
Many of these approaches were applied in phase 2 of the research. 
 
Bias is one issue which can affect robustness of quantitative research (validity 
and reliability) and rigour of qualitative research (trustworthiness). There are 
many different forms of bias, which are described in Table 2.12 
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Table 2.12: Types of bias (Adapted from Bowling 2009) 
Type of bias or 
error 
Description 
Acquiescence 
response set  
Participants will more frequently endorse a statement 
than disagree, ‘yes-saying’ 
Design bias Faulty methods, sampling and analysis  
Evaluation 
apprehension 
Participant anxiety may lead to giving responses which 
they think are expected  
Interviewer bias The interviewer may subconsciously, or consciously, bias 
by appearing to hold certain values or by asking leading 
questions 
Non-response bias Non-response reduces effective sample size. Differences 
between responders and non-responders reduces 
generalisability 
Recall (memory) 
bias 
Selective memories in recalling events 
Reporting bias Failure of the participant to reveal full information 
Sampling bias Non-representative selection of participants  
 
Approaches to minimising bias are described throughout chapter 4 (section 
4.2.10) and 5 (5.2.5). 
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2.6 Theoretical model and need for theory in research 
This doctoral research was conducted within a theoretical framework, which is 
described in detail in this section.  
 
2.6.1 Definition of ‘theory’ 
Meleis (2007) defines theory as ‘an organised, coherent, and systematic 
articulation of a set of statements related to significant questions in a discipline 
that are communicated in a meaningful whole. It is a symbolic depiction of 
aspects of reality that are discovered or invented for describing, explaining, 
predicting, or prescribing responses, events, situations, conditions, or 
relationships. Theories have concepts that are related to the discipline's 
phenomena. These concepts are related to each other to form theoretical 
statements.’  (Meleis  2011) Considering theory in research enhances robustness 
and rigour, and the relevance and impact of the findings. A theoretical 
framework assists researchers in understanding how the results they obtain fit 
into a larger framework. Furthermore, research informs new theories as new 
data can challenge our current explanatory models.  
 
The United Kingdom Medical Research Council guidance on ‘Developing and 
implementing complex interventions’ (described in Chapter 1) highlights the role 
of cognitive, behavioural and organisational theoretical lenses. (Craig et al. 
2008) This guidance describes four elements of: development; 
feasibility/piloting; evaluation; and implementation. Theory is a key aspect of 
development, ‘…you also need to be aware of the relevant theory, as this is 
more likely to result in an effective intervention, than is a purely empirical or 
pragmatic approach’. 
 
2.6.1 Theories in current research 
Theories can provide useful “lenses” to assist researchers in focusing on 
particular aspects of complex systems.  (Reeves et al. 2008) The interview 
schedule and Delphi statements were developed with reference to two key 
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theories/ theoretical frameworks: Normalization Process Theory (NPT) and the 
Theoretical Domains Framework (TDF), as described in chapter 4 and 5. 
 
2.6.1.1 Normalization Process Theory (NPT) 
NPT is a sociological, theoretical framework used to evaluate the 
implementation of healthcare initiatives. NPT explains ‘…the social processes 
through which new or modified practices of thinking, enacting and organising 
work are operationalised in healthcare and other institutionalised settings’.  
(May and Finch 2009) NPT helps to identify issues in implementation, 
particularly around integrating and embedding into pre-existing social and 
professional contexts. The model seeks to explain why some practices become 
normalised into practice, while others do not. NPT focuses on the contexts 
surrounding work, including the nature of the work, who performs the work, the 
manner in which the work is performed and how the work is perceived and 
understood. NPT analyses the individual and collective efforts of a group to 
accomplish particular work goals.  (May et al. 2011) The principal mechanisms 
of NPT are summarised in table 2.13. 
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Table 2.13: Process components of NPT (adapted from May and Finch 2009) 
Mechanism Components 
Coherence  Routine embedding depends on work that 
defines and organises practices as cognitive 
and behavioural ensembles 
 Embedding work is shaped by factors that 
promote or inhibit actors' perception of 
practices as meaningful 
 Production and reproduction of coherence in 
a practice requires actors to collectively 
invest meaning in it 
Cognitive participation  Routine embedding depends on work that 
defines and organises actors who are 
implicated in practices 
 Embedding work is shaped by factors that 
promote or inhibit actors' participation 
 The production and reproduction of practices 
requires actors to collectively invest 
commitment in them 
Collective action  Routine embedding is dependent on work 
that functionally defines a practice 
 Embedding work is shaped by factors that 
promote or inhibit actors' enacting it 
 The production and reproduction of practices 
require that actors collectively invest effort 
in them 
Reflexive monitoring  Routine embedding is dependent on work 
that defines and organises everyday 
understanding of a practice 
 Embedding work is shaped by factors that 
promote or inhibit evaluation 
 The production and reproduction practices 
require that actors collectively invest in 
understanding them 
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NPT was applied in this doctoral research within the context of medicines 
management and was selected as being particularly relevant due to its use 
increasingly as part of implementation research. It was important to explore 
issues of coherence, cognitive participation, collective action and reflective 
monitoring from the perspectives of health professionals in phase 2 and to 
consider in the development of the statements in the Delphi Technique in phase 
3. However, this theory focuses less on the behaviours and behavioural 
determinants of individuals, hence the Theoretical Domains Framework (TDF) 
was used alongside NPT.  
 
2.6.1.2 Theoretical Domains Framework (TDF) 
TDF is not a theory but a framework derived from 33 theories of behaviour 
change. TDF was developed by a group of psychological theorists, health service 
researchers and health psychologists. (Michie et al. 2005) The aim of TDF is to 
‘…simplify and integrate a plethora of behaviour change theories and make 
theory more accessible to, and usable by, other disciplines’ hence it was 
considered most appropriate for this research. TDF is organised into 14 
overarching domains as described in Table 2.14.  
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Table 2.14: Summary of refined Theoretical Domain Framework (adapted from 
Cane, O’Connor and Michie 2012) 
Domain Examples 
Knowledge Awareness of things (e.g. procedures) and tasks 
Skills Abilities and learnt proficiencies (e.g., 
interpersonal skills) 
Social/Professional Role and 
Identity 
Coherent set of personal behaviours and 
expressed traits in a particular setting (e.g., 
professional identity as a nurse) 
Beliefs about Capabilities Personal beliefs about one’s own capabilities 
(e.g., self-confidence) 
Optimism Positive expectations for the future 
Beliefs about Consequences Expectations about all consequences, both 
positive and negative 
Reinforcement Influences that increase the likelihood of 
particular behaviours (e.g., rewards) 
Intentions Conscious decisions to perform certain 
behaviours 
Goals Mental representations of desirable outcomes 
(e.g., target-setting) 
Memory, Attention and 
Decision Processes 
The ability to retain information, focus effectively 
on specifics in the environment, and choose 
between alternatives 
Environmental Context and 
Resources 
Circumstances and aspects of the environment 
that influence the individual positively or 
negatively (e.g., climate) 
Social influences Specifically, interpersonal influences (e.g., group 
norms) 
Emotion Feelings and associated behaviours (e.g., fear) 
Behavioural Regulation The ability to influence one’s own behaviour, 
(e.g., self-monitoring) 
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TDF has been used extensively within healthcare-related research, embedded 
into research methodologies ranging from RCTs to phenomenology. Fields of 
study have included: smoking cessation; physical activity; hand hygiene; acute 
low back pain; and schizophrenia.  (Cane, O’Connor and Michie 2012) The 
rationale for including TDF as part of the study was that by identifying the 
behavioural determinants around aspects of medicines management, is that this 
would enable more effective development of interventions to alter behaviour.  
 
2.7 Schematic summary of the research approaches  
 
Figure 2.2: Methodological phases of current research 
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CHAPTER 3: Use of the Drug Burden Index: A systematic review 
 
3.1 Introduction to the chapter 
This chapter provides the aim, method, results and discussion of a Joanna 
Briggs Institute (JBI) registered systematic review of the Drug Burden Index 
(DBI) and consideration of its inclusion within tools for medicines management 
of elderly, hospitalised patients.  
 
There were several reasons for this specific focus on anticholinergic agents as 
part of this doctoral medicines management research, as outlined in Chapter 1. 
These agents are particularly problematic in the elderly (Kay et al. 2005, Chew 
et al. 2008, Rudolph et al. 2008) and there is a notable lack of detailed 
coverage within generic potentially inappropriate prescribing scales (e.g. 
STOPP/START, Beer’s criteria). 
 
Anticholinergic agents or drugs with anticholinergic properties are widely used in 
the elderly, and include drugs for urinary incontinence, antidepressants and 
antihistamines.  (Chew et al. 2008) Anticholinergic agents act by blocking the 
actions of the neurotransmitter acetylcholine.  (Rudolph et al. 2008) Cholinergic 
receptors are classified into muscarinic and nicotinic, with muscarinic receptors 
categorised into five subtypes M1-M5; three of these subtypes play a 
fundamental role in cognitive function.  (Kay and Granville 2005) Adverse 
anticholinergic effects in the elderly can be severe and debilitating, including: 
dry mouth and sore throat; dental caries; diplopia; glaucoma; urinary retention; 
tachycardia; loss of co-ordination; confusion and agitation; memory problems; 
incoherent speech; mental confusion; and orthostatic hypotension leading to 
falls.  (Cilag, Abbott and Center 2001, Inouye, Schlesinger and Lydon 1999, 
Aizenberg et al. 2002)  
 
The cumulative effect of prescribing multiple medicines that block muscarinic 
receptors in the cholinergic nervous system is termed the ‘anticholinergic 
burden’. Many factors have been noted to influence the ‘anticholinergic burden’ 
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including: age-related pharmacodynamic and pharmacokinetic changes; 
polypharmacy (inappropriate and appropriate) drug regimens with 
anticholinergic effects; drug-drug interactions; exposure to certain drugs; 
reliability of the blood brain barrier, and co-morbid disease states, particularly 
dementia.  (Durán, Azermai and Vander Stichele 2013) The ‘anticholinergic 
burden’ is therefore of great relevance and should be a key consideration in 
prescribing and monitoring of medicines in elderly, hospitalised patients.  
 
Several scales have been developed to measure the ‘anticholinergic burden’. 
Duran et al. reported a systematic review of anticholinergic risk scales in the 
elderly, with the aim of developing a uniform list of anticholinergic drugs, 
differentiating for anticholinergic properties.  (Durán, Azermai and Vander 
Stichele 2013) Primary studies were included in the review if they provided: a 
finite list of anticholinergic drugs; a grading score of anticholinergic potency; 
and validation in a clinical setting. Studies published up to September 2012 and 
indexed in Medline were included. The review identified 454 articles; 422 of 
which were excluded during title and abstract screening and 28 during full text 
screening. A further three studies were identified from sources such as Google 
Scholar giving seven studies for data extraction. Seven different ‘risk’ scales 
were identified, with considerable variation in terms of the specific drugs 
included on the scales and the grading of anticholinergic potency. Synthesis of 
study findings gave a list of 100 drugs (47 graded as high anticholinergic 
potency and 53 as low anticholinergic potency). There are several key 
limitations to this review: there is a lack of consistency between the terms 
‘anticholinergic burden’ and ‘anticholinergic risk’; Medline was the only database 
searched; there was no critical appraisal step within the review; and the review 
did not name the different scales. To date, there have been no published studies 
which have employed the list synthesised in this review. 
 
More recently, Salahudeen et al. reported a systematic review to compare 
anticholinergic burden quantified by the anticholinergic risk scales which were 
derived through expert opinion.  (Salahudeen, Duffull and Nishtala 2015) 
Primary studies were included in the review if: the quantification tool was based 
on expert opinion; and reported the use of expert opinion quantification 
scale/tool to measure anticholinergic burden. The search was conducted in 
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Medline, Embase and PsycINFO covering the period 1984 - September 2014. 
Searching identified 932 studies, which was reduced to seven following title, 
abstract and full text screening. These seven papers reported use of: 
Anticholinergic Drug Scale; Anticholinergic Burden Classification; Clinician-rated 
Anticholinergic Score; Anticholinergic Risk Scale; Anticholinergic Cognitive 
Burden Scale; Anticholinergic Activity Scale; and Anticholinergic Loading Scale. 
The key finding was that there was no standardised tool and that the rating of 
anticholinergic activity for medicines between scales was inconsistent. One key 
limitation of this review was only including scales based on expert opinion. 
Additionally, there was no critical appraisal step.  
 
A recent narrative review conducted by Kouladjian et al. provided an overview 
of the research and clinical applications of the Drug Burden Index (DBI); and its 
advantages and limitations, compared with other pharmacologically developed 
measures of high-risk prescribing (Figure 3.1). The review was based on a 
search of Medline and PubMed databases for articles published from January 
2000.  (Kouladjian et al. 2014) The key finding was that the DBI was a novel 
pharmacological evidence-based tool to measure anticholinergic and sedative 
agents.  
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Figure 3.1: Summary of aspect of the DBI (adopted from Kouladjian et al. 
2014) 
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The DBI was developed in 2007 by Hilmer et al. and is used to quantify the 
anticholinergic and sedative burden.  One key advantage of DBI over other 
scales is that it also captures the use of sedative agents. Sedative agents can be 
defined as those drugs that cause physiological and mental slowing of the body. 
With prolonged use, sedative agents can lead to the development of symptoms 
of abuse, dependence and withdrawal. Examples of sedative agents are 
hypnotics (sleep promoting drugs), anxiolytics (anti-anxiety agents). Sedative 
agents enhance neurotransmitter gamma-aminobutyric acid (GABA) effects that 
regulate and depress the nervous system and cause reduced pain, sleepiness 
and reduce anxiety.  (Rothberg et al. 2013) Adverse sedative effects in the 
elderly can be severe similar to adverse anticholinergic effects and lead to falls. 
 
Anticholinergic (Nishtala et al. 2009) and sedative (Rothberg et al. 2013) agents 
are consistently reported as commonly prescribed medicines in elderly, and 
inappropriate use of these medicines is associated with adverse outcome. (Bell 
et al. 2012) 
The DBI is calculated as follows: 
Drug Burden =    D__     
                       D + δ  
 
D is the daily dose of anticholinergic or sedative medicine, and  
δ the minimum efficacious dose as approved by the Food and Drugs 
Administration in the United States of America (USA).  
 
Hilmer et al. employed the index in a study which aimed to evaluate the 
association between DBI and cognitive and functional outcomes.  (Hilmer et al. 
2009) This was a cross-sectional study of community dwelling older persons 
participating in the Health, Ageing and Body Composition (ABC) initiative in the 
USA. This seminal study established that increasing DBI had a positive 
correlation with deterioration in functions of grip strength and gait. In addition, 
a unit increase in DBI was a prediction of deterioration in gait speed of 0.04 
m/s.   
 
Table 3.1 and 3.2 gives comparison of DBI with other anticholinergic burden 
scales.  
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Table 3.1: Comparison of the development and application of anticholinergic scales (by publication year) with the Drug 
Burden Index (adapted from Kouladjian et al. 2014) 
  DBI 
(2007) 
ADS 
(2006) 
ABC 
(2006) 
CrAS 
(2008) 
ARS 
(2008) 
ACB 
(2008) 
AAS 
(2010) 
ACL 
(2011) 
Conceptual basis of scale Pharmacological first principles 
- Serum radioreceptor assays or SSA 
- Extensive literature reviews (including systematics review) 
- Interdisciplinary clinician rating scales or expert opinion  
 
✓ 
 
 
 
 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
 
 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
 
 
✓ 
 
✓ 
 
 
 
✓ 
 
✓ 
Scoring system or calculation equations used 
- Categorical or numerical scale used 
- Pharmacological equation used 
- Summation or accumulation of effect 
- Dose consideration 
 
 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
 
 
✓ 
 
✓ 
 
✓ 
 
 
 
✓ 
 
 
✓ 
 
 
✓ 
 
 
✓ 
 
 
✓ 
 
 
✓ 
 
 
✓ 
 
 
✓ 
 
 
✓ 
 
 
✓ 
 
 
Medicine identification resource 
- Country-specific product information/label  
- Others (e.g. literature appraisals) 
 
✓ 
 
 
✓ 
 
 
 
 
✓ 
 
 
 
✓ 
 
 
 
✓ 
 
 
 
✓ 
 
 
 
✓ 
 
 
 
✓ 
Number of anticholinergic medicines considered  Variable
128* 
117 27 60 49 88 99 49 
*Number of medicines included in the DBI calculation includes sedative and anticholinergic medicines and varies according to each country’s formulary 
at the time of the study; the number reported here is the number of anticholinergic and sedative medicines that a cohort of 2,172 older adults in the 
USA was exposed to (Hilmer et al. 2009); Abbreviations: SAA, serum anticholinergic activity; ADS, Anticholinergic Drug Scale; ABC, Anticholinergic 
Burden Classification; CrAS, Clinician-rated Anticholinergic Score; ARS, Anticholinergic Risk Scale; AAS, Anticholinergic Activity Scale; ACL, 
Anticholinergic Loading Scale; ACB, Anticholinergic Cognitive Burden Scale; DBI, Drug Burden Index. 
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Table 3.2: Comparison of aspects of sedative rating scales (by publication year) with the Drug Burden Index (adapted from 
Kouladjian et al. 2014)  
  DBI (2007) Sedative load 
(2003) 
Sloane et al. 
(2008) 
CNS drug 
(2009) 
Conceptual basis of scale  
- Pharmacological first principles 
- Extensive literature reviews (including systematics review) 
- Interdisciplinary clinician rating scales or expert opinion  
 
✓ 
 
 
 
 
✓ 
 
✓ 
 
✓ 
 
 
 
✓ 
 
✓ 
 
 
 
Scoring system or calculation equations used 
- Categorical or numerical scale used 
- Pharmacological equation used 
- Summation or accumulation of effect 
- Dose consideration 
 
 
 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
Medicine identification resource 
- Anatomical Therapeutic Classification System 
- Iowa Drug Information System Codes 
- Country-specific product information/label  
 
 
 
 
 
✓ 
 
✓ 
 
 
 
✓ 
 
✓ 
 
 
 
✓ 
 
 
✓ 
Number of sedative medicines considered  Variable128* 340 106 53 
*Number of medicines included in the DBI calculation includes sedative and anticholinergic medications and varies according to each country’s formulary 
at the time of the study; the number reported here is the number of anticholinergic and sedative medications that a cohort of 2,172 older adults in the 
USA was exposed to (Hilmer et al. 2009); Abbreviations: DBI, Drug Burden Index; CNS, central nervous system. 
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The DBI is, therefore, a potentially powerful tool to: 
i. quantify the effects of anticholinergic and sedative agents,  
ii. to aid review of these medicines and  
iii. and to quantify the effects of interventions to reduce the DBI.  
 
There is potential to use the DBI alongside other more generic tools or criteria 
which highlight potentially inappropriate prescribing, as an overall package as 
part of medicines management. 
 
Since 2007, the DBI had been studied in various countries and clinical settings.  
A scoping search of Medline, International Pharmaceutical Abstracts (IPA), 
Cumulative Index of Nursing and Allied Health Literature (CINAHL), PsycArticles, 
and Cochrane Library identified a volume of literature focusing on the DBI. To 
date no systematic review had been published or protocol registered with the 
Joanna Briggs Institute (JBI), the Cochrane Collaboration or the Centre for 
Reviews and Dissemination. Since the DBI was published in 2007, the scoping 
search timeline was from 2007 to 2013, to identify those articles published in 
the English language. The PI also contacted Professor Hilmer (the corresponding 
author for the seminal work on the DBI) via email to confirm that she was 
neither conducting nor was aware of any such review.  
 
The review focused on the use of the DBI to identify potentially inappropriate 
prescribing of anticholinergic and sedative agents in elderly patients in 
institutionalised care (e.g. hospital or care home settings). This provided an 
opportunity to systematically search, locate, appraise, synthesize, summarize 
and interpret the best available evidence using standard JBI approaches. The 
findings of this review would be of particular relevance to practitioners caring 
for elderly patients in institutionalised settings, providing quality information on 
any associations between DBI and health outcomes (e.g. related to adverse 
drug reactions), and the impact of medicines review on DBI and these 
outcomes.  
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A review protocol was developed according to best practice (Pearson, Wiechula 
and Lockwood 2005) and submitted for review by PI and Principal Supervisor. 
Following peer review, subsequent modification and further peer review, the 
protocol was registered with the JBI Database of Systematic Reviews & 
Implementation Reports and published in 2014.  (Al Shemeili and Stewart 2014)  
 
3.1.1 Aim and objectives 
The aim of the review was to critically appraise, synthesize and present 
evidence of the use of the Drug Burden Index (DBI) to identify potentially 
inappropriate prescribing of anticholinergic and sedative agents in elderly 
patients in institutionalised care. 
 
More specifically, this review sought to answer the following review questions: 
 
1. in which specific settings and patient groups had the DBI been applied? 
 
2. what outcomes had been studied? (e.g. occurrence and incidence of 
adverse drug reactions, physical functioning, mental functioning, cause of 
admission to hospital etc.) 
 
3. had the use of DBI impacted prescribing of anticholinergic and sedative 
agents in elderly patients in institutionalised care? (e.g. cessation of 
therapy, prescribing altered to other agents, reduction in adverse drug 
reactions etc.) 
 
3.2 Methods 
3.2.1 Inclusion criteria 
The standard systematic review PICO approach was employed. 
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3.2.1.1 Types of participants 
The review focused specifically on ‘elderly patients’ as described within the 
studies. If no classification was given within studies then those studies reporting 
on patients aged 65 years and over were included. Furthermore, the review 
focused on patients receiving care within either hospital or care home settings 
(institutionalised care). The care of these patients and hence the use of the DBI 
was likely to be markedly different to those home dwelling patients and hence 
less relevant to this doctoral research of hospitalised patients. 
 
3.2.1.2 Types of intervention(s) 
While the intervention was the use of the DBI, a scoping review of the literature 
had identified only a small number of studies where this tool was used as an 
intervention. Most studies used an observational design solely involving 
application of the tool.  
 
3.2.1.3 Types of comparisons 
Patients with a zero DBI score (i.e. no prescription of anticholinergic or sedative 
medicines) compared to DBI score; or different levels of DBI scores between 
sub-samples of patients. Most studies had no comparison (as described above). 
 
3.2.1.4 Types of outcomes 
This review considered studies that included the following outcome measures: 
 
1. DBI scores (in observational studies). 
 
2. impact of DBI on outcomes such as physical and mental functioning; 
adverse effects of anticholinergic and sedative medicines. 
 
3. changes to therapy following application of DBI as a tool to identify 
potentially inappropriate prescribing.  
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3.2.1.5 Types of studies 
The review considered quantitative studies relevant to the application of the DBI 
and hence these were observational in nature, specifically prospective and 
retrospective cohort studies, case control studies and analytical cross-sectional 
studies. While qualitative studies could elucidate practitioners’ beliefs and 
attitudes on the use of the DBI, these were not relevant for the review 
questions. Furthermore, the scoping review did not identify any qualitative 
research on the DBI.  
 
3.2.2 Search strategy 
The search strategy aimed to find both published and unpublished studies. A 
two-step search strategy was utilized in this review. 
 
1. ‘Drug Burden Index’ was a specific term and hence was the only search 
term employed. To ensure that all relevant papers were captured, ‘Drug 
Burden Index’ was searched in the titles, keywords, abstracts and text. 
 
2. To ensure full coverage of all the literature, the reference lists of all 
papers and reports were reviewed for any previously unidentified studies.  
 
The first paper describing the DBI was published in 2007 and hence studies 
published from 2007 to July 2015 in the English language were included in the 
review.  
 
The databases searched were: 
 
1. Medical Literature Analysis and Retrieval System Online (MEDLINE) 
Medline is a database provided by the United States National Library of 
Medicine covering basic research and clinical sciences. It contains over 14 
million records (U.S. National Library of Medicine 2015) 
 
2. International Pharmaceutical Abstracts (IPA) 
IPA is an online database produced in conjunction with the American 
Society of Health-System Pharmacists. It provides a comprehensive 
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collection of information on drug use and development from 1971 
(EBSCO Health 2015) 
  
3. Cumulative Index of Nursing and Allied Health Literature (CINAHL) 
CINAHL contains references to journals articles from hundreds of nursing 
journals from the UK, USA and other countries (EBSCO Health 2015) 
   
4. PsycARTICLES 
PsycARTICLES is a database offering complete coverage of all subject 
areas relevant to psychological science. It includes the full text of nearly 
200,000 articles, from more than 100 journals. These journals are 
published by the American Psychological Association, the Canadian 
Psychological Association and the Hogrefe Publishing Group (American 
Psychological Association 2015) 
 
5. Cochrane Database of Systematic Reviews 
Archibald Cochrane (1909-88), a British epidemiologist, introduced the 
Cochrane Collaboration which identifies, appraises and synthesises 
research based evidence and presents it in an accessible format 
(Cochrane Library 2015) 
 
The search for unpublished studies/grey literature was conducted in: Google 
Scholar (online search engine of published outputs); Science.gov (gateway to 
government sciences information provided by US government); Robert Wood 
Johnson Institute; and Dissertations Abstract International (bibliography of 
American and international dissertations published by University Microfilms 
International). 
 
The search string was applied with results and exceptions recorded. Titles of 
papers returned by the search were screened independently by two reviewers, 
in relation to the review title, aim, research questions, and inclusion criteria, 
followed by abstracts and full papers. In case of uncertainty or disagreement 
between two reviewers a third reviewer was consulted. 
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3.2.3 Assessment of methodological quality 
The papers selected for retrieval were assessed by two independent reviewers 
for methodological validity prior to inclusion in the review, using standardised 
critical appraisal instruments from the JBI Meta Analysis of Statistics 
Assessment and Review Instrument (JBI-MAStARI) (Appendix 3.1). Any 
disagreements that arose between the reviewers were resolved through 
discussion, or with a third reviewer. 
 
3.2.4 Data collection  
Quantitative data were extracted from papers included in the review using the 
standardised data extraction tool from JBI-MAStARI (Appendix 3.2). The data 
extracted included specific details of the interventions, populations, study 
methods and outcomes of significance to the review question and specific 
objectives. 
 
3.2.5 Data synthesis 
Due to differences in study design and the lack of homogeneity of reported 
data, a meta-analysis using JBI-MAStARI was considered inappropriate. A 
narrative synthesis approach was used to present study findings. 
 
3.3 Results 
3.3.1 Description of studies  
Seven articles (three cohort studies, three mixed cohort and cross-sectional 
studies and one cross-sectional study) were identified. The Transparent 
Reporting of Systematic Reviews and Meta-Analyses (PRISMA) flowchart is 
given in Figure 3.2. 
 
A total of 44 titles were retrieved from databases (Medline, IPA, CINAHL, 
PsycArticles, Cochrane), of which 11 were duplicates within the same 
databases, leaving 33 titles to be screened by two independent reviewers. Title 
screening excluded 11 duplicate articles between different databases. Following 
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abstract screening 11 articles was excluded, as they were not addressing the 
review topic questions (i.e. setting of practice not institutionalised care). 
Following full paper screening by the PI and principal supervisor, seven articles 
fulfilled the inclusion criteria. No further articles were identified from review of 
the reference lists of these seven articles. There were therefore seven studies 
for critical appraisal (see Table 3.3). 
 
Table 3.3: number of studies retrieved  
Number of articles retrieved Number selected for critical 
appraisal 
44 7 
 
The list of excluded articles and the reason for exclusions are presented in 
Appendix 3.3 
 
In terms of study design, three of the papers considered in this review used a 
mixed cross-sectional design and cohort (Lowry et al. 2011, Best et al. 2013, 
Mangoni et al. 2013) although one did not clearly specify this within the 
methods section.  (Lowry et al. 2011) The other studies used a cross-sectional 
design (Bosboom et al. 2012) and a cohort design. (Nishtala et al. 2009, Wilson 
et al. 2011, Wilson et al. 2012) 
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Figure 3.2: PRISMA flowchart for the search and study selection process 
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3.3.2 Methodological quality  
The methodological quality of the included studies, based on using JBI-MAStARI, 
is reported in Table 3.4. There were only minor disagreements between the two 
reviewers, which were resolved through discussion.  
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Table 3.4: JBI-MAStARI quality assessment of reviewed studies 
Criteria / Author, Year 
Nishtala 
et al. 
(2009) 
Lowry et 
al. 
(2011) 
Wilson et 
al. 
(2011) 
Rosboom 
et al. 
(2012) 
Wilson et 
al. 
(2012) 
Best et al. 
(2013) 
Mangoni 
et al. 
(2013) 
Is sample representative of 
patients in the population as a 
whole? 
Y Y Y U Y Y U 
Are the patients at a similar 
point in the course of their 
condition/illness? 
Y Y Y Y Y Y Y 
Has bias been minimised in 
relation to selection of cases and 
of controls? 
Y Y Y Y Y Y Y 
Are confounding factors 
identified and strategies to deal 
with them stated? 
Y Y U Y Y Y Y 
Are outcomes assessed using 
objective criteria? 
Y Y Y Y Y Y Y 
Was follow up carried out over a 
sufficient time period? 
Y N/A Y N/A Y N/A N/A 
Were the outcomes of people 
who withdrew described and 
included in the analysis? 
Y Y Y Y Y Y Y 
Were outcomes measured in a 
reliable way? 
Y Y Y Y Y Y Y 
Was appropriate statistical 
analysis used? 
Y Y Y Y Y Y Y 
Y, yes; N, no; U, unclear; N/A, not applicable (cross-sectional design hence no follow-up) 
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Table 3.5 shows the number of studies included and excluded based on the 
study quality assessments. 
 
 Table 3.5: MASTARI- number of studies included and excluded 
Number of studies included Number of studies excluded 
7 0 
 
It is clear from Table 3.4 that all studies were of very high quality (hence 
inclusion in data extraction). However, none of the studies provided any 
rationale to support the sample sizes. This is more relevant for the two which 
contained hypotheses within the study aims. The study of Rosbloom et al. 
(Bosboom et al. 2012) omitted any description of power while that of Best et al. 
(Best et al. 2013) did provide justification of sample size required at a given 
power of 80% to detect differences in DBI. However, it is not too clear what this 
difference referred to (presumably changes from admission to discharge from 
hospital). This estimation was based on earlier work in a different setting and 
should have been recalculated using the baseline data in this study, particularly 
as no difference was observed in the full study. It is worth noting that sample 
size is not considered by JBI within critical appraisal.    
 
3.3.3 Data extraction and synthesis 
Data extraction from these seven studies is given in Table 3.6. Due to 
differences in study design and the lack of homogeneity of study aims and 
outcomes, a meta-analysis (e.g. in relation to impact studies) using JBI-
MAStARI was considered inappropriate. A narrative synthesis approach was 
used to present study findings. 
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Table 3.6: Data extraction of reviewed studies 
Authors, 
Year, 
Country, 
Setting, 
Design 
Study aim(s) Participants Outcome 
measures 
Findings Authors’ 
conclusions 
Nishtala et 
al. (2009) 
Australia 
62 aged-
care homes 
Cohort 
study 
 
To evaluate 
whether 
residential 
medicines 
management 
review 
recommendations 
made by 
pharmacists and 
their uptake by 
GPs impacted 
DBI in older 
people living in 
aged-care homes 
 
Random sample 
(unclear what 
proportion of 
patients randomly 
sampled and if any 
stratification per 
pharmacist or per 
home) of 500 
patients from 62 
aged care homes.  
 
Patients were ≥65 
years who had 
received an 
accredited clinical 
pharmacist 
conducted 
Residential 
Medication 
Management 
Reviews (RMMR) 
from a single RMMR 
service provider 
Review of each 
resident’s case 
notes, which were 
written by the 
accredited 
pharmacists.  
Information 
gathered 
diagnoses, 
current 
medication, 
relevant 
pathology results, 
resident interview 
notes and 
consultations 
made with facility 
staff and doctors. 
Also recorded 
outcome of the 
pharmacist review 
in terms of 
changes to 
medicines.  
DBI calculated 
pre- and post- 
review by the 
At baseline, mean number 
of anticholinergic and 
sedative medications per 
patient were 0.9 (0.9 SD) 
and 0.2 (0.4) respectively. 
DBI scores were 
significantly lower than 
those obtained prior to the 
review after uptake of 
recommended changes by 
the GP by (p<0.001). The 
median DBI exposure was 
reduced from 0.5 
(equivalent to one 
minimum efficacious dose 
of an anticholinergic or 
sedative medication per 
resident) to 0.33 
(equivalent to half a 
minimum efficacious dose 
of an anticholinergic or 
sedative medicine per 
resident). 
The mean decrease in DBI 
from pharmacist 
recommendations was 
0.12 (95% CI 0.09, 0.14), 
The study 
demonstrates that 
accredited clinical 
pharmacist 
conducted 
medicines reviews 
could reduce 
prescribing of 
sedative and 
anticholinergic 
drugs, resulting in 
a significant 
decrease in the 
DBI score of the 
study population 
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researchers to 
determine any 
differences (not 
part of the 
pharmacist 
review) 
representing a 20% 
decrease in mean baseline 
DBI for residents. When 
GPs implemented 
pharmacists’ 
recommendations, the DBI 
decreased by a mean of 
12% from baseline (mean 
decrease 0.07; 95% CI 
0.05, 0.08) 
Lowry et al. 
(2011) 
UK 
Two acute 
geriatric 
units in 
Aberdeen,  
Mixed cross-
sectional 
and cohort 
study 
To investigate 
the association 
between the DBI 
score and the 
Barthel Index, an 
established scale 
to measure 
performance in 
basic activities of 
daily living, in a 
consecutive 
series of older 
hospitalized 
patients.  
To assess the 
predictive yield of 
the DBI score on 
2 objective short- 
term outcomes 
namely, length of 
stay (LOS) and 
in-hospital 
mortality 
The study sample 
consisted of a 
consecutive series 
of patients > 60 
years admitted to 2 
acute geriatric 
medicine units from 
February 1, 2010, 
to June 30, 2010. 
Sample size of 362 
Main outcome 
measure, Barthel 
Index 
(performance in 
activities of daily 
living). Secondary 
outcomes of 
length of hospital 
stay and in-
patient mortality 
Median (range) DBI (total) 
of 0.48 (0-1), DBI 
anticholinergic 0 (0-0.5) 
and sedative 0 (0-0.5). 
Zero score for total 
(48.1%), anticholinergic 
(54.4%) and sedative 
(58.6%). 
The median score for the 
Barthel Index was 75 
(range, 5-100; IQR, 60-
90). Proportional odds 
ordinal logistic regression 
showed that higher DBI 
scores were all 
significantly and 
independently associated 
with being in lower Barthel 
Index categories after 
adjusting for age, sex, 
residency status, Charlson 
Comorbidity Index, 
dementia, total number of 
Higher DBI scores 
on admission are 
strongly associated 
with reduced 
physical function 
and predict an 
increased LOS in 
older hospitalized 
patients 
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non-
anticholinergic/sedative 
drugs, and hospital 
admission site. 
Higher DBI scores all 
predicted increased Length 
Of Stay (LOS) in univariate 
analysis and after 
adjusting for age, sex, 
residency status, 
dementia, Charlson 
Comorbidity Index, 
number of 
nonanticholinergic/ 
sedative drugs, hospital 
site, and Barthel Index 
category. The DBI scores 
did not predict in-hospital 
mortality 
Wilson et al. 
(2011) 
Australia, 
Residential 
Aged Care 
Facilities  
Northern 
Sydney 
Central 
Coast Area 
Health 
(NSCCH) 
service area  
Cohort 
To evaluate the 
association 
between higher 
DBI and fall rates 
in a population of 
older people 
living in RACFs 
602 participants 
who were taking 
part in an RCT of 
the effect of 
sunlight and 
vitamin D on falls 
Individuals were 
eligible if they were 
ambulant, aged 70 
and older, and 
likely to survive for 
12 months as 
judged by facility 
staff. Exclusion 
The main 
outcome measure 
was the number 
of falls recorded 
over the 12-
month study 
period 
The main variable 
of interest was 
the DBI 
35.2% were taking 
anticholinergics, 42% 
sedatives and 16.6% both. 
DBI total mean 0.60, DBI 
anticholinergic 0.27, DBI 
sedative 0.33 (with SDs) 
There were 998 falls 
during the 1-year study 
period; 330 residents 
(55%) fell one or more 
times in this period, and of 
these, 135 fell once, 69 fell 
twice, 35 fell three times, 
30 fell four times, and 61 
The DBI in older 
people living in 
RACFs is 
significantly and 
independently 
associated with 
falls. Intervention 
studies specifically 
designed for this 
population are 
required to 
determine whether 
cessation or 
reducing the dose 
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study 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
criteria were skin 
cancer within the 
last 3 years and 
taking vitamin D or 
calcium 
supplements in the 
last 6 months. 
Verbal and written 
consent were 
obtained, and in 
cases of cognitive 
impairment, 
consent was sought 
from the 
appropriate person 
as defined by 
legislation 
During the 1 year 
study period, 65 
participants 
(10.8%) died 
during the 
observation period, 
and 11 (1.8%) 
withdrew from the 
study, giving the 
cohort a follow-up 
period of 574.2 
person-years 
fell five or more times. The 
fall rate equates to 1.74 
falls per person-year, and 
the median time to fall was 
120 days from the baseline 
assessment date. A 
statistically significant and 
ordered time to fall for 
individuals in the none, 
low, and high DBI 
categories was apparent 
(log rank chi square 
=18.38(2) P<.001). Six-
month fall rates were 
30%, 39% and 51% for 
participants in the 0, low, 
and high DBI categories 
respectively 
The multivariate analyses 
showed that the fall rate 
was greater if the 
individual was male, had a 
history of falling, was 
cognitively impaired, used 
a cane or a walker, was 
incontinent during the day 
and night, and had a low 
or high DBI 
and number of 
anticholinergic or 
sedative medicines 
can prevent falls 
Rosboom et 
al. (2012) 
 
 Western 
Aimed to 
determine the 
association 
between self-
Participants were 
obtained from the 
DIRECT study 
dementia in 
Measured QoL-AD 
ratings.  
Measured PIMs by 
Beers, DBI and 
124 participants (56.9%) 
were exposed to one 
potentially inappropriate 
medicines. In terms of 
The use of PHM is 
common and is 
inversely 
associated with the 
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Australia 
 
Low-level or 
high-level 
residential 
aged care 
facilities in 
Perth 
 
Cross-
sectional 
study 
reported health 
related quality of 
life and the use 
of potentially 
harmful 
medications as 
defined by Beers, 
DBI (for this 
review) and 
polypharmacy 
(≥5medications) 
Also tested the 
hypothesis that 
Self-reported 
health related 
quality of life 
would be 
inversely 
associated with 
inappropriate 
prescribing as 
defined by Beers, 
DBI >0 (for this 
review) and 
polypharmacy 
residential care: 
education 
intervention trial)  
All participants in 
this study were the 
permanent 
residents of a low-
level or high-level 
RACF were, aged 
≥65 years, with a 
clinical diagnosis of 
dementia and 
MMSE total score of 
≤24. The exclusion 
criteria were: 
medically unstable 
or as suffering from 
delirium, or in the 
terminal stages of a 
co-morbid illness; 
or unable to 
participate in 
completion of 
assessment 
instruments in 
English 
The initial sample 
of 351 was reduced 
to 226 capable of 
self-reporting the 
QoL-AD instrument 
polypharmacy DBI, 178 (78.8%) were 
exposed to medications 
with DBI>0: 82 (46.1%) 
anticholinergic and 96 
(53.9%) sedative 
medicines.  
The mean QoL-AD total 
score by self-rating was 
41.5±5.9 (range 26–58), 
corresponding to a mean 
QoL-AD % MaxSc of 
69.2±9.9 (range 43.3-
96.7). 
DBI>0 was associated with 
the self-reported QoL-AD, 
after adjustment for other 
factors. DBI>0 tripled the 
odds of participants being 
in the middle or lowest 
tertile of QoL ratings 
self-reported 
HRQoL in PWD 
living in RACFs. 
With regard to 
clinical tools, the 
data suggests that 
DBI and 
polypharmacy may 
be better 
predictors of 
HRQoL than PIMs 
by Modified Beers 
criteria 
Wilson et al. 
(2012) 
To ascertain 
whether the DBI 
602 participants 
who were taking 
The main 
outcome measure 
97.8% were taking 
medicines. Of these, 
No significant 
associations 
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Australia 
Residential 
Aged Care 
Facilities 
Northern 
Sydney 
Central 
Coast Area 
Health 
(NSCCH) 
service area 
Cohort 
study 
score is a 
predictor of 
mortality and if 
this association is 
dose related 
part in an RCT of 
the effect of 
sunlight and 
vitamin D on falls. 
RACFs excluded 
individuals with a 
high score on the 
Impact Illness 
Severity Scale at 
the time of 
recruitment (2006-
2009) 
 
was mortality as 
recorded in 
nursing notes 
followed by 
review of 
individual subject 
and dates of birth 
(the NSW 
Registry of Births, 
Dates and 
Marriages) 
41.9% were exposed to 
sedatives, 33.6% 
anticholinergic and 17.6% 
taking both. Mean baseline 
DBI in the cohort was 
0.57, 0.33 sedative and 
0.25 anticholinergic 
Significant determinants of 
a high DBI were female, 
BMI ≥ 222, using a 
walking frame, taking 9 or 
more non-DBI prescription 
medicines, total number of 
medicines and a higher 
CCI (Charleson 
Comorbidity Index) score  
DBI scores were not 
associated with 1-year 
mortality data (but sample 
sizes may not have been 
adequate to identify a 
clinically important 
difference). Actually 
highlights this in the 
conclusion 
between 
increasing DBI and 
mortality were 
seen 
Best et al. 
(2013) 
Australia 
550 bed 
university-
teaching 
hospital in 
Sydney 
To investigate 
the changes in 
polypharmacy 
and the drug 
burden index 
(DBI) occurring 
during 
hospitalisation for 
Patients with the 
age of ≥65 years 
and admitted under 
the care of the 
geriatric medicine 
or rehabilitation 
teams. 
Consecutive 
The reasons for 
admission were 
determined from 
the aged care 
discharge 
summary. The 
clinical case notes 
were also 
The mean (±SD) age of 
the population was 84.6 ± 
7.0 years, 62% were 
female and 40% were 
admitted from residential 
aged-care facilities. On 
admission, DBI exposure 
was observed in 50% of 
DBI was 
associated with an 
increased risk of 
hospital admission 
for delirium only. 
Polypharmacy was 
not associated 
with any of the 
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Mixed cross-
sectional 
and cohort 
study 
older people. The 
secondary aim 
was to examine 
the associations 
of these two 
measures with 
the length of 
hospital stay and 
admission for 
falls or delirium 
 
patients (n= 392) 
discharged from 
hospital between 1 
January and 30 
June 2011 were 
identified from 
hospital records. 
The final study 
population 
consisted of 329 
older people 
discharged from 
hospital, with 63 
patients excluded 
for a variety of 
reasons 
reviewed if 
clarification was 
required 
Medicines at 
admission and 
discharged were 
extracted from 
medical notes 
All diagnoses, 
including delirium, 
were diagnosed 
by the attending 
doctor and 
recorded on the 
discharge 
summary or 
clinical notes 
The length of 
hospitalisation 
was recorded to 
the nearest whole 
day, from the 
date of admission 
to the date of 
discharge as 
listed on the aged 
care discharge 
summary 
the cohort 
DBI and polypharmacy 
exposure decreased during 
hospitalisation, but only 
the number of medications 
taken decreased by a 
statistically significant 
margin (P= 0.02). Patients 
with a high DBI (≥1) were 
approximately three times 
more likely to be admitted 
for delirium than those 
with no DBI exposure 
(odds ratio, 2.95; 95% 
confidence interval, 1.34–
6.51) 
There was no association 
between increasing DBI 
and fall-related admissions 
clinical measures 
Mangoni et 
al. (2013) 
The 
Netherlands, 
Academic 
The study aimed 
to assess 
possible 
associations 
between 
The study sample 
consisted of 
patients 65 years 
or older admitted 
with hip fractures 
Postoperative 
complications, 
hospital length of 
stay, and 3-
month and 1-year 
No significant associations 
were observed between 
the number of 
anticholinergic drugs, 
ADSSs (including the 
The main results of 
this study showed 
poor associations 
between ADSSs 
(including DBI) 
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Medical 
Centre, 
Amsterdam  
Mixed cross-
sectional 
and cohort 
study 
anticholinergic 
drug scoring 
systems (ADSS) 
and serum 
anticholinergic 
activity (SAA) 
and their 
capacities to 
predict all-cause 
mortality in older 
hospitalized 
patients 
Drug Burden 
Index (DBI) was 
one of the four 
ADSS, specifically 
focusing on the 
anticholinergic 
element 
and scheduled for 
surgery between 
May 2005 and 
November 2008 
The sample 
comprised those 
patient eligible 
(following 
application of 
exclusion criteria) 
and those not 
consenting. From 
an initial 313 
patients, 71 were 
included in the 
study 
all-cause 
mortality 
Serum 
anticholinergic 
activity 
determined and in 
terms of DBI, the 
anticholinergic 
element score 
derived 
anticholinergic element of 
the DMI), and SAA 
In univariate analysis, SAA 
was higher in patients with 
preadmission cognitive 
impairment (4.3±3.9 
versus 2.4±2.1 pmol/mL, 
p = 0.009) and in-hospital 
delirium (median 4.0 
versus 2.1 pmol/mL, p= 
0.02) 
SAA was positively 
associated with age and 
Katz Activities of Daily 
Living score and negatively 
associated with the 
number of non-
anticholinergic medicines 
In multivariate linear 
regression preadmission 
cognitive impairment (β= 
2.12±0.71, p = 0.004) 
and the number of non-
anticholinergic drugs (β= 
0.29±0.13, p = 0.03) were 
independently associated 
with SAA 
and SAA in older 
hospitalized 
patients awaiting 
hip surgery 
This suggests that 
factors other than 
anticholinergic 
drug prescribing 
might influence 
the in vitro 
measurement of 
SAA in addition to 
the known 
inherent 
limitations of the 
technique 
Further studies are 
required to confirm 
these findings in 
different and 
larger patient 
groups and to also 
assess the relative 
impact of the SAA 
versus ADSSs on 
adverse medical 
and psychiatric 
outcomes in older 
patients 
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In relation to the review questions: 
 
i) in which specific settings and patient groups had the DBI been applied? 
 
The studies were based largely in Australia (Nishtala et al. 2009, Wilson et al. 
2011, Bosboom et al. 2012, Wilson et al. 2012, Best et al. 2013), the 
Netherlands (Mangoni et al. 2013), and the United Kingdom.  (Lowry et al. 
2011) They were conducted in either aged care facilities (Nishtala et al. 2009, 
Wilson et al. 2011, Bosboom et al. 2012, Wilson et al. 2012) or geriatric 
medicine units of hospitals. (Lowry et al. 2011, Best et al. 2013, Mangoni et al. 
2013) 
 
There were slightly varied patient inclusion criteria, with most (Wilson et al. 
2011, Bosboom et al. 2012, Wilson et al. 2012, Best et al. 2013, Mangoni et al. 
2013) including those older than 65 years, one (Lowry et al. 2011) older than 
60 years while one study was more general, randomly selecting participants of 
various ages in residential aged care facilities.  (Nishtala et al. 2009) Sample 
sizes varied from 226 (Bosboom et al. 2012) to 602. (Wilson et al. 2011, Wilson 
et al. 2012) 
 
The following sources of information (largely medical notes and less commonly 
via patient interview) were used to gather medicines information: 
 
 the use of two investigators to review each patients’ medical notes (but 
not clear if they both reviewed each patient and worked independently) 
(Nishtala et al. 2009, Lowry et al. 2011, Wilson et al. 2011, Wilson et al. 
2012), 
 
 from clinical records by trained research assistants and face to face 
interviews (Bosboom et al. 2012), 
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 from medical notes, patient medicines admission data (Best et al. 2013) 
and 
 
 from medical notes at 3 and 12 months post surgery (Mangoni et al. 
2013). 
 
In terms of computing for the DBI, almost all the studies provided a clear and 
detailed approach to their derivation.  
 The DBI was calculated using formula (DBI= Σ D/δ+D) where D 
represented the total daily dose of sedative or anticholinergic medication, 
and δ was the minimum efficacious daily dose according to the Food and 
Drugs Administration in the USA (Nishtala et al. 2009), 
 
 the DBI was calculated using formula (DBI= Σ D/δ+D) where D 
represented the total daily dose of sedative or anticholinergic medication, 
and δ was the minimum efficacious daily dose according to the British 
National Formulary (Lowry et al. 2011, Mangoni et al. 2013), 
 
 the DBI was calculated using formula (DBI= Σ D/δ+D) where D 
represented the total daily dose of sedative or anticholinergic medication, 
and δ was the minimum efficacious daily dose according to Australian 
approved product information (Wilson et al. 2011, Wilson et al. 2012, 
Best et al. 2013) and 
 
 one study  (Bosboom et al. 2012) did not provide this level of detail.  
 
While these studies provided information on the source of the minimum 
efficacious dose, it is clear that the source varied and hence there is potential 
for lack of consistency if different doses are listed in the different sources. One 
further potential issue may be the lack of detail regarding the classification and 
identification of medicines as ‘anticholinergic’ and/or ‘sedative’.  
   
121 
In general, there was a lack of detailed information on who calculated the DBI 
and whether or not there was any reliability check on the calculation. 
Furthermore, in cohort studies which involved following patients over a period of 
time, it appeared that the DBI was calculated only at one point in time, which 
may not have reflected any changes in medicines. An example would be Wilson 
et al. 2011 (Wilson et al. 2011), DBI was calculated only once (at baseline) and 
medicines may have changed at follow-up. 
 
There were inconsistent approaches to the presentation of DBI scores ranging 
from: percentage of patients with zero scores (total, anticholinergic and 
sedative) (Wilson et al. 2011, Wilson et al. 2012, Best et al. 2013); percentage 
of patients with scores > 0 (total, anticholinergic and sedative) (Bosboom et al. 
2012); mean scores (with standard deviations) (Mangoni et al. 2013); and 
median scores.  (Lowry et al. 2011) While some of the studies presented DBI 
scores as continuous data, others categorised patients as high and low DBI 
scores. It was not always evident what was meant by ‘higher’ etc. Again, this 
diversity of approaches reduces the potential of being able to combine different 
study measures.  
 
ii) what outcomes had been studied? 
 
The aims of all studies were very different and this was reflected in a wide 
diversity of outcome measures, including falls, quality of life etc. As described 
earlier, this meant that a meta-analysis was not appropriate.  
Lowry et al. used the Barthel Index as the main outcome measure. This is an 
established scale, which measures a person’s performance in activities of daily 
living. The secondary outcome measure was the length of the patient’s stay in 
the hospital and in-patient morbidity.  (Lowry et al. 2011) DBI was treated as a 
continuous variable in this study. Higher DBI scores (total, anticholinergic and 
sedative) were found to be significantly and independently associated with lower 
Barthel categories (after adjusting for variables such as age, sex etc.) hence 
lower score for activities of daily living. Similarly, higher DBI scores were all 
found to predict increased length of stay, after adjustment but not in-patient 
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mortality. One limitation is the lack of clarity over the interpretation of ‘higher’ 
DBI scores within the paper.  
 
Wilson et al. calculated DBI at baseline and recorded falls over a 12 month 
period as the outcome measure. (Wilson et al. 2011) A number of covariates 
(e.g. comorbidities, medical history, sociodemographic information) were 
considered. In this study, DBI was treated as a categorical variable (0, <1, ≥1), 
with high DBI (≥1) being significantly and independently associated with falls.  
 
Rosboom et al. used a different categorisation for DBI and classified patients 
taking at least one anticholinergic agent or one sedative agent as DBI (i.e. >0 
DBI). They also identified potentially inappropriate prescribing using the 
modified Beer’s criteria. The outcome measure was the quality of life 
Alzheimer’s disease questionnaire. They found that 78.8% of patients had a DBI 
>0 and that 54.9% had one or more potentially inappropriate medicines 
(according to the modified Beer’s). While the use of potentially inappropriate 
medicines was not associated with the quality of life scores (after adjustment 
for covariates), the DBI score was. (Bosboom et al. 2012) 
 
In a further study, Wilson et al. categorised DBI scores as 0 (none), 0-1 (low) 
and ≥1 (high) and measured mortality data as the outcome. DBI scores were 
presented as mean scores (with standard deviations). While there was no 
association between DBI and mortality, the authors did conclude that the 
sample size was most likely underpowered. (Wilson et al. 2012) 
 
Best et al. used the length of stay and admission for falls or delirium as 
outcome measures related to DBI scores. Additionally, they investigated the 
changes in DBI during hospital stay. DBI scores were categorised as low (<1) 
and high (≥1) and also presented as both mean and median values. While the 
DBI scores reduced during stay, this did not reach statistical significance. After 
adjustment for covariates, those with high DBI scores were three times more 
likely to be admitted for delirium than those with no DBI exposure. No data 
were provided in relation to DBI scores and falls. (Best et al. 2013) 
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As part of a large study, Mangoni et al. calculated the anticholinergic component 
of the DBI scale and presented as median and range. The outcome measures 
were postoperative complications, hospital length of stay, and all-cause 
mortality.  (Mangoni et al. 2013) No independent of postoperative complications 
or increased length of stay were identified. However, many factors, including 
the DBI anticholinergic score were significantly associated with one year 
mortality. 
 
iii) had the use of DBI impacted prescribing of anticholinergic and sedative 
agents in elderly patients in institutionalised care? 
 
Nishtala et al. examined the impact of clinical pharmacist medicines review on 
DBI scores. The DBI scores were calculated retrospectively at baseline (prior to 
review), after the review and after uptake of recommendations by physicians. 
DBI scores were presented as median (and interquartile ranges). The median 
scores decreased significantly after pharmacist review, with the pharmacist 
recommending medicines that lowered the patients’ DBI by an average of 20%. 
(Nishtala et al. 2009) 
 
3.4 Discussion  
The aim of this review was to critically appraise, synthesize and present 
evidence of the use of the Drug Burden Index (DBI) to identify potentially 
inappropriate prescribing of anticholinergic and sedative agents in elderly 
patients in institutionalised care. 
 
3.4.1 Key findings 
One key finding of this systematic review is that there is a lack of studies which 
have focused on any aspect of the use of the DBI in institutionalised care, with 
only seven studies (three cohort studies, three mixed cohort and cross-sectional 
studies and one cross-sectional study) identified. These studies had only been 
conducted in three countries (Australia, the Netherlands, the UK), mostly 
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Australia (n=5). While the studies were generally of high quality, there was a 
lack of sample size justification, particularly for those with research hypotheses 
and this may impact the conclusions. Furthermore, there was a lack of detail on 
the sources of information used to categorise medicines as antcholinergic and/or 
sedative. DBI scores were presented in many different ways, both continuous 
and categorical. DBI scores (or categories) were found to be associated with an 
array of outcomes, including activities of daily living, length of hospital stay, 
falls and quality of life. None of the studies used the DBI prospectively as a tool 
to identify the need to alter potentially inappropriate prescribing; one used it 
retrospectively to check if the pharmacists’ interventions, as part of a medicines 
review service, had resulted in decreased DBI scores, and identified statistically 
significant reductions in scores.  
 
3.4.2 Study strengths and limitations 
A key strength of this systematic review is that it was conducted using the JBI 
approach, with the review protocol being peer reviewed through JBI and 
published (Al Shemeili and Stewart 2014) prior to the review being conducted. 
This highlights that there was a need for the review and a gap in the literature. 
The JBI focuses on supporting reviews which will provide evidence based 
information on effectiveness, meaningfulness, appropriateness, and feasibility of 
healthcare interventions. Best practice was followed in conducting the review in 
that two independent reviewers completed the templates for quality assessment 
and data extraction and indeed the review cannot proceed on the JBI software 
until there is complete agreement.  
 
However, there are several limitations to this review and hence the findings 
should be interpreted with caution. As described, the data extraction and 
synthesis is derived from only seven studies and hence there is a need for 
further investigation into the predictive ability of the DBI in hospitalised older 
people. Also the heterogeneity of study methods and outcome measures 
eliminated the possibility of meta-analysis, hence reducing the strength of 
evidence on the use of the DBI to identify potentially inappropriate prescribing 
of anticholinergic and sedative agents in elderly patients in institutionalised 
care. 
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The DBI has only been studied in three countries and hence there is limited 
information on its use on a global scale. This is particularly relevant to this 
doctoral research which is based in the UAE. Different cultural issues of 
prescribing and medicines use more generally may limit the generalisability of 
the findings.  
 
Due to the lack of qualitative studies identified in the scoping search, the review 
was restricted solely to quantitative studies. There is a clear research gap of in-
depth studies on health professionals’ perspectives of the use, utility and value 
of the DBI in practice. 
 
3.4.3 Interpretation of findings  
Chapter 1 presented the evidence base, derived from systematic reviews, of 
various elements of the medicines management model. While there is evidence 
to support the use of generic tools to support the identification of potentially 
inappropriate prescribing in the elderly, there is less specific guidance around 
anticholinergic and sedative agents. The DBI has potential, hence this 
systematic review was conducted to explore its use in institutionalised care, and 
as a predictive tool. 
 
Only one study used the DBI in the context of medicines management and this 
study used it retrospectively after the pharmacist recommendations to measure 
the impact on DBI scores.  (Nishtala et al. 2009) There is a need to research the 
DBI to support intervention in terms of medicines appropriateness. Such studies 
should have a prospective RCT design (the highest level of evidence) with one 
group of practitioners using the DBI to guide prescribing compared to a control 
group of normal practice.  Studies such as these would require prospective 
calculation of sample size to determine a clinically important difference in 
prescribing at a minimum power of 80%. 
 
In using the DBI, there is a need to standardise the sources of information in 
two regards. The medicines patients are taking at the point of admission to 
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hospital should be determined using the principles of medicines reconciliation 
(as described in Chapter 1) and have consideration of patient adherence.  
(Greenwald et al. 2010, Mueller et al. 2012) Furthermore, there should also be 
emphasis on ‘as required’ medicines as these are excluded from the DBI 
calculation. However, many medicines such as opiate analgesics have significant 
sedative effects.  (Rothberg et al. 2013) In relation to the calculation of the 
DBI, there are several issues to consider. A standard information source should 
be used for the efficacious dose rather than the varied sources used in the 
studies in this review. A standard approach is required for drugs which have 
different doses for different indications. There is also a need to standardise the 
sources for determining whether or not a medicine is classified as 
anticholinergic or sedative.  As described earlier, Duran et al. reported a 
systematic review of anticholinergic risk scales in the elderly, with the aim of 
developing a uniform list of anticholinergic drugs, differentiating for 
anticholinergic properties. (Durán, Azermai and Vander Stichele 2013) Such an 
approach could be useful in relation to the DBI. There is also a need to 
standardise the reporting of DBI scores as either categorical or continuous 
outcomes.  
 
Faure et al. reported a cohort study, conducted in France, to assess exposure of 
anticholinergic and sedative medicines in elderly patients. (Faure et al. 2013) 
Given the issues around global comparison of DBI score (indications and 
dosages varying from one country to another), δ (the minimum efficacious dose 
as approved by the Food and Drugs Administration in the USA) was redefined. 
In order to allow appropriate comparison of DBI across countries, a calculation 
was proposed using a common δ to represent the defined daily dose (DDD), the 
assumed average maintenance daily dose for the most common indication, in 
accordance with the World Health Organization (WHO). This study calculated 
DBI and DBI-WHO for 337 individuals aged 85 and over admitted to three 
geriatric hospitals. The results suggested that DBI-WHO and DBI were 
correlated on admission (correlation coefficient (r) = 0.96, P < 0.001) and on 
discharge (r= 0.97, P <0 .001). The authors concluded that it may be more 
appropriate to use DDD to calculate DBI-WHO which might lead to a quality 
indicator in medicines management.  
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One advantage of the DBI (or DBI-WHO) is that it provides a total score for the 
anticholinergic and sedative burdens as well as the separate components and 
hence may be useful as part of medicines management. This is particularly 
important given the adverse profiles of these agents and hence the outcomes of 
higher DBI scores found in this systematic review have been linked to these 
agents. (Durán, Azermai and Vander Stichele 2013) The seven studies focused 
on different outcome measures related to the prescribing of anticholinergic and 
sedative medicines and hence DBI scores. While this may be strength in 
providing more complete information, it reduced the potential for meta-analysis 
and hence actually weakens the evidence base.  
 
3.4.4 Conclusion 
This systematic review has identified that there is a limited literature base on 
the use of the DBI in elderly, hospitalised patients. However, there appears to 
be a link between higher DBI scores and several outcomes around the risk of 
functional impairment. There is a need for research studies which employ the 
DBI as a tool to guide interventions to promote appropriate prescribing and for 
studies which explore practitioners’ awareness and perspectives of DBI. 
 
3.4.5 Implications for further research phase 
This is the first systematic review of the use of DBI and complements the 
evidence base for other medicines management related tools and processes 
outlined in Chapter 1. Given the reservations highlighted, the DBI may have a 
place in medicines management alongside more generic tools which promote 
rationalisation of potentially inappropriate prescribing and promote appropriate 
prescribing in the elderly. These aspects will be considered as part of a set of 
tools in the next phases of this doctoral research into medicines management.   
 
 
128 
 
CHAPTER 4: Qualitative interviews with health professionals in Abu 
Dhabi 
 
4.1 Introduction to the chapter 
This chapter provides a detailed description of qualitative interpretative 
phenomenological interviews with samples of health professionals (doctors, 
nurses and pharmacists) in a hospital practice in Abu Dhabi. The research aims 
and objectives are provided followed by a description of the method, findings, 
discussion, conclusion and summary.  
 
This research phase focused on medicines management healthcare structures, 
processes and outcomes. A conceptual model and framework for health services 
and quality of care was proposed by Donabedian in 1990, describing the 
elements of structures, processes and outcomes as follows: 
 
 structures, which are the characteristics of the care delivery setting and 
includes attributes of material resources (e.g. facilities, equipment, and 
financing), human resources (e.g. the number of qualified personnel) and 
the organisational structure (e.g. healthcare staff, methods of peer 
review, methods of reimbursement); 
 
 processes, which detail what is actually carried out as part of giving and 
receiving care (e.g. practitioner’s activities in making a diagnosis, 
recommending or implementing treatment, or other interactions with the 
patients);  
 
 outcomes, which attempt to describe the patients’ resultant status of 
health. Improvements in patients’ knowledge and understanding, and 
changes in patients’ behaviours and levels of satisfaction may also be 
included under a broad definition of outcome. (Donabedian  1990) 
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Donabedian (1990) described this framework to facilitate assessing the quality 
of care by providing a structure for examining in detail the elements of 
structures, processes and outcomes. This framework, which is shown in Figure 
4.1, is considered to be flexible enough to apply to many situations.  
 
 
 
Figure 4.1: the relationship between the three related concepts of structures, 
processes and outcomes. (Donabedian A.1980) 
 
Donabedian’s model is a linear framework which has been criticised for being an 
over simplification, omitting key factors such as individual patient characteristics 
and environmental features that may significantly impact assessment of quality 
of care. Coyle and Battles proposed a modified framework which considers 
antecedents in addition to structural and care process variables impacting the 
resultant outcome of care. (Coyle and Battles 1999) 
 
Antecedents are described as those factors that affect the structures, processes 
and outcomes and are thought to have the greatest impact on resultant 
outcomes. These comprise the environmental context of an individual, an 
individual’s characteristics (e.g. genetics, socio-demographics, health habits, 
beliefs attitudes, preferences) and environmental factors (e.g. social, cultural, 
political, personal, physical).  
 
The research in this chapter describes medicines management healthcare 
related structures, processes and outcomes in relation to the patient journey 
or flow from the point of admission to hospital to the point of discharge back 
to the patient’s home or other care setting. The terminology of Donabedian is 
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employed, while also considering the expanded list of variables of Coyle and 
Battles. 
 
Modern hospitals and health services are organisationally complex 
entities, employing several thousand staff working in professional, functional 
and geographical groups. Each of these groups has an internal, usually 
hierarchical structure, and traditionally orientates its work by the views held 
within its dominant professional or organizational membership. Patients, 
however, move horizontally across healthcare settings, primary care based 
medical practices and hospitals. Their journeys take them from unit to unit, 
receiving care from different groups as they go. (NHS Institute 2012) A recent 
report from the UK Health Foundation on improving the patient journey or 
patient flow defined and described the term ‘flow’ as,  
‘the progressive movement of people, equipment and information through a 
sequence of processes. In healthcare, the term generally denotes the flow of 
patients between staff, departments and organisations along a pathway of 
care’. (The Health Foundation2013) 
 
In addition, flow is about the how, where, when and who of care provision, and 
not about the what of clinical care decisions. Flow is described in terms of  
 
 how services are accessed, 
 
 when and where assessment and treatment are available and 
 
 who it is provided by. 
 
Increasing efficiency (i.e. improving quality and reducing costs) has traditionally 
been the responsibility of different functions (and executives) across healthcare 
organisations. It is understood increasingly that these are inextricably linked. 
(NHS Institute 2012) Improving structures, processes and outcomes of care is a 
shared agenda; the full benefit is only achieved if a co-ordinated patient 
pathway approach is taken across all departments.  
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In terms of medicines management, there is a need to understand the 
structures, processes and outcomes throughout the patient journey or flow. 
These structures, processes and outcomes will also be considered in relation to 
aspects previously described in this thesis, specifically: medicines review, 
medicines reconciliation, medicines adherence and potentially inappropriate 
prescribing. 
 
4.1.1 Aim and objectives 
The aim of this phase of the research was to explore the views, experiences and 
perceptions of health professionals in Abu Dhabi in terms of the medicine 
management healthcare structures, processes and outcomes for elderly, 
hospitalised patients.  
 
The detailed objectives were to explore health professionals’ views, experiences 
and perceptions of the following: 
 
i. medicines related issues (e.g. selection, adverse drug reactions, 
adherence), 
 
ii. current healthcare structures (e.g. personnel, resources) and processes 
(e.g. training, documentation, communication) of medicines 
management, 
 
iii. potential to optimise patient outcomes (e.g. clinical, economic) and 
 
iv. changes to structures and processes (e.g. personal, professional, 
organisational etc.) required to optimise patient outcomes. 
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4.2 Methods 
4.2.1 Research Design 
A qualitative interpretative phenomenological methodology of in-depth semi-
structured, face-to-face interviews with samples of those health professionals 
most involved in medicines management was employed. This was considered 
most appropriate in terms of the research aim to provide in-depth, rich 
information around views, experiences and perceptions of medicines 
management. As described in chapter 2, interpretative phenomenology seeks to 
generate rich description and understanding of the phenomenon of medicines 
management in elderly, hospitalised patients.  
 
Qualitative research and the use of open-ended, in-depth, probing questioning 
gave the participants the opportunity to respond in their own words, rather than 
forcing them to choose from the fixed responses of quantitative approaches.  
 
Face to face interviews of health professionals in Abu Dhabi were undertaken for 
this research. This was considered to be the most appropriate method of data 
generation to allow participants from a range of backgrounds, professions and 
experiences to talk about their personal views and perceptions without 
potentially being inhibited when openly discussing and sharing information with 
others. For example, less experienced nurses or pharmacists might not discuss 
fully issues of poor prescribing practice in the presence of high-grade medical 
staff in a focus group setting, with implications for data trustworthiness.  
 
4.2.2 Setting 
This research was conducted within Abu Dhabi, which is one of the seven 
Emirates. Abu Dhabi was selected for this research phase for several reasons as 
follows: 
 
i. Abu Dhabi is largest in terms of geographical size and population 
numbers, has the highest rate of healthcare expenditure and more 
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established governance systems than the other zones. (National Bureau 
of Statistics 2010), 
 
ii. sampling of health professionals within this zone provided a range of 
views, experiences and perspectives which were likely to be transferable 
to the other zones and 
 
 
iii. for logistical reasons of resources and time which would have been 
incurred in travelling to other zones. 
 
Conducting the research within Abu Dhabi was likely to generate research 
findings which could be transferred to the other six Emirates within the UAE, 
and potentially the Middle East and beyond.  
 
Eighteen public hospitals and institutions in Abu Dhabi (shown in Figure 4.2) 
had been authorised by HAAD to conduct research studies on human subjects.  
(SEHA annual report 2012)  
 
 
 
Figure 4.2: Map of Abu Dhabi, highlighting the location of all 18 hospitals 
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Table 4.1: The hospitals and institutions in Abu Dhabi authorised to conduct 
human research (adapted from SEHA annual report 2012) 
 
1- Sheikh Khalifa Medical City 
SKMC’s staff numbers more 
than 4183. It has total capacity 
of roughly 764 beds.  
 
 
2- Corniche Hospital 
Corniche is the UAE’s leading 
referral hospital for obstetric 
and neo-natal care. It has a 
professional staff of about 
1,200.  
 
3- Ambulatory Healthcare 
Services 
AHS operates 62 ambulatory 
and primary healthcare clinics. 
The four AHS subsidiaries are 
Ambulatory Care Centres 
(ACCs), Disease Prevention & 
Screening Centres (DPSCs), 
School Health Services (SHS) 
and Mobile Clinic Solutions 
(MCS).  
 
4- Abu Dhabi Blood Bank 
Abu Dhabi Blood Bank is the 
major donor centre and blood 
bank in Abu Dhabi. It is part of 
the Transfusion Medicine 
Services Division of the 
Department of Laboratory 
Medicine at Sheikh Khalifa 
Medical City (SKMC).  
 
5- Mafraq Hospital  
Mafraq Hospital has a bed 
capacity for roughly 451 beds 
 
6- Mafraq Dialysis Centre 
Mafraq Dialysis Centre is a 
state-of-the-art dialysis clinic 
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and a professional staff of 
almost 2000.  
situated in Mafraq. 
 
7- Al Rahba Hospital 
Al Rahba is a 114-bed hospital 
with a professional staff of 
about 845.  
 
8- Al Ain Hospital 
Al Ain hospital is a 412-bed 
hospital. It has a professional 
staff of 2000. 
 
9- Tawam Hospital 
Tawam Hospital has 461 beds 
and a professional staff that 
numbers over 3400.  
 
10- Al Wagan Hospital 
Al Wagan Hospital is a primary 
care and critical access 
hospital with two wards, 
ambulatory treatment clinics, 
general dentistry facilities, and 
a critical access emergency 
department. 
 
11- Al Sila Hospital 
Sila Hospital is a 36-bed facility 
with a total staff of 16 doctors, 
40 nurses, 17 allied health, and 
15 administrative personnel.  
 
12- Dalma Hospital 
Dalma Hospital provide 
emergency services as well as 
specialised medical care in the 
fields of Internal Medicine, 
Paediatrics, Obstetrics and 
Gynaecology, General Surgery 
and Dialysis.  
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13- Ghiathy Hospital 
Ghiathy Hospital is a 30-bed 
facility with a team of 22 
doctors, two surgeons, 48 
nurses, and 20 technicians and 
paramedics.  
 
14- Marfa Hospital 
Marfa Hospital is a 28-bed 
rural community secondary 
hospital with a professional 
staff of 20 physicians and 
surgeons, 49 nurses, and 26 
technicians and paramedics.   
 
15- Madinat Zayed Hospital 
Madinat Zayed is a 155-bed 
secondary hospital. It is well 
equipped and provides all basic 
and specialized medical 
services. 
 
16- Liwa Hospital 
Liwa Hospital provides 
emergency services as well as 
outpatient services in the fields 
of General Medicine, 
Paediatrics and Mother and 
Child Health.   
 
17- Zayed Military Hospital 
Zayed Hospital is a 365-bed 
tertiary care hospital. It 
provides medical services to the 
families of the UAE Armed 
Forces with a professional staff 
of about 2000. 
 
 
18- Imperial College London 
Diabetes Centre  
Imperial College Diabetes 
Centre is a one-stop, state-of-
the-art, outpatient facility that 
specialises in diabetes 
treatment, research, training 
and public health awareness. 
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The sampling frame comprised these 18 hospitals. The following sample 
inclusion criteria were applied: 
 
i. hospitals within Abu Dhabi city centre, for reasons of logistics considering 
distance to travel for interviews. 
 
ii. hospitals with more than 250 beds, to provide a sample of health 
professionals most likely to have a range of views, experiences and 
perceptions. 
 
Six hospitals met these criteria, one of which was excluded as it cared for 
obstetric and neonatal patients thus interviewing these staff would not have 
provided data useful to the research aims and objectives.  
 
The research was conducted in five major hospitals in Abu Dhabi which were: 
  
i. Sheikh Khalifa Medical City (SKMC)  
ii. Al Ain Hospital 
iii. Tawam Hospital 
iv. Mafreq Hospital 
v. Zayed Military Hospital 
 
The five study hospitals provided care for 85% of the Abu Dhabi population. 
(SEHA annual report 2012) 
 
4.2.3 Research governance 
The research was reviewed and approved by the following: 
 
i. the ethical review panel of the School of Pharmacy and Life Sciences at 
Robert Gordon University (see Appendix 4.1) 
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a. a detailed research protocol was prepared and reviewed by team 
research members. 
b. the protocol was submitted to the ethical review panel and 
approval received four weeks later. 
 
All five hospitals had independent ethical review processes, documentation, 
requirements and committees. Approval was sought and obtained from: 
 
i. Ethics and Research Committee in Al Mafraq Hospital (see Appendix 4.2) 
a. the completed ethical application form for Mafreq Hospital and the 
ethical approval letter from the School of Pharmacy and Life 
Sciences at RGU were submitted online to the Ethics and Research 
Committee at Al Mafreq Hospital. 
 
ii. Al Ain Hospital Ethics Committee (see Appendix 4.3) 
a. the completed ethical application form for Al Ain Hospital and the 
ethical approval letter from the School of Pharmacy and Life 
Sciences at RGU were submitted online to Ethics Committee at Al 
Ain Hospital. 
 
iii. Institutional Review Board/Research Ethics Committee in SKMC (see 
Appendix 4.4) 
a. the completed ethical application form of SKMC and the ethical 
approval letter from the School of Pharmacy and Life Sciences at 
RGU were submitted online to Institutional Review Board/Research 
Ethics Committee (IRB/REC) at SKMC. 
 
iv. Al Ain Medical District Human Research Ethics Committee in Tawam 
Hospital (see Appendix 4.5) 
a. the completed ethical application form of Tawam Hospital and the 
ethical approval letter from the School of Pharmacy and Life 
Sciences at RGU were submitted online to Ethic & Research 
Committee at Tawam Hospital. 
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v. Ethic and Research Committee in Zayed Hospital (see Appendix 4.6) 
a. the completed ethical application form of Zayed Hospital and  the 
ethical approval letter from the School of Pharmacy and Life 
Sciences at RGU were submitted online to Ethics Committee at 
Zayed Hospital. 
b. in addition, the researcher had to present for a face-to-face 
interview with the ethical committee at Zayed Hospital. The 
interview focused on research method, participants’ recruitment 
and data generation. 
 
All approvals were in place prior to sampling and recruiting any research 
participants. Throughout the research, all study materials were stored in 
accordance with the Standard Operating Procedures of the School of Pharmacy 
and Life Sciences and the governance policies of Robert Gordon University. 
Signed, informed consent was obtained from all participants. 
 
4.2.4 Participant inclusion and exclusion criteria 
The inclusion criteria were those health professionals mainly involved in 
medicines management (i.e. doctors, nurses and pharmacists) and also working 
in hospitals in the public sector within Abu Dhabi. Those working in specialties 
not caring for elderly patients (e.g. maternity and paediatrics) were excluded.  
 
4.2.5 Participant sampling 
This total sampling frame of the five hospitals was estimated to be around 
1,000 health professionals. This estimation was based on the experience of the 
researcher, who had five years’ experience working as a hospital clinical 
pharmacist in Abu Dhabi, and one of the supervisors who was a leading hospital 
consultant physician with many years of experience in Abu Dhabi. The hospitals 
were unable to give the likely numbers of professionals meeting the inclusion 
criteria.  
 
Sampling was undertaken purposively to explore a range of views, experiences 
and perceptions of medicines management in elderly, hospitalised patients. 
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Several authors describe purposive sampling (also referred to as judgmental, 
selective or subjective sampling) as a non-probability sampling technique.  
(Mack et al. 2005), (Bowling  2009) and (Garson  2012)  This approach was 
selected over other forms of sampling described in chapter 2 for several 
reasons: it was most appropriate for the research aim and qualitative design; it 
was most likely to generate rich and complex data arising from diversity in 
views, experiences and perceptions; and offer further insight into factors that 
might not have been considered.  Francis et al. (2010) describe that purposive 
sampling conducted using pre-specified `stratification’ factors will lead to 
heterogeneity in the sample. The `stratification’ factors used in this study were: 
profession, years of experience, training and countries of practice. These were 
considered by the research team to be key variables in forming views, 
experiences and perceptions, although it was acknowledged that there could be 
other non-identified factors. 
 
4.2.6 Participant recruitment 
As information around these sampling criteria was not easily available, a two 
staged process of sampling and recruitment took place. The process of 
participant recruitment, including ethical approval in the UAE, is given in Figure 
4.3. 
 
Stage 1 
All doctors, nurses and pharmacists working in the five study hospitals were 
emailed. As part of the ethical approval, it was agreed that the human 
resources department of each hospital would send the invitation email. The text 
for the email was drafted and agreed by the research team (see Appendix 4.7). 
The email also contained the following: 
 
i. a link to the participant information leaflet (see Appendix 4.8) which was 
developed according to the guidance for National Health Service (NHS) 
ethical committee submissions in the UK. (National Research Ethics 
Service 2011) 
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ii. a short online sampling questionnaire (see Appendix 4.9). The 
questionnaire contained items on profession, years of experience, 
education and training, and countries of practice. 
 
iii. instructions for those working with elderly patients (i.e. those over the 
age of 60 years) to express their interest in participation in the research 
interviews by completing and submitting the questionnaire electronically. 
 
The questionnaire was developed in Survey Monkey.  
 
Stage 2 
Responses to the questionnaire were collated and used to purposively select 
participants. Those selected were contacted by email to arrange a convenient 
location, date and time of interview. 
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Participant Recruitment
 
 
Health Authority of 
Abu Dhabi (HAAD)
 
To identify authorised hospital for 
clinical research in Abu Dhabi
Tawam Hospital
(Ethical application 
submitted online) 
Mafreq Hospital
(Ethical application 
submitted online) 
Al Ain Hospital
(Ethical application 
submitted online) 
Zayed Hospital
(Ethical application submitted 
online+ interview face to face) 
SKMC
(Ethical application 
submitted online) 
18 hospitals authorised for clinical 
research in Abu Dhabi
Five major hospitals selected for 
research
 
IRB/REC  
SKMC
 
 
Al Ain Ethics 
Committee
 
 
 Al Ain Medical 
District (HREC)
 
ERC
Mafreq
ERC
Zayed
8 weeks to get Ethical 
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8 weeks to get Ethical 
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8 weeks to get Ethical 
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approval from
8 weeks to get Ethical 
approval fro
8 weeks to get Ethical 
approval from
8 weeks to get Ethical 
approval fro
8 weeks to get Ethical 
approval from
8 weeks to get Ethical 
approval fro
 
Nurses 
Pharmacists 
Doctors
 
 
Nurses 
Pharmacists 
Doctors
 
 
Nurses 
Pharmacists 
Doctors
 
 
Nurses 
Pharmacists 
Doctors
 
 
Nurses 
Pharmacists 
Doctors
 
Invitation email sent 
from HR to 
Invitation e ail sent 
fro  HR to 
Invitation email sent 
from HR to 
Invitation e ail sent 
fro  HR to 
Invitation email sent 
from HR to 
Invitation e ail sent 
fro  HR to 
Invitation email sent 
from HR to 
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 Participant 
Information Sheet
 Short Online 
Questionnaire
 Participant 
Information Sheet
 Short Online 
Questionnaire
 Participant 
Information Sheet
 Short Online 
Questionnaire
 Participant 
Information Sheet
 Short Online 
Questionnaire
 Participant 
Information Sheet
 Short Online 
Questionnaire
Email containedE ail contained Email containedE ail contained Email containedE ail contained Email containedE ail contained Email containedE ail contained
 
Responses to the questionnaire were collated 
and used to purposively select participants 
 
6 weeks were given to 
participate in the research
6 weeks were given to 
participate in the research
 
Figure 4.3: the process of ethical approval and participant recruitment 
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4.2.7 Sample size 
Marshall  (1996) states quite simply that,  ‘an adequate sample size for 
qualitative research is one that appropriately answers the research question’, 
noting that the quality of data generated is more important than either the 
number of participants or volume of data.  He later comments that, ‘in practice, 
the number of required subjects usually becomes obvious as the study 
progresses, as new categories, themes or explanations stop emerging from the 
data (data saturation)’. 
 
Glaser and Strauss  (1967) describe the concept of data saturation as the point 
in data generation when no new additional data are found that develop aspects 
of a conceptual category. Guest, Bunce and Johnson (2006) claim that 
saturation has ‘become the gold standard by which diversity samples are 
determined in health science research’.  
 
Francis et al. (2010) more recently suggest an alternative approach for 
determining the point of data saturation. Their approach is described in terms of 
four principles, illustrated as follows:  
 
i. initial analysis sample - the researchers should first specify a priori the 
sample size at which the first round of analysis will be complete. 
 
ii. stopping criterion - Francis et al. (2010) describe that ‘the researchers 
should specify a priori how many more   interviews will be conducted, 
without new shared themes or ideas emerging, before the research 
team can conclude that the data saturation has been achieved’.  
 
iii. independent coders - the initial analysis sample should be reviewed 
independently by a member of the research team to promote rigour. 
 
iv. the data saturation methods and findings should be reported so that 
the readers can evaluate the evidence (credibility).  
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The approach described by Francis et al. was adopted in this study, with an 
initial analysis sample size of 15 (5 each for doctors, nurses and pharmacists). 
The stopping criterion was tested after each of two consecutive interviews. As 
the study included three different professions, each profession had two 
consecutive interviews until no additional themes or viewpoints emerged, as 
depicted in Figure 4.4. Two independent researchers coded the interviews and 
made comparisons before confirming that data saturation had been achieved. 
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Sample Size
(n)
 
Initial analysis 
sample
(15)
 
Pharmacists
(5)
Doctors 
(5)
Nurses
(5)
 
Coded and themes by two independent researchers 
 
 
Nurses
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Doctors
 
Add 2dd Add 2dd Add 2dd 
 
No new themes 
emerging from 
interviewing 
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emerging from 
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r ctic )
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Figure 4.4: process of sampling and data saturation 
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4.2.8 Data generation  
The interviews were arranged at the convenience of the participants, with 
informed consent (see Appendix 4.10) obtained prior to the interview 
commencing. The interviews were audio-recorded using a digital voice recorder 
(Olympus-WS811). 
 
A semi-structured face-to-face approach was employed to allow for collaborative 
(researcher and participant) contribution to the content of the interviews. The 
interview schedule was developed with reference to two key theories/ 
theoretical frameworks: NPT and TDF, as described in chapter 2. 
 
May and Finch (2009) highlight the importance of theory in research, noting the 
relevance of NPT to healthcare research, ‘material practices become routinely 
embedded in social contexts as the results of people working, individually or 
collectively, to implement them’. This happens through the four mechanisms of 
the NPT, which are coherence (what is the work?), cognitive participation (who 
does the work?), collective action (how does the work get done?) and reflexive 
monitoring (how is the work understood?).  
 
As described in Chapter 2, the TDF summarises key elements of 33 theories 
with determinants of behaviour or practice clustered into 14 domains. Those 
domains most relevant (professional role and identity, beliefs about capabilities, 
beliefs about consequences, goal, knowledge and environmental context and 
resources, see Table 4.2) were used to guide construction of the interview 
schedule, which was organised around structures, processes and outcomes 
throughout the patient journey. While the emphasis was placed on these six 
domains during the interview, the interviewees were also invited to add any 
other relevant information.  
 
The interview schedule was reviewed by members of the research team, which 
included a leading international pharmacy practice educationalist, a 
psychologist, a pharmacist with strategic development experience, and a 
leading medical consultant from the UAE.  The interview schedule was then 
piloted with two academics at RGU with significant hospital clinical pharmacy 
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experience, following which minor modifications were made to question 
sequencing and wording (credibility). The final interview schedule is given in 
Appendix 4.11.  
 
Table 4.2 illustrates the mapping of selected items of the interview schedule to 
the theories i.e. NPT and TDF. 
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Table 4.2: Mapping of selected items of the interview schedule to the theories 
(NPT and TDF) 
 
Normalization Process Theory 
 
Mechanism  
 
Key content of interview schedule items 
Coherence 
Defines and organises the components 
in an implementation process 
Perceptions of the overall goals of the 
different processes involved in the 
medicines management model 
Cognitive participation 
Work that defines and organises the 
actors involved in an implementation 
process 
Which profession is responsible for and 
undertakes specific processes (e.g. 
medicines history taking) in relation to 
medicines management  
Collective action  
Work that defines and organises the 
enacting of an implementation process 
What detailed tasks are actually carried 
out in delivering any process (e.g. 
medicines history taking) 
Reflexive monitoring 
Defines and organizes assessment of 
the outcomes of an implementation 
process 
How effectiveness each task is 
monitored; any changes made of 
processes  
Theoretical Domains Framework 
 
Domain Key content of interview schedule items 
 
Professional role & identity  Descriptions of the current roles of 
different health professionals 
throughout the medicines management 
processes 
Beliefs about capabilities Views on how well they carried out 
these processes  
Beliefs about consequences Perceptions of the resultant effect of 
performing processes  
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Goals Perceptions of why a process is 
delivered 
Environmental context and 
resources 
What structures are employed (e.g. 
documentation etc.) and in which 
setting 
Knowledge 
 
Knowledge of SOPs, tools (e.g. DBI, 
Beers and STOPP/START)  
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4.2.9 Data Analysis 
Oliver, Serovich and Mason (2005) describe the differences between the two 
most commonly used transcribing techniques: naturalised (verbatim) in which 
every utterance is transcribed in as much detail as possible; and denaturalised, 
in which idiosyncratic elements of speech (for example stutters, pauses and 
nonverbal speech and involuntary vocalisations) are removed. Each interview 
was transcribed verbatim (ie naturalised) as soon as possible following the 
interview to allow further refining of the interview schedule and consideration of 
saturation, and hence the need for further interviews to be determined. The first 
three interview transcripts were reviewed independently by a member of the 
research team to ensure reliability of the transcription process. Each interviewee 
was allocated a code to avoid the need to include interviewee names on the 
transcript. A separate log was maintained linking codes to interviewees.  
 
Bowling  (2009) highlights that qualitative research can result in large amounts 
of richly detailed data and that a very transparent approach to data analysis 
needs to be employed to avoid claims that the findings are highly subjective and 
open to interpretation. Braun and Clarke (2006) suggest that qualitative data 
analysis should consist of identifying, coding with reference to relevant 
theoretical frameworks, and categorising themes. Boyatzis  (1998) defines a 
theme as ‘a pattern in the information that at minimum describes and organises 
the possible observations and at maximum interprets aspects of the 
phenomenon’. 
 
Different processes for thematic analysis were described in detail in Chapter 2 
and are outlined briefly. Braun and Clarke (2006) describe six phases of 
thematic analysis (see Table 4.3) for qualitative research.  
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Table 4.3: Phases of thematic analysis (adapted from Braun and Clarke, 2006) 
1. Familiarisation  Transcribing data, reading and re-reading the data, 
noting down initial ideas. 
2. Generating initial 
codes 
Coding interesting features of the data in a systematic 
fashion across the entire data set, collating data 
relevant to each code. 
3. Searching for 
themes 
Collating codes into potential themes, gathering all 
data relevant to each potential theme. 
4. Reviewing 
themes 
Checking if themes work in relation to the coded 
extracts (Level 1), and the entire data set (Level 2), 
generating a thematic ‘map’ of the analysis. 
5. Defining and 
naming themes 
Ongoing analysis to refine the specifics of each theme, 
and the overall story the analysis tells, generating clear 
definitions and names for each theme. 
6. Producing the 
report 
The final opportunity for analysis. Selection of vivid, 
compelling extract examples, final analysis of selected 
extracts, relating back of the analysis to the question 
and literature, producing a scholarly report of the 
analysis. 
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This approach is very similar to the Framework Approach developed by Ritchie 
and Spencer (2002), which is increasingly and frequently used in healthcare 
research where the research objectives are well defined in advance of any 
fieldwork. Lacey and Luff (2007) describe the Framework Approach in five 
phases of data analysis (see Table 4.4) 
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Table 4.4: Phases of Framework Approach (adapted from Lacey and Luff, 2007) 
1. Familiarisation  Whole or partial transcription and reading of the data. 
2. Identifying a 
thematic 
framework 
This is the initial coding framework which is developed 
both from a priori issues and from issues emerging 
from the familiarisation stage. This thematic 
framework should be developed and refined during 
subsequent stages. 
3. Indexing The process of applying the thematic framework to the 
data, using textual codes to identify specific pieces of 
data which correspond to differing themes. 
4. Charting Using headings from the thematic framework to create 
charts of data to be read easily across the whole 
dataset. Charts can be either “thematic” for each 
theme across all respondents (cases) or by “case” for 
each respondent across all themes. 
5. Mapping and 
interpretation 
Searching for patterns, associations, concepts, and 
explanations in data, aided by visual displays and 
plots. 
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This approach to coding and thematic analysis was considered more appropriate 
than other approaches (e.g. grounded theory) as the research objectives and 
theoretical frameworks were well described and there was no intention to derive 
new theories. (Lacey and Luff 2007) 
 
The development of the coding framework and thematic analysis was also 
undertaken independently by another member of the research team, findings 
compared and discussed to reach consensus. NVivo software 10.0 was used as 
an aid to data management. The process of data generation and analysis is 
given in Figure 4.5. 
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Figure 4.5: Processes of data generation and analysis 
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4.2.10 Promoting research quality 
A number of steps were taken throughout to enhance the rigour of the research.  
Establishing the validity (accuracy or truth) and reliability (consistency) of 
findings in qualitative research is thought to be more problematic than in 
quantitative research. While Bowling  (2009) and Gerrish and Lacey  (2010) 
describe methods to enhance validity and reliability, others argue that these 
concepts are more appropriate to quantitative research and that in qualitative 
research, the concept of trustworthiness may be more appropriate.  
 
Guba  describes trustworthiness as four separate elements of credibility, 
transferability, dependability and confirmability, as described in chapter 2. The 
following measures were adopted to enhance trustworthiness (Guba  1981):  
 
i. the researcher was trained in qualitative interviewing and data analysis 
(credibility, aiming to reduce design and interviewer bias) 
 
ii. the researcher position and stance (as a pharmacist in UAE interested in 
medicines management) were clearly described (credibility, aiming to 
reduce interviewer bias) 
 
iii. members of the research team brought additional perspectives, 
particularly non-pharmacy and psychology (credibility, aiming to reduce 
interviewer bias) 
 
iv. a clearly described sampling strategy was described (credibility, aiming to 
reduce sampling bias) 
 
v. the draft interview schedule was grounded in theory and reviewed 
(credibility, aiming to reduce design bias) 
 
vi. the interview schedule developed iteratively (credibility)  
 
vii. all participants were clearly characterised and described in the results 
(credibility, aiming to reduce reporting bias) 
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viii. participants were given the opportunity to review and comment on the 
transcripts (member checking) (credibility, aiming to reduce reporting 
bias) 
 
ix. the coding framework and thematic analysis were independently reviewed 
by a member of the supervisory team (credibility, aiming to reduce 
design bias) 
 
 
4.3 Results 
4.3.1 Sampling questionnaire  
Eighty-three completed sampling questionnaires were received in response to 
the emails being sent by the human resources department in each of the five 
hospitals. The total number of emails sent in each hospital could not be 
obtained (despite repeated requests) and hence the overall response rate is 
unknown. The respondents were 33 doctors, 31 nurses and 19 pharmacists. 
Table 4.5 gives the summarised questionnaire data and Table 4.6 the 
demographics of the individuals (n=32) agreeing to be interviewed.  
 
 
 
 
 
 
 
 
 
158 
 
 
Table 4.5: Summarised sampling questionnaire data (N=83) 
Questionnaire Item  Response 
categories 
% (n) 
Managing elderly in day-to-day 
work 
Yes 
No 
83%   (69) 
14%   (12) 
Missing (2) 
Years of practice 5 years or less 
6-10 years 
11-15 years 
16-20 years 
21-25 years 
26-30 years 
31-35 years 
More than 35 years 
 
21%   (18) 
25%   (21) 
13%   (11) 
10%    (9) 
15%   (13) 
6%      (5) 
3%      (3) 
2%      (2) 
Missing (1) 
Countries in which practised as a 
health professional  
UAE only  
UAE and other  
38%   (32) 
59%   (49) 
Missing (2) 
Agree to take part in interview  Agree 
Not Agree 
38%   (32) 
55%   (46) 
Missing (5) 
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Table 4.6: Demographic data and codes of those agreeing to be interviewed 
(N=32)  
 
 N, nurse; P, pharmacist; D, doctor. 
 
 
 
 
A-N1 
Nurse 
11-15 years 
Philippine  
T-N1 
Nurse 
6-10 years 
UAE 
Z-N1 
Nurse 
16-20 years 
India 
Z-N2 
Nurse 
6-10 years 
Europe  
M-N1 
Nurse 
16-20 years 
UAE 
 M-N2 
Nurse 
6-10 years 
UAE 
 K-N1 
Nurse 
11-15 years 
Egypt 
K-N2 
Nurse 
5 years or 
less 
Libya 
A-D1 
Neurologist  
21-25 years 
UK 
A-D2 
ICU doctor 
6-10 years 
India 
Z-D1 
Internist  
26-30 years 
USA 
Z-D2 
Internist 
16-20 years 
USA 
K-D1 
GP 
5 years or 
less 
UAE 
K-D2 
Cardiologist  
More than 35  
India 
K-D3 
Cardiologist  
6-10 years 
Pakistan 
M-D1 
Internist 
26-30 years 
Egypt 
M-D2 
ICU 
6-10 years 
Egypt 
A-P1 
Pharmacist  
6-10 years 
Egypt 
A-P2 
Pharmacist 
16-20 years 
UK 
A-P3 
Pharmacist 
5 years or 
less 
UAE 
A-P4 
Pharmacist 
5 years or 
less 
UAE 
T-P1 
Pharmacist 
6-10 years 
USA 
T-P2 
Pharmacist 
16-20 years 
UK 
T-P3 
Pharmacist 
5 years or 
less 
UAE 
Z-P1 
Pharmacist  
21-25 years 
Egypt 
Z-P2 
Pharmacist 
5 years or 
less 
USA 
Z-P3 
Pharmacist 
6- 10 years 
India 
M-P1 
Pharmacist 
16-20 years 
Sudan 
M-P2 
Pharmacist 
21-25 years 
USA 
K-P1 
Pharmacist 
11-15 years 
Oman 
K-P2 
Pharmacist 
16-20 years 
Pakistan 
K-P3 
Pharmacist 
6-10 years 
UAE 
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Saturation of themes was deemed to occur after interviewing 7 nurses, 13 
pharmacists and 7 physicians. Figure 4.6 illustrates the process of purposively 
sampling interviewees, interview setting and determining data saturation. 
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Figure 4.6: Processes of sampling and saturation 
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4.3.2 The key themes emerged from the qualitative interviews 
This section provides a detailed description of each of the key themes and 
subthemes from the perspectives of the different professionals, namely the 
doctors, pharmacists and the nurses.  
 
Theme 1 - Need for appropriate polypharmacy in elderly patients with 
multimorbidities  
One key theme which emerged during data analysis was the need for 
appropriate polypharmacy (‘prescribing of many medicines which are suitable’) 
in this patient group. During discussion, one pharmacist noted the lack of a 
clear definition for polypharmacy, 
“Polypharmacy does not have a clear definition….. “ 
(Pharmacist Z1, Clinical) 
 
While respondents appeared to hold diverse views on aspects of medicines 
management in relation to the goal of achieving appropriate polypharmacy in 
elderly patients, they were largely aware of the association between 
mulitmorbidities and polypharmacy (appropriate or inappropriate).  
 
Subtheme 1 – Consequences of polypharmacy 
Among the many consequences of polypharmacy highlighted by doctors, nurses 
and pharmacists were issues of drug interactions, adverse effects and poor 
adherence, 
“This is again a big issue of elderly patients. They have polypharmacy - 
they have a lot of medications. Sometimes the family does not know the 
medications. Multiple medications for same disease or different disease 
that will make it difficult for the patient and the family. Compliance will 
go down usually. Drug-drug interaction will be high. Side effects will be 
high” 
(Doctor M1, Internist) 
 
“…… but at least with multiple co-morbidities and to treat side effects of 
the major treatment plans we have to give a cascade of medications like 
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if we give aspirin we have to give PPI, and if the PPI causes some sort of 
constipation or diarrhoea we have to treat the constipation or diarrhoea 
with a third medication, and it is a chain reaction” 
(Pharmacist Z1, Clinical) 
 
“We have a lot of these patients who especially having multiple medical 
problems. Somehow it is a problem, because some medication we should 
not give it together” 
(Nurse M1) 
 
Subtheme 2 - Responsibilities for managing polypharmacy 
Some doctors were of the opinion that they dealt with the management and 
control of their specialist condition only, and while this may have involved an 
element of polypharmacy in the use of several medicines, they considered 
polypharmacy to be the responsibility of others. As one neurologist described,  
“In my practice, when epilepsy is not controlled I use polypharmacy to kill 
the seizures; we try to stick to the baseline neurologic condition. 
Polypharmacy, usually it is the internist or general medicine doctors who 
figure that out” 
(Doctor A1, Neurologist) 
 
This individual distinguished between the appropriate use of several anti-
epileptics within his specialised field of practice and general polypharmacy 
(whether appropriate or inappropriate) to be the domain of others. 
Several doctors noted the need for specialist and multidisciplinary input. 
“……… If you have a lot of these issues and you have a problem we need 
to involve our clinical pharmacist with these kind of problems especially 
for multiple, polypharmacy.” 
(Doctor A2, ICU) 
 
“As physicians, we should know what the drug-drug interactions are as a 
safety feature, and then we have clinical pharmacists who come in, make 
recommendations” 
(Doctor Z1, Internist) 
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”most of the time these elderly patients have multiple comorbidities. So 
their management actually requires multidisciplinary approach by various 
teams” 
(Doctor A2, ICU) 
 
Many of the pharmacists also considered that they had a clinical role in these 
patients,  
“I will say this is a group of patients who really deserve to have an extra 
effort to optimise their medications” 
(Pharmacist K1, Clinical) 
 
“I take care especially the elderly patients with polypharmacy. I review 
their medication profiles, their labs, their vital signs, and I keep the high-
risk patient at follow-up on daily basis” 
(Pharmacist K2, Clinical) 
 
 “I am seeing the elderly and paediatric are the same. We need to 
carefully look after them and to optimise their drug use.” 
(Pharmacist A2, Clinical) 
 
However, some also commented that the clinical service currently provided was 
not always sufficient, 
“It’s not like optimising. It is hard to reach the optimum goal, but at least 
we are working on it and trying to improve it, see where the gaps are and 
trying to fill it” 
(Pharmacist K3, Clinical) 
 
The current clinical pharmacy service was focused on targeting specific medical 
conditions and drug groups, 
“As much as we can we optimise it, but it is not up to the required 
standards. Like if the patient is facing osteoporosis we are trying to deal 
with it. If the patient has some GERD or other symptoms we are dealing 
with it. We are trying to avoid using sedating agents or anticholinergic 
agents as much as we can, but generally speaking it is not up to the 
required standard” 
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(Pharmacist Z2, Clinical) 
 
Some doctors suggested that a multidisciplinary team approach was needed to 
adequately manage polypharmacy and that should be led by a geriatrician,   
“I emphasize more on multidisciplinary approach. Well, it should be more 
coordinated with direct involvement by the geriatrician. We have certain 
issues regarding this multidisciplinary approach. If different specialties 
have to be involved in dealing with the patient, we have a little bit of 
difficulty in coordinating them” 
(Doctor A2, ICU) 
 
 “I think if we just keep getting that reinforcement and constant 
education from the geriatrician saying don’t do this, don’t do that, it will 
become habit and will give knee-jerk reaction that we don’t have to keep 
doing this” 
  (Doctor Z1, Internist) 
 
None of the nurses interviewed described any role in promoting appropriate 
polypharmacy. 
 
Subtheme 3 - Need for a systematic approach to a full medicines review  
Several doctors and pharmacists discussed the need for a systematic approach 
to a full medicines review in elderly patients. 
“These kind of patients they need analysis, meaning you need to analyse 
their problem like system by system, problem by problem. You don’t take 
them in general like any healthy personal, because they have a lot of 
interactions…….” 
(Doctor A2, ICU) 
 
A similar approach was described by one of the clinical pharmacists,  
“I always first try to understand that what we are treating and how we 
are treating and is there any alternative or easier any solution for this 
regimen to be simplified. So usually I review the medications and I focus 
on the what alternative, whether are extended release or modified 
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release or is there any therapeutic substitution, which is equivalent and 
safe” 
(Pharmacist K2, Clinical) 
 
In undertaking the review, the need to discontinue as many medicines as 
possible was highlighted, particularly in the context of patient safety,  
“We try to avoid unnecessary medications, like lot of patients take B 
complex, which has got no significant role to play, so we just cut down 
those unnecessary medications” 
(Doctor K1, GP) 
 
“……at least eliminate whatever is not important for the patient and put 
what is important and not cause any harm to the patient” 
(Pharmacist K3, Inpatient) 
 
Another approach was the use of fixed dose combinations in order to reduce the 
number of medicines and improve adherence. As one of the doctors stated,  
“Polypharmacy is one of the common term these days because the 
patient comes with multiple illnesses, multiple ailments, and he is having 
hypercholesterolemia, he is having coronary artery disease, he is having 
hypertension, so he ends up taking about four or five medications. If he 
is on two or three antihypertensive medications, we have a got a 
combination of two or three in one pill, so we try to give one pill with the 
three-in-one, which reduced three tablets to one tablet”. 
(Doctor K1, GP) 
 
 “The patient will not take his medicines after seeing this, you know 
number of medicines. So sometimes, I say, “sir, doctor, why don’t you 
just go for this polypill”” 
(Nurse Z1) 
 
Some senior doctors were of the view that after specialist care in hospital, 
elderly patients with multimorbidities required regular input from a health 
professional to provide more general care, 
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“Get some geriatrician after our primary care as a cardiologist or as acute 
problem has been resolved, the patient should be followed up with 
someone more close, more free, and more frequent” 
(Doctor K2, Cardiologist) 
 
Subtheme 4 - Contribution of healthcare structures and processes to 
inappropriate polypharmacy  
Several aspects of the structures and processes of the healthcare system in the 
UAE were discussed by doctors, nurses and pharmacists. They considered the 
system to be contributing to inappropriate polypharmacy. These included: 
individual patients being treated by multiple prescribers, sometimes for the 
same indication; poor documentation; and a lack of inter- and intra-professional 
communication. These aspects were highlighted by a junior doctor,  
“….. they shift from one doctor to another and nobody explains to them. 
You know, some of the medications have the generic name and different 
trade names and they keep using both, they do not know about it…… I 
look at the medication compared to the system we have in the chart. The 
problem, many times there is no documentation about the medication” 
(Doctor Z2, Internist) 
 
“I think, physicians when they prescribe they are not checking each other 
which the doctor prescribed and he will just come and prescribe and go” 
(Pharmacist M2, Clinical) 
 
“If the patient comes like, goes to the facilities under SEHA, then we can 
follow it through Cerner, our program, but he went to private sectors, so 
in this case we will ask him and take the information from the patients or 
caregiver or family member and this happens through the nurse mainly.” 
(Pharmacist K3, Clinical) 
 
“Sometimes when we are talking with the patient and sometimes they 
will bring their medication. They have two bags of medication which — 
almost the same generic name but different brand name”. 
(Nurse A1) 
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Theme 2 – Need for systematic approach to medicines history taking 
All interviewed highlighted the need to obtain an accurate, up to date, list of 
medicines being taken at the point of admission to hospital. 
 
Subtheme 1 – Sources of information  
Interviewees described one particular issue of obtaining information from 
elderly patients who could be confused and the need to use as many sources of 
information as possible including family members and carers. While this was 
described in the context of all patient admissions, the issues of multimorbidities 
and polypharmacy in the elderly highlighted the need for a systematic 
approach.  
“We have something called medication reconciliation in the hospital in 
which we have the patient medications like home medications. We usually 
ask them to bring their medications so that anything not available in the 
patient charts so that we enter those medications that are taken from 
even from outside from retail pharmacies, from other hospitals” 
(Pharmacist T1, Clinical) 
 
“I try to gather whatever from the online record or record whatever, but 
still I will ask the family to bring it. Because this is very important to 
know what the patient is on, what to continue, what to hold, and later on 
after discharge … This is again a big issue of elderly patients. They have 
polypharmacy - they have a lot of medications. Sometimes the family 
does not know the medications” 
(Doctor M1, Internist) 
 
“I look at the admission note from the primary, you know from the 
internal resident, see what medications they are and they call me as 
consultant of the patient, I go through that and I usually go to the patient 
room and ask them. Patients’ especially elder ones they are hard-headed. 
They do not listen. They go from one doctor to another and they keep 
sometimes taking the same medications on different names” 
(Doctor Z2, Internist) 
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 “We are asking them to bring from home all of their medications and we 
are checking all of the medications and we are asking them “do you have 
any issues with such medications, “are you taking this regularly?” “What 
is your routine?”, “what is the time you are taking?”  
(Nurse K1) 
 
Some noted issues of elderly patients when being able to provide full and 
accurate medicines history,  
”If the patient came to our hospital confused or disoriented, we always 
check who sit or taking care of the patient at home. So we ask the 
caregiver about the patient in term of his medication, his physical status, 
also his eating and drinking status.” 
(Nurse T1) 
 
During discussion, the pharmacists described in detail the new Hospital 
Information System (HIS) that linked all SEHA hospitals and clinic in Abu Dhabi. 
SEHA chose Cerner as its Health Information Technology supplier because of 
Cerner’s flexible platform and ability to support large-scale implementations 
such as ensuring medication safety, reducing medical errors and improving 
access to information.    
“The good thing about this new system that it covers all the 
governmental hospitals in Abu Dhabi. So you can know what is the drug 
history of our patient who has been admitted in another hospital” 
(Pharmacist K1, Clinical) 
 
One limitation of the system was not linked to private sectors,  
“If the patient comes like, goes to the facilities under SEHA, then we can 
follow it through Cerner, our program, but he went to private sectors, so 
in this case we will ask him and take the information from the patients or 
caregiver or family member and this happens through the nurse mainly.” 
(Pharmacist K3, Clinical) 
 
Some of the pharmacists noted that it was not always clear who was 
responsible for medicines history taking and reconciliation, 
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“Before admission, we have no relation with the patient, but upon 
admission if we receive calls to come to reconcile patients’ medications, 
we go immediate to the point of admission and we reconcile the patient’s 
medications” 
(Pharmacist Z2, Clinical) 
 
On admission, one nurse pointed out that patient medicine’s history always 
taken by an ER doctor, noting that this was not always clear who did it. 
“Actually, we are all secondary for this one because most of this were 
always taken by the doctor .. as per their decision of what were going to 
do with the patient .. “what their problem?” or “their medication” or 
“previous medication or allergies”” 
(Nurse A1) 
 
Another nurse pointed out that the use of pharmacist for medicines history 
taking and reconciliation was not consistent, 
“documentation … first patient admitted in ER then we inform the doctor 
and then the doctor will document all medication history. But all the 
documentation happened after the admission and sometimes we asked 
for help from clinical pharmacist” 
(Nurse T1) 
 
Theme 3 – Need to improve communication and documentation  
Generally, doctors, nurses and pharmacists all highlighted the need for more 
effective and efficient multidisciplinary team working around aspects of 
medicines management when caring for elderly patients with multimorbidities. 
They described particular issues relating to poor intra and interdisciplinary 
communication or documentation.  
 
Subtheme 1 - Lack of communication  
Several doctors stressed the need to improve communication at all levels,  
“We have certain issues in communication which will be resolved by 
multidisciplinary approach. For example if different specialties have to be 
involved in dealing with same patient, we have a little bit difficulty in 
coordinating them”   
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(Doctor A2, ICU) 
 
One doctor used the whole team (i.e. doctor, pharmacists and nurses) on the 
same patient to minimise poor communication, noting that this approach was 
not used by all. 
“Sometimes, there is gap. It is different from doctor to doctor. I try 
usually to have the whole team on the same patient” 
(Doctor M1, Internist) 
 
Pharmacists also noted issues related to the processes of communicating with 
doctors. As described by one respondent, different modes of communication had 
been tried and none were particularly met their expectations,  
“We are trying verbal communication, also electronic communications, 
sometimes we will put notes on patient’s profile, so the physician can look 
at it, but the communication in general is, we are not meeting our 
expectations with communication. Physicians they don’t have specific 
time to be available for us as a pharmacy. We are trying to reach them, 
but sometimes they are busy with other patients “ 
(Pharmacist K3, Inpatient) 
 
“I cannot say it is a perfect practice. Communication is also difficult 
between healthcare professionals especially during the peak time or 
during the rush time we have a very difficult way to communicate with 
each other even in the same location. “ 
(Pharmacist Z2, Clinical) 
 
While nurses also described issues of communication, these did not appear to 
be as marked as those described by the doctors and pharmacists. They however 
felt that their communication with the pharmacists was only occasional. 
“It is not that an issue, you know. Because there is a policy control 
everything at the end. But still the lack of communication is there” 
(Nurse M1) 
 
Communication at ward level with the pharmacists was noted to be infrequent,  
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“We are dealing most of the time with doctors. When it comes to the 
pharmacists, really we are not dealing with them, except if there is 
something that really needs to be adhered we will call the pharmacy” 
(Nurse K1) 
 
Electronic based information was also noted to be problematic, as described by 
one doctor,  
“Because the communication nowadays is computer-based, meaning that 
I see the patient, I read the note, and I think the other doctor will read 
my note and exclude the information from the note, but this usually does 
not happen” 
(Doctor K1, GP) 
 
Pharmacists viewed the same electronic system more favourably, considering 
the Hospital Information System (HIS) to be an effective tool in enhancing 
communication, 
“The HIS is a very good tool for communication. Whenever there is 
something that needs to be communicated, the emails are a second tool 
to use, the system gives us the privilege you can address these notes to 
the MRP (most responsible physician), so it goes to him as an email or as 
a note to alert him that there is something to be considered” 
(Pharmacist K1, Clinical) 
 
Subtheme 2 - Lack of documentation  
There were mixed views on the quality and extent of documentation of 
medicines and medicines related in patient records.  
 
Generally the doctors and pharmacists expressed reservations, with some 
doctors repeating the work of others,  
“It will be medical residents who do it. But I go over it again. You know 
you have to.” 
(Doctor Z1, Internist) 
 
 “I look at the medication compared to the system we have in the chart. 
The problem, many times there is no documentation about the 
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medication. Most people write documentation. Some don’t write it. Some 
write incoherent handwriting” 
(Doctor Z2, Internist) 
 
While most of the pharmacists described a systematic approach to review of 
patients’ medicines and documentation of issues,  
“I go through their medication charts and the labs, and vital signs and if 
there is some feedback, I always give the feedback in verbal and in 
addition I give my medication review also in the patient chart 
documentation.” 
(Pharmacist K2, Clinical) 
 
Several admitted that they did not always record any identified issues,   
“be honest, sometimes I forget to document like, I forget to document on 
daily basis, so sometimes there are something that I forget to document, 
but I try to do my best to document like every intervention I do.” 
(Pharmacist T1, Clinical) 
 
There appeared to be a more defined process if there is an ADR for specific 
medicines as described by some,  
“Number of adverse reaction or number of admission due to adverse 
reaction of drug is extremely low. Any adverse reaction to medications we 
have a protocol to inform to the pharmacy as well as document in the 
literature, patient’s file, and also inform to the nurse and nursing-in-
charge for that patient is probably having sensitivity or adverse reaction 
with particular medication.“ 
(Doctor K2, Cardiologist) 
 
“We will have it in our system under adverse reaction, under medication. 
There is certain part under allergy and there is adverse reaction, and we 
need to document that” 
(Nurse K1) 
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 “Regarding adverse drug reactions, if there was a suspicion that this 
may have been because of a drug, we have an adverse drug reaction 
policy and clear documentation” 
(Pharmacist T1, Clinical) 
 
Theme 4 – Need to improve patients’ adherence to medicines 
The issues of non-adherence of elderly patients were discussed at length. Many 
viewed this as a key issue in the care of elderly patients. 
 
Subtheme 1 – Non-adherence as a consequence of multimorbidities and 
polypharmacy 
Several shared similar views of the links between multimorbidities, 
polypharmacy and adherence, 
“The poor adherence is more frequent compared to overdosing or extra 
doses taken and the poor adherence I think, the polypharmacy is number 
one factor for this “  
(Pharmacist K1, Clinical) 
 
“We try to reduce their medication because you know if the elder patients 
see lots of medication he /she will refuse to take it” 
(Nurse K1) 
 
 “Especially with long-term medications like anti-hypertensive, anti-
diabetes, and bronchodilators, we usually get patients for non-adherence 
to their medication regimen. “ 
(Doctor A2, ICU) 
 
Subtheme 2 – patients’ lack of knowledge   
Doctors, nurses and pharmacists described many issues related to difficulties in 
patients’ knowledge which led to non-adherence.  
 
These issues included the lack of knowledge of the need to continue long term 
therapy, 
“Many patients who have been given medication, after about few months 
they feel comfortable and normally they think why do I am taking this 
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medication. So they start reducing their own and sometimes they stop 
also. Once we crosscheck, patient says nobody told me that this 
medication I have to take lifelong” 
(Doctor K1, GP) 
 
“Some people do not comply.... they stop the medication without the 
knowledge of the doctor, so their blood pressure shoots up, so they come 
to hospital and get admitted” 
(Doctor M1, Internist) 
 
One pharmacist described elderly patients taking more medicine than prescribed 
to gain increased effect, 
 “I think this patient is too worried that he has taken everything that he 
can, not understanding that he has taken the same thing or some 
patients think oh, if one tablet will make my blood pressure lower, oh, if I 
take two it is going to be lowered more. I think it is mostly education part 
in understanding fully what the medicine is, how to take the medicine, 
and what is important about taking medicine” 
(Pharmacist Z1, Clinical) 
 
One described issue of concerns over adverse drug reactions, 
“…. elderly patients say the medicine makes their body more prone to get 
sick and the other thing is lack of education may be and then lack of 
family support” 
(Nurse Z1) 
 
Subtheme 3 – Need for patient/carer/family counselling  
While all interviewees were able to describe at length the need for and 
importance of counselling elderly patients and their carers/family, it appeared 
that this tended to take place at the point of discharge from hospital. 
 
 A range of professionals were involved as described by one pharmacist, 
“First of all, it is the responsibilities for the doctor to tell the patient that 
he is upon discharge and he will tell him what kind of medications he will 
take. On our part as pharmacists, we do the patient counselling and when 
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we dispense medications, give the patient counselling, and also document 
this that we educated the patient about his medications. We try to 
educate the caregiver, educate family members. We try to target many 
caregivers, not only on the caregiver himself, also the family members, 
sometimes anyone who is involved or near to the patient.” 
(Pharmacist K3, Inpatient) 
 
In some instances, the input of pharmacist was targeted at patients prescribed 
high risk medicines, 
“There is a program for counselling the patient on select drugs, which 
have been identified as either high-alert high-risk medications. So I am 
involved in the education of the patients regarding high-alert medications 
like warfarin and some other drugs.” 
(Pharmacist M1, Clinical) 
 
“Any patient who has been on warfarin in the hospital will have to be 
counselled by clinical pharmacist” 
(Pharmacist K1, Clinical) 
 
This approach was also described by nurses, 
“There are some medications some pharmacists will come and explain to 
the patient about it. Certain medications like vancomycin or inhalers and 
all of these will be educated by the pharmacists.” 
(Nurse M1) 
 
One doctor described the importance of counselling family/carer, particularly if 
the patient was cognitively impaired, 
“if they are cognitive impaired, we don’t usually counsel on them, we 
counsel in the caregiver/family … we inform family about the medication 
and why they have to be on this medication and how long they have to 
take it”  
(Doctor A1, Neurologist) 
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None of the interviewees described the need to educate and counsel patients at 
several points during stay, nor the need to focus on aspects other than 
impacting knowledge. 
 
Theme 5 - Need for guidelines and policies to support medicines 
selection 
Several doctors and pharmacists raised aspects such as a standardised 
approach of policies and guidance to support medicines selection in this 
population of patients.  
 
Subtheme 1 - Awareness of and adherence to guidelines and policies  
There were diverse views on organisational and clinician approaches to 
medicines selection. Two pharmacists gave detailed accounts of the 
organisational level approaches in their hospitals, comprising Pharmacy and 
Therapeutic Committees which aimed to provide recommendations on preferred 
medicines to medical staff. While not specifically relating to medicines for 
elderly, hospitalised patients, it was evident that this was a generic approach for 
all patients.  
“Physicians in our hospital they cannot prescribe whatever they want to 
prescribe. We have here what is called ‘pharmacy & therapeutic 
committee’, generates a list for our hospital and this pharmacy and 
therapeutic committee is a multidisciplinary team constitutes from all the 
departments dealing with the drug.” 
(Pharmacist A2, Clinical) 
 
“each hospital has its own PTC [Pharmacy and Therapeutics Committee] 
and then at SEHA level we have the PTC that controls all other PTCs, they 
are controlling the formulary we have, so that, like the physicians have 
only those options and now they are in the process of applying the order 
sets, so I think order sets will also help in limiting the choices.” 
(Pharmacist T1, Clinical) 
 
This pharmacist, however, noted that the process of medicines selection was 
less controlled at the individual doctor level,  
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 “Most of our physicians are basically free to prescribe whatever they 
want” 
(Pharmacist T1, Clinical) 
 
One doctor expressed his frustration in the lack of freedom to prescribe any 
medicine,  
“The problem is a lot of times we do not get the drugs that we want. If I 
give them this antibiotic and they have to jump through a lot of hoops to 
get the medication, are they really going to end up getting it? No. It is 
going to go back to the noncompliance” 
(Doctor Z1, Internist) 
 
There was also a notable lack of use of guidelines and policies to support 
medicines choice and that selection was normally at the discretion of the doctor, 
but acknowledging that specific clinical guidelines may be referred to,   
“It is like physician discretion rather than based on any guideline, but we 
rely on like international guidelines such as for epilepsy, American Heart 
Association in Stroke and then we have other guidelines for so many 
other things” 
(Doctor A1, Neurologist) 
 
Some doctors were of the view that there was a need for the development and 
implementation of guidelines for elderly patients,   
“Elderly – we try to establish guidelines. I think we are a little bit behind. 
We should do even better. There are some policies in the hospital where 
we follow, but I think we should do better, definitely” 
(Doctor M1, Internist) 
 
“There should be more strict policies for elderly patients. So you have to 
be familiar with those medications and side effects and drug-drug 
interaction. So I think if somebody is really focused on this will hopefully 
prevent some side effects or some other issues. So it will be very helpful 
if it is available.” 
(Doctor Z1, Internist) 
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When asked specifically about their awareness and use of any lists of drugs 
potentially inappropriate in the elderly or drugs commonly omitted in the 
elderly, only one pharmacist was aware of Beers Criteria and admitted not using 
routinely,  
“Yes, sometimes. Yeah. It is not always the case, but sometimes I use 
this list and first I got through the idea of this list in 2011 when I was 
doing research from my pharmacotherapy, so I found this article in 
annual of pharmacotherapy, the Beers Criteria, and I shared with other 
colleagues for some patients it is useful and helpful.” 
(Pharmacist K2, Clinical) 
 
The general response from the other pharmacists and all doctors on their 
awareness was, “No, no I am not”. Notably, none of the nurses gave detailed 
responses in relation to questions on medicines selection. 
 
Theme 6 - Need for an educated and trained multidisciplinary team  
Another key theme which emerged during data analysis was the need for a 
focused education and training programme for health professionals to optimise 
all aspect of medicines management. 
 
Subtheme 1 - Need for specialised education and training 
Doctors, nurses and pharmacists strongly proposed that there was an inherent 
need for specialised education and training in medicines management for elderly 
patients, highlighting several issues including medicines selection.  
 
As several doctors stated that they need specific training on elderly medication. 
“You need to have training, because like paediatrics, geriatric population 
needs specific involvement. Even the pharmacokinetics is different like 
the paediatrics.” 
(Doctor A2, ICU) 
 
“Absolutely we need this. We need specialised training, we need courses, 
and we need a lot of issues” 
(Doctor K1, GP) 
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“That will be very helpful. Because in this elderly, there are specific 
medications where you use, which you do not use it in young” 
(Doctor M1, Internist) 
 
“Their doses are different and we cannot give someone adult the same 
dose like young or whatever. They have different way of approaching 
things and drug interaction in the elderly is a little bit different” 
(Doctor Z2, Internist) 
 
Pharmacists were of the view that they needed specialised training to improve 
their skills, 
“I don’t have any specific skills and every time I have to search a lot for 
specific medications whether it can be given or not or what will be 
outcome, what will be the administration of medication especially to these 
patients ....... it would be up to having some specialised training or… I 
personally believe that now is the era of the specialised treatment, so the 
treatment should be optimised…” 
(Pharmacist K1, Clinical) 
 
“If we have someone who is with specialised cares and practices these 
patients get the outcome in a better way, then it will reduce the burden 
on the society” 
(Pharmacist K2, Clinical) 
 
“I would encourage that especially for UAE where we have like, I guess, a 
huge number and large population of elderly people. So to keep this 
valued population, we need to have like someone specialised in this.” 
(Pharmacist K3, Inpatient) 
 
“This population needs, I think, they need a lot of adjustments like 
medication adjustment.. I think that is why there should be someone who 
is specialised who monitor those patients and who know how to do 
adjustments or how to adjust the patient’s medication” 
(Pharmacist T1, Clinical) 
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Nurses’ also shared these views, 
“If there is training, it is really, you know we can improve our knowledge. 
I mean, if anything is lacking, you know, we could understand “ 
(Nurse Z2) 
 
“It is better you have to have a special geriatric nurse for geriatric 
patients. It is better.” 
(Nurse K1) 
 
 
Table 4.7 provides a summary of the themes and subthemes. These are 
mapped to TDF domains (Table 4.8) and NPT mechanisms (Table 4.9).  
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Table 4.7: A summary of key themes and subthemes 
Key Themes Subthemes 
Theme 1  
 
Need for appropriate polypharmacy in 
elderly patients with multimorbidities  
 
Subtheme 1 - Consequences of polypharmacy 
Subtheme 2 - Responsibilities for managing polypharmacy 
Subtheme 3 - Need for a systematic approach to a full medicines review  
Subtheme 4 - Contribution of healthcare structures and processes to inappropriate polypharmacy  
Theme 2 
Need for systematic approach to medicines 
history taking 
Subtheme 1 - Sources of information  
 
Theme 3 
Need to improve communication and 
documentation  
Subtheme 1 - Lack of communication  
 
Subtheme 2 - Lack of documentation  
Theme 4 
Need to improve patients’ adherence to 
medicines 
Subtheme 1 - Non-adherence as a consequence of multimorbidities and polypharmacy 
 
Subtheme 2 - patients’ lack of knowledge   
 
Subtheme 3 - Need for patient/carer/family counselling  
Theme 5 
Need for guidelines and policies to support 
medicines selection 
Subtheme 1 - Awareness of and adherence to guidelines and policies  
 
Theme 6 
 
Need for an educated and trained 
multidisciplinary team  
Subtheme 1 - Need for specialised education and training 
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Table 4.8: Themes and subthemes mapped to TDF domains 
Theoretical Domains Framework 
Domain Themes & Subthemes 
Professional role & identity  
(Coherent set of behaviours and displayed 
personal qualities of an individual in a 
social or work setting) 
Several subthemes mapped to the domain of professional role and identity. Most notably, 
interviewees expressed diverse views around roles and responsibilities in managing 
polypharmacy from those doctors who viewed that their remit was solely around managing 
the conditions within the specialist field of practice to those more concerned with 
polypharmacy (theme 1, subtheme 2). Other similar themes were around less clearly 
defined roles and responsibilities in medicines history taking (theme 2, subtheme 1), 
patient/carer/family counselling (theme 4, subtheme 3), medicines selection (theme 5, 
subtheme 1) and optimising medicine management for elderly patients (theme 6, 
subtheme 1). 
 
Beliefs about capabilities 
(Acceptance of the truth, reality, or validity 
about an ability, talent, or facility that a 
person can put into constructive use) 
While not explicitly discussing beliefs about their individual capabilities regarding the 
different aspects of medicines management, the interviewees emphasised the need for 
specialised education and training in medicines management for elderly patients, 
highlighting particularly the complexities of medicines selection (theme 6, subtheme 1). 
 
Beliefs about consequences 
(Acceptance of the truth, reality, or validity 
about the outcomes of a behaviour in a 
given situation) 
Several respondents highlighted the consequences of polypharmacy in terms of drug 
interactions, the occurrence of adverse effects and poor patient medicines adherence 
(theme 1, subtheme 1). Awareness of these consequences appeared to influence 
behaviours of some interviewees in relation to their practices of conducting full medicines 
reviews in elderly patients (theme 1, subtheme 3). 
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Several interviewees described that the consequences of their experiences of cognitive 
impairment and confusion in elderly patients resulted in them using several sources of 
information (including family members and carers) to ensure as complete a medicines 
history as possible (theme 2, subtheme 1) 
All interviews demonstrated their awareness of the heightened issue of non-adherence in 
elderly patients due to inappropriate polypharmacy (theme 4, subtheme 1), patients’ lack 
of medicines knowledge  (theme 4, subtheme 2) all of which impacted their behaviours 
relating to medicines counselling (theme 4, subtheme 3).  
 
Environmental context and resources 
(Circumstances of a person’ s situation or 
environment that discourages or 
encourages the development of skills and 
abilities, independence, social competence, 
and adaptive behavior) 
Several themes and subthemes mapped to domain of environmental context and resources 
and how these affected behaviours of individuals. Many interviewees commented on the 
issue of individual patients being treated by multiple prescribers, sometimes for the same 
indication, and the problem of poor documentation (theme 3, subtheme 2); and a general 
lack of inter- and intra-professional communication (theme 3, subtheme 1). As a result 
doctors, nurses and pharmacists considered the healthcare system to be contributing to 
inappropriate polypharmacy (theme 1, subtheme 4). 
Several doctors and pharmacists were of the view that more standardised approach to the 
development and use of policies and guidance to support medicines selection would be of 
benefit (theme 5, subtheme 1). 
 
Knowledge 
(An awareness of the existence of 
something)  
Interviewees expressed diverse views around their awareness of polypharmacy and its 
association with interactions, adverse drug reactions, and impacting patient medicines 
adherence (theme 1, subtheme 1). 
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While some interviewees were aware of the existence of international guidelines to support 
their prescribing in the elderly, there was a major gap in knowledge specific tools such as 
Beers, STOPP/START to aid appropriate prescribing and identify potentially inappropriate 
prescribing in the in elderly (theme 5, subtheme 1). 
Goals 
(Mental representations of outcomes that 
an individual wants to achieve) 
Several of the themes and subthemes map to the domain of goals, particularly around the 
need for appropriate polypharmacy (theme 1), need for a systematic approach to 
medicines history taking (theme 2) and need to improve patient adherence (theme 4).  
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Table 4.9: Themes and subthemes mapped to the four mechanisms of NPT 
Normalization Process Theory 
Mechanism  Themes & Subthemes 
Coherence 
Defines and organises the components of a 
practice  
While respondents appeared to be aware of the different processes in relation to medicines 
management in elderly hospitalised patients (i.e. medicines history taking, reconciliation, 
medicines selection, counselling etc.), there appeared to be less coherence around actually 
defining these processes and demonstrating consistent, shared beliefs in a structured 
manner. For example, all were aware of the consequences of polypharmacy (theme 1, 
subtheme 1) but there were varied responses to defining appropriate polypharmacy (theme 
1, subtheme 2). Also there were varied responses in terms of the approach to a full 
medicines review (theme 1, subtheme 3). There was more coherence around the goals of 
patient counselling in relation to medicines adherence (theme 4, subtheme 3).  
Cognitive participation 
Defined and organises the people 
implicated in a complex intervention and 
brings a practice into practice, organising 
ways that people join and support a 
practice 
There were diverse views around task allocation in relation to the different elements on 
medicines management in elderly hospitalised patients. Specific responsibilities and roles 
around managing polypharmacy were unclear (theme 1, subtheme 2), as were those 
relating to conducting medicines reviews (theme 1, subtheme 3).  For example, on 
occasions pharmacists were involved in processes of medicines reconciliation, but this did 
not appear to be a clearly allocated task (theme 2).  
It appeared that doctors, nurses and pharmacists were all involved in patient medicines 
counselling with no clearly defined remit assigned to each profession (theme 4, subtheme 
3) 
However, all interviewees were aware of the need to undertake education and training in 
relation to medicines management in elderly hospitalised patients (theme 6, subtheme 1) 
Collective action  This mechanism related to the actual work or skills involved in delivering the tasks relating 
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Defines and organising the enacting of a 
practice through skill set and task 
allocation, and performance with 
accountability and interconnected work 
to medicines management.  
The actual approach to medicines review varied amongst doctors in different specialties and 
between different professions such as pharmacists and nurses (theme 1, subtheme 3). All 
those involved in medicines history taking described the use of multiple sources in an 
attempt to gather as much information as possible (theme 2, subtheme 1). Interviewees 
were aware of the suboptimal inter and intraprofessional communication (theme 3, 
subtheme 1) and documentation (theme 3, subtheme 2).  
All discussed the need to counsel the family and carers in addition to (and sometimes 
instead of) the patient (theme 4, subtheme 3). There were diverse descriptions of the use 
of policies and guidelines in relation to medicines selection (theme 5, subtheme 1).  
Reflexive monitoring 
Defines and organises assessment of the 
outcomes of a practice in terms of effects, 
communal and individual appraisal 
There was very little description or discussion of how the patient outcomes of the processes 
of medicines management were assessed, either at individual patient or population levels. 
However, many expressed the need of a multidisciplinary team approach for better 
medicines review (theme 1, subtheme 3) and for specialised education and to optimise 
patient outcomes (theme 6, subtheme 1).  
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4.4 Discussion  
This section provides an overview of the key findings in relation to the aims and 
objectives, consideration of the study strengths and weaknesses, discussion and 
interpretation of the findings in relation to the published literature, reflection on 
research progress and how these findings impacted the next phase of the 
research. 
 
4.4.1 Key findings 
The aim of this phase of the research was to explore the views, experiences and 
perceptions of health professionals in Abu Dhabi in terms of the medicine 
management healthcare structures, processes and outcomes for elderly, 
hospitalised patients. 
 
Analysis of the data from 27 qualitative, face to face interviews with doctors, 
nurses and pharmacists in Abu Dhabi identified key themes around their views, 
experiences and perceptions of aspects of medicine management. The key 
themes were around the need for: appropriate polypharmacy in elderly patients 
with multimorbidities; a systematic approach to medicines history taking; 
improved communication and documentation; improved patients’ adherence to 
medicines; guidelines and policies to support medicines selection; and an 
educated and trained multidisciplinary team.  
 
Further analysis mapped these themes to two theoretical frameworks. The TDF 
was used in relation to domains of determinants of behaviour at the individual 
practitioner level. The domains which were most dominant were: professional 
role and identity; beliefs about capabilities; beliefs about consequences; 
environmental context and resources; knowledge; and goals. NPT was used at 
the organisational level with little evidence of coherence, cognitive participation, 
collective action and reflexive monitoring. There is clearly overlap between 
these two theories in that individual behaviours and behavioural determinants 
will influence the organisational activities.  
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For example,  
 
 coherence may be influenced by goals, knowledge and beliefs about 
consequences, 
 cognitive participation may be influenced by professional role and 
identity, 
 collective action may be influenced by knowledge, beliefs about 
capabilities and professional role and identity and 
 reflexive monitoring may be influenced by beliefs about consequences. 
 
4.4.2 Study strengths and limitations 
Prior to discussing and interpreting the findings, there is a need to reflect on the 
strengths and limitations of the study. 
 
There are a number of strengths to this study. To date, while several studies 
have used a qualitative approach to research aspects of medicines management 
(e.g. medicines selection and prescribing) there is an absence of published 
qualitative studies relating to the full spectrum of medicines management 
activities as described in this thesis. (Horne et al., 2001; Chong et al., 2012; 
Cullinan et al., 2014) This study has therefore generated novel knowledge and 
understanding in this area.  
 
Throughout this qualitative study, attention was paid to aspects of research 
trustworthiness. As described earlier (section 4.2.10) consideration was given to 
credibility, transferability and dependability: members of the research team 
brought medicine and psychology perspectives in addition to the pharmacy 
perspective; the sampling strategy was described clearly; the draft interview 
schedule was grounded in theory and reviewed by three expert team members; 
the interview schedule was developed iteratively; and the coding framework and 
thematic analysis were independently reviewed by a member of the supervisory 
team.  
 
In addition, the approach to sample size and determination the point of 
saturation were guided using that described by Francis et al. (2010). Data 
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saturation was considered to be achieved after 27 interviews (seven doctors, 
seven nurses and 13 pharmacists). However, while data saturation was 
obtained for the overall sample, it may have not been achieved for the 
individual professions.  If the interviews had continued to the point of saturation 
in each profession, it is likely that the number of pharmacists would have 
exceeded the doctors and nurses. This may reflect the diverse roles of 
pharmacists and the evolving nature of ward based clinical pharmacy in the 
UAE. There are several other limitations to this study and hence the findings 
should be interpreted with caution. Given their number of steps and processes 
involved in obtaining ethical and management approvals in the UAE, the 
research was limited to five major hospitals and all of these were from the 
public sector. Although qualitative findings do not seek to be generalizable, the 
research was conducted within Abu Dhabi city only and hence the research 
findings may not be transferrable to other hospitals in Abu Dhabi (particularly 
those from the private sector), the other six Emirates within the UAE, the Middle 
East and beyond.  
 
There were several issues around sampling. The total number of doctors, nurses 
and pharmacists with direct patient contact in the five hospitals was an estimate 
due to the unavailability of the numbers of professionals meeting the inclusion 
criteria. This estimation was based on the experience of the researcher and a 
leading hospital consultant physician with many years of experience in Abu 
Dhabi. Furthermore as the email invitation was sent from the human resources 
departments in each hospital, the number of professionals receiving the email 
was unknown.  
 
While the response rate to the sampling survey could not be calculated, the 
total number of responses was very low, and it may have been that those most 
interested in the research topic responded, introducing a response bias and 
affecting the credibility and transferability of the qualitative findings. A 
systematic review of the literature on maximising response rates to online 
surveys reported by Fan and Yan (2010) highlighted several key factors which 
could have yielded a higher response.  The most notable of these would have 
been to have made contacted each member of the sample prior to sending the 
recruitment email. While this may have increased the response, it was not 
   
191 
feasible in this study as the research team had no contact with the sample. 
More pharmacists than doctors or nurses responded to the survey; this 
response may have been due to their awareness that the main researcher was a 
pharmacist and had been a colleague of some. Furthermore, not all survey 
respondents were willing to participate in the interviews. This may have been 
due to a number of factors including: the time commitment for the interview; 
the recoding of the interview; or their perceptions of being identified in any 
study report. Again, these issues may have had implications for data 
trustworthiness. 
 
While combining two theories may have brought benefits in terms of providing 
findings relevant at both individual and organisation levels, this may have 
complicated both undertaking the interviews and data analysis, and also 
impacted the duration of the interviews. Notably, the emphasis was placed on 
selected TDF domains and while interviewees were encouraged to add any other 
relevant comments, the lack of attention placed on domains such as ‘social 
influences’ may have impacted the findings.  
 
4.4.3 Interpretation of findings 
This section is informed by a comprehensive literature search of Medline, 
CINAHL, and International Pharmaceutical Abstracts (see Appendix 4.12 for 
search strategy) of qualitative research in relation to structure and processes of 
medicines management from the health professional perspective. Five relevant 
studies were identified which are described in Table 4.10.  
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Table 4.10: Data extraction for five relevant qualitative studies 
Reference Specified 
Aim/objective 
Setting 
(country, 
institution) 
Design Participants Outcome 
measures 
Key Findings Conclusion 
(Horne et 
al. 2001) 
To elicit the views 
and experiences of 
GPs and hospital 
doctors about 
existing 
arrangements for 
shared care applied 
to the prescribing of 
specialist medicines. 
South 
Thames 
region (UK). 
Qualitative 
study based 
on semi-
structured 
interviews. 
GP sample 
comprised 39 
males and 
nine females.  
 
The sample of 
hospital 
doctors 
comprised 12 
consultants 
and one senior 
registrar.  
The interviews 
focused on how 
far experiences 
with shared 
care compared 
to the 
arrangements 
currently in 
place for 
prescribing 
specialist 
medicines; 
identified 
barriers and 
facilitators of 
effective shared 
care. 
The themes centred 
around issues of clinical 
responsibility, ‘cost-
shifting’, availability of 
medicines, GP 
satisfaction, and the 
nature of the 
prescribing relationship 
GPs appeared 
dissatisfied with 
arrangements for 
prescribing 
specialist 
medicines, while 
hospital doctors 
were generally 
satisfied.  
(Skoglund, 
Segesten 
and 
Björkelund 
2007) 
To describe GPs’ 
thoughts on 
prescribing and 
evidence-based 
knowledge 
concerning drug 
therapy. 
South 
eastern part 
of Vastra 
Gotaland 
(Sweden). 
Audio 
recorded focus 
group 
interviews 
transcribed 
verbatim.  
A total of 16 
GPs out of 178 
from the 
south eastern 
part of the 
region 
strategically 
chosen to 
represent 
urban and 
rural, male 
and female, 
long and short 
GP 
experience. 
The outcome 
measure was 
focused on GPs’ 
thoughts on 
prescribing and 
on evidence-
based 
knowledge 
concerning drug 
therapy. 
The categories were: 
benefits, time and 
space, and expert 
knowledge 
The benefit was a 
merge of positive 
elements, all aspects of 
the GPs’ tasks 
Time and space were 
limitations for GPs’ 
tasks. EBM as a 
constituent of expert 
knowledge should be 
more customer 
adjusted to be able to 
be used in practice. 
GPs’ thoughts on 
evidence based 
medicine and 
prescribing 
medication were 
highly related to 
reflecting on 
benefit and results. 
The interviews 
indicated that 
prompt and 
pragmatic benefit 
is important.   
(Chong, 
Aslani and 
Chen 2013) 
To explore the 
perspectives of 
health care 
Australian 
health care 
setting, 
Individual 
semi-
structured 
 31 health 
care 
providers: 4 
The outcome 
measure was 
focused on 
Participants 
acknowledged 
medication non-
Participants were 
able to identify 
issues and 
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providers on 
antidepressant 
medication non-
adherence in clinical 
practice 
within the 
state of New 
South Wales 
interviews 
were 
conducted 
with a 
purposive 
sample of 31 
health care 
providers 
psychiatrists, 
4 GPs, 11 
pharmacists, 7 
mental health 
nurse, 5 social 
workers  
medication 
adherence 
issues in 
depression and 
participants’ 
strategies in 
addressing 
them. 
adherence to be a 
complex problem in 
depression, and 
attributed this problem 
to patient, medication 
and environmental-
specific issues. 
Five approaches in 
addressing non-
adherence were 
reported: patient 
education, building 
partnerships with 
patients, 
pharmacological 
management, 
developing behavioural 
skills and building 
supportive networks. 
Challenges to the 
management of non-
adherence were lack of 
time and skills, 
assessment of 
medication adherence, 
transition period 
immediately post-
discharge and conflicts 
in views between 
providers. 
strategies in 
addressing 
antidepressant 
non-adherence; 
however, barriers 
were also identified 
that could impact 
on providers’ 
ability to address 
this issue 
effectively. 
(Vogelsmeie
r et al. 
2013) 
To illuminate 
interprofessional 
factors that 
complicate effective 
and efficient 
medication 
reconciliation and to 
report clinicians’ 
perceptions of 
medication 
reconciliation as 
Three 
Veterans   
Administrati
on hospitals 
(United 
States. 
Qualitative 
study using 
focus groups 
of physicians, 
nurses and 
pharmacists. 
Three focus 
groups were 
conducted at 
each of three 
veterans 
administration 
hospitals. 
Participants 
were 13 
physicians,  
19 nurses and 
The outcome 
measure was 
focused on 
specific 
discussions 
about 
medication 
reconciliation.  
Two primary thematic 
questions emerged 
from the discussion 
about medication 
reconciliation: what 
does medication 
reconciliation really 
mean?; and who is 
actually responsible for 
the process? 
Participants from each 
Translating the 
intent of 
medication 
reconciliation into 
effective practice 
requires 
acknowledgment of 
the involved 
professionals’ 
diverse 
perspectives on 
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related to adverse 
drug events. s  
16 
pharmacists.  
profession had differing 
perspectives about the 
purpose and processes 
of medication 
reconciliation. 
 
the independent, 
joint, and 
overlapping 
functions of 
medication 
management as 
well as recognizing 
the limitations of 
technology. 
(Cullinan et 
al. 2014) 
Aims of this study 
were; using the TDF, 
(1) explore hospital 
doctors’ perceptions 
as to why PIP 
occurs, (2) identify 
the barriers to 
addressing the 
issues identified, 
thus identifying 
potential targets for 
intervention and (3) 
to use the behaviour 
change wheel to 
determine which 
intervention types 
would be best 
suited. 
Four 
Hospital:  
two public 
hospitals, 
owned and 
funded by 
the Health 
Service 
Executive 
and 
voluntary 
hospitals, 
run by 
voluntary/ 
private 
boards  
(Ireland)   
Semi-
structured 
interviews 
based on the 
Theoretical 
Domains 
Framework 
(TDF), a tool 
used to apply 
behaviour 
change 
theories, were 
conducted 
with 22 
hospital 
doctors. 
A total of 22 
hospital 
doctors, 
representative 
of doctors 
prescribing for 
older people in 
the hospital 
setting and 
represented 
doctors 
working in 
both geriatrics 
and in general 
medicine. 
Content 
analysis was 
conducted to 
identify 
domains of the 
TDF that could 
be targeted to 
improve 
prescribing for 
older people. 
Content analysis 
identified 5 of the 12 
domains in the TDF as 
relevant; (1) 
environmental context 
and resources, (2) 
knowledge, (3) skills, 
(4) social influences 
and (5) 
memory/attention and 
decision processes. 
Using the behaviour 
change wheel, the 
types of interventions 
deemed suitable were 
those based on training 
and environmental 
restructuring. 
This study showed 
that doctors felt 
there was 
insufficient 
emphasis on 
geriatric 
pharmacotherapy 
in their 
undergraduate/pos
tgraduate training. 
An intervention 
providing 
supplementary 
training, with 
particular 
emphasis on 
decision processes 
and dealing with 
social influences 
would be justified 
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The study of adherence to antidepressants reported by Chong, Aslani and Chen 
focused on one specific therapeutic category and is therefore less relevant to 
the research presented in this thesis. (Chong, Aslani and Chen, 2013) The 
remaining four studies focused on more general elements of medicines 
management structures and processes.  
 
The key finding of Vogelsmeier et al., in a study of health professionals in the 
US, that there is a need for more efficient deployment of staff in medicines 
reconciliation is in line with the findings of this research. (Vogelsmeier et al., 
2013) This relates specifically to the themes of need for a systematic approach 
to medicines history taking and the need to improve communication and 
documentation, aligning to TDF behavioural determinant of professional role and 
identity, and NPT mechanism of cognitive participation. Skoglund, Segesten and 
Bjorkelund, in a focus group study of 16 GPs in Sweden, indicated that the 
practice of evidence based medicine in relation to prescribing was more 
pragmatic, considering individual patient benefit. (Skoglund, Segesten and 
Bjorkelund, 2007) These findings relate to the themes of the need for 
appropriate polypharmacy in elderly patients with multimorbidities and the need 
for guidelines and policies to support medicines selection. The findings also align 
to the TDF behavioural determinant of beliefs about consequences (of applying 
evidence based practice) and goals.  
 
Cullinan et al., in studying employing qualitative interviews with 22 hospital 
doctors in Ireland, highlighted the lack of emphasis on geriatric clinical 
pharmacotherapy in their undergraduate course and the need to consider social 
influences on prescribing decision making. These findings relate to the theme 
around the need for an educated and trained multidisciplinary team. These align 
to the TDF behavioural determinants of knowledge and beliefs about capabilities 
(Cullinan et al., 2014). It should be noted that while social influences did not 
emerge as a key determinant in this doctoral research, this may have been due 
to the limitation attention to this domain in the interview schedule. 
 
In an earlier study, Horne et al. interviewed 39 GPs and 12 hospital doctors in 
the UK on their experiences with shared care. While the hospital doctors were 
generally satisfied, the GPs were clearly dissatisfied with the arrangements 
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relating to more specialised medicines. No reasons were provided to explain the 
lack of satisfaction. (Horne et al., 2001) These finding relate to the themes of 
need to improve communication and documentation, and the need for 
guidelines and policies to support medicines selection. These may relate to the 
TDF behavioural determinants of knowledge, beliefs about capabilities and 
environmental contest and resources. In terms of NPT, they may relate to the 
mechanisms of coherence in terms of a lack of shared beliefs and collective 
action.  
 
The key finding of this phase of the doctoral research is that there was a 
diversity of approach in respect of all the processes in relation to medicines 
management, as defined in this project: medicines reconciliation and history 
taking at the point of admission to hospital; medicines selection during the 
inpatient stay; constant review of medication; planning for counselling to 
promote medicines adherence; and communication of information at the point 
of discharge from hospital. There were also issues in relation to the structures 
around policies, guidelines and systems of documentation. There appears to be 
a need for a more systematic approach to medicines management in elderly, 
hospitalised patients, which will require further consideration of these structures 
and processes. This key finding is directly related to the aim of this phase of the 
study.  
 
The detailed thematic analysis aligned to NPT highlighted a lack of coherence 
around medicines management among the elderly patients in Abu Dhabi. There 
appeared to be an absence of shared belief around the aims of medicines 
management, defining appropriate polypharmacy (or indeed polypharmacy 
itself) and the approaches taken to enabling appropriate polypharmacy. 
However, there was clear knowledge around the implications and consequences 
of inappropriate polypharmacy, particularly around the potential for increased 
incidence and severity of adverse drug reactions, drug interactions, complicating 
adherence. In terms of the other mechanisms of NPT, there was little evidence 
of cognitive participation (defining the professions) and collective action (task 
allocation) with no clear allocation of the processes of medicines reconciliation, 
history taking and counselling. While medicines selection was more clearly the 
remit of the physicians, there was confusion relating to multiple prescribers 
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(particularly in primary care) prescribing for the same indication, and 
responsibility for medicines review within the hospital setting. There is clearly a 
need for considering task allocation with clearly defined roles and 
responsibilities, all of which will also require improved standards for 
documentation and inter and intra-professional communication.  All of these 
issues could be captured within agreed SOPs. There is then a need to promote 
reflexive monitoring to evaluate the outcomes of the processes which will 
require agreeing clear service aims and objectives, all of which must centre on 
optimising patient outcomes.  
 
Two studies have applied NPT to analyse data relating to the management of 
heart failure. Gallacher et al. interviewed 47 patients with chronic heart failure 
managed in UK primary care settings. They identified that the NPT mechanisms 
of coherence, cognitive participation and cognitive action aided their 
understanding of the patient perspective of developing an understanding of 
treatments, interacting with others to organize care, attending appointments, 
taking medications, enacting lifestyle measures, and appraising treatments. 
They concluded that NPT could be used as a framework in developing 
interventions at the individual practitioner and organisational levels to enhance 
the patient experience. (Guthrie et al. 2012) Lowrie et al. conducted focus 
groups with pharmacists and semi-structured interviews with individual patients 
in the UK to explore and portray in detail, the perspectives of patients receiving 
and pharmacists delivering an enhanced performance community pharmacy 
heart failure service. They used NPT to allow understanding of the patient 
perspective in terms of: coherence, learning about heart failure and its 
consequences, cognitive participation, engaging with others; collective action, 
methods for managing symptoms and treatments; and reflexive monitoring, 
changing routine. While the discussion elaborates the benefits of NPT, there is 
little emphasis on the multidisciplinary care team. (Lowrie et al. 2014)  
These two studies differ from the current research by focusing on the patient 
perspective, which may be more relevant in the primary care setting.    
 
There is a consensus in the literature that behaviour change is key to increasing 
the uptake of evidence into healthcare practice. (Francis, O'Connor and Curran 
2012) This has also been endorsed in the Medical Research Council framework 
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for evaluating complex interventions, as described in chapter 1.(Craig et al. 
2008)  Francis, O'Connor and Curran (2012) highlight that designing behaviour-
change interventions first requires problem analysis, which would ideally be 
informed by theory. The NPT mechanisms and the TDF behavioural 
determinants have provided a theoretical approach to identifying the behaviour 
determinants in relation to medicines management. The TDF is particularly 
useful in this study to identify the individual practitioner behaviours to change.  
Michie, van Stralen and West developed the Behaviour Change Wheel (BCW) to 
aid characterising and designing behaviour change interventions ((Michie, van 
Stralen and West 2011). This behaviour change wheel can be used to link 
behavioural determinants to specific interventions. The BCW is similar to the 
TDF in that it was developed from 19 frameworks of behaviour change. It 
consists of three layers. 
 
Figure 4.7: The BCW (adapted from Michie, van Stralen and West, 2011) 
 
The hub describes the behaviours using the COM-B ('capability', 'opportunity', 
'motivation' and 'behaviour') model, which is similar to the TDF behavioural 
determinants. Surrounding the hub is a layer of nine intervention functions to 
choose from based on the particular COM-B analysis. The outer layer, the rim of 
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the wheel, identifies seven policy categories that can support the delivery of 
these intervention functions. The potential use of the BCW in developing 
interventions relating to medicines management is discussed in more detail in 
chapter 6.  
 
Selection of medicines is complex in elderly patients. Interviewees in this study 
(particularly the physicians and pharmacists) described the need for clinical, 
evidence based therapeutic and pharmacological guidelines to support 
medicines selection and review. While there is a vast volume of international 
clinical guidelines, the failure of these to account for patients with 
multimorbidities has been highlighted. Guthrie et al., in an editorial article, 
highlighted that, ‘clinical guidelines almost entirely focus on single conditions’ 
and that ‘guidelines could be made more useful for people with multimorbidity if 
they were delivered in a format that brought together relevant 
recommendations for different chronic conditions and identified synergies, 
cautions, and outright contradictions’. (Guthrie et al. 2012) They suggest that it 
may be possible to improve morbidity through the use of technology to link the 
most appropriate medicines with each patient’s specific circumstances. In a later 
paper, Hughes, McMurdo and Guthrie further explored the challenges of 
applying UK clinical guidelines to those with multimorbidities. (Hughes, McMurdo 
and Guthrie 2013) The considered the extent to which National Institute of 
Health and Clinical Excellence (NICE) guidelines dealt with patient comorbidities, 
patient centred care and if patients complied with their treatment 
recommendations. They reviewed five NICE clinical guidelines (type-2 diabetes 
mellitus, secondary prevention for people with myocardial infarction, 
osteoarthritis, chronic obstructive pulmonary disease and depression), and 
noted the extent to which the guidelines accounted for patient comorbidity, 
patient centred care and patient compliance. They noted that, ‘comorbidity and 
patient adherence were inconsistently accounted for in the guidelines, ranging 
from extensive discussion to none at all’. There is therefore a clear need to 
further consider patients with multimorbidities in the development of clinical 
guidelines. 
 
Chapter 1 outlines the issue of potentially inappropriate prescribing in the 
elderly, describing a systematic review of criteria to aid the identification of 
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potentially inappropriate prescribing. (Hill Taylor et al. 2013) Notably, none of 
the interviewees in this study reported any awareness of criteria such as Beers 
and STOPP/START, and none reported using such criteria in their daily practice. 
Furthermore, none were aware of tools such as the Drug Burden Index to 
determine anticholinergic burden. This is an area which requires further 
attention and research. There are no published papers which report the use of 
such criteria within the Middle East. While it may be necessary to review these 
criteria for their appropriateness to Middle Eastern practice and culture, these 
provide a useful starting point.  
 
Several of the key themes which emerged during this research are related to 
the systematic reviews which were described in chapter 1.  
 
In a recent systematic review of the literature on interventions (alone or in 
combination) to improve the appropriate use of polypharmacy for older people, 
Patterson et al. highlighted the lack of clarity around the impact of interventions 
to improve appropriate polypharmacy, such as pharmaceutical care, on health 
outcomes despite the impact relating to reducing potentially inappropriate 
prescribing. (Patterson et al. 2014) The findings of this research demonstrate 
the lack of clarity of professional roles and goals around medicines review in the 
elderly hence it is even less likely positive outcomes in relation to health status 
can be realised. 
 
One further finding of this research is the expressed need to improve patients’ 
adherence to their medicines. The review of systematic reviews in the field of 
medicines adherence described in chapter 1 Kardas, Lewek and Matyjaszczyk 
(2013) and a recent systematic review of 109 RCTs published since 2007 
Nieuwlaat et al. (2014) highlight that the vast majority of the primary literature 
is of poor quality (high potential for bias, few studies of clinical outcomes) and 
that improving adherence is complex and may be multifactorial. There may be 
merit in employing tools such as the TDF and BCW in the development of 
tailored interventions. The findings of this research impact the remainder of the 
doctoral research. Areas of further research outwith the doctoral research are 
described in chapter 6.  
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4.4.4 Conclusion 
This phase of the research has generated novel knowledge and understanding in 
medicines management activities. Doctors, nurses and pharmacists in Abu 
Dhabi are quite aware of the issues in different processes in relation to 
medicines management in elderly hospitalised patients (i.e. medicines history 
taking, reconciliation, medicines selection, counselling etc.). It appears the 
causes are at individual level (e.g. education, training, defined roles) and 
organisational level (e.g. developing policies and guidelines). This study has 
identified key areas for targeting of intervention studies in the future, changes 
that need implementation and the need for specialised training and education. 
 
4.4.5 Implications for further research phase 
 The findings of  
 
i. Narrative overview of systematic reviews on medicines reconciliation, 
medicines adherence and potentially  inappropriate prescribing (chapter 
1) 
 
ii. JBI systematic review of the use of the DBI (chapter 3) 
 
iii. Qualitative interviews to explore the views, experiences and perceptions 
of health professionals in Abu Dhabi in terms of healthcare structures, 
processes and outcomes relating to medicine management for elderly, 
hospitalised patients (chapter 4) 
 
were used in the development of consensus statements employed in the next 
phase of the research, specifically in relation to the structures and processes for 
medicines management in elderly, hospitalised patients in the UAE.   
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Chapter 5: The Delphi study  
 
5.1 Introduction to the chapter 
The concept of medicines management should allow healthcare professionals 
and patients to maximise benefits from the use of medicines and reduce 
associated risks. (National Prescribing Centre  2002) In Chapter 1, a medicines 
management model for the patient journey in secondary care was proposed 
encompassing 
 
 medicines history taking/ medicines reconciliation 
 
 selection and prescribing of medicines 
 
 monitoring medicines  
 
 counselling and information provision 
 
Chapter 1 provided a narrative overview of systematic reviews on medicines 
reconciliation, medicines adherence and potentially inappropriate prescribing. 
 
In the first phase of doctoral research, a systematic review was undertaken 
using the Joanna Briggs Institute (JBI) approach. The aim of the review was to 
critically appraise, synthesise and present evidence of guidelines and tools to 
manage the risk of adverse effects of anticholinergic agents (as exemplars of 
high-risk medicines) in elderly patients.  
 
The second research phase focused on medicines management related 
healthcare structures, processes and outcomes in Abu Dhabi.  
 
   
203 
In this final phase of the doctoral research, a consensus based approach was 
adopted which involved identifying and recruiting key stakeholders (who were 
the expert panel members) in relation to medicines management in elderly 
patients to explore levels of consensus around statements derived from the 
previous research phases.  
 
Essentially, consensus methods utilize a group of experts in a particular field to 
gather evidence and insight into a research topic. (Fink et al. 1984, Falzarano 
and Zipp 2013) These approaches are particularly suited to the development of 
professional norms and areas of practice where published evidence is lacking. In 
these situations, there will undoubtedly be potential for diverse personal and 
subjective opinions that need to be considered. Consensus methods attempt to 
systematically and objectively gather, organise and synthesise this diversity in 
an attempt to provide a single consensus. Consensus development is the 
process through which the members of the group attempt to reach agreement 
towards this single group opinion. Although in many cases agreement 
summarising a single perspective is not achieved, data will be gathered 
identifying the central tendency of expert opinion.  
 
5.1.1 Aim and objectives 
The aim of this phase of the research was to determine consensus in relation to 
strategic and operational approaches around medicines management for elderly, 
hospitalised patients in the UAE. 
The primary objectives were: 
 
1. to develop and validate a series of statements in relation to the 
structures, processes and outcomes in relation to strategic and 
operational approaches around medicines management  
 
2. to determine the levels of consensus of key stakeholders (the expert 
panel members) around these statements 
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3. to determine any additional statements derived from key stakeholder 
feedback 
 
4. to determine any reasons for not achieving consensus 
 
The secondary objectives were 
 
5. to determine key stakeholder views on the potential for the findings to 
aid the development of policies, quality indicators and professional norms 
  
6. determine participant’s views of their involvement in the consensus 
approach, and its potential for future healthcare developments. 
 
5.2 Methods 
5.2.1 Research Design 
A quantitative, positivistic approach was employed in this phase of the study. 
 
A Delphi technique, using an expert panel of key stakeholders in the UAE, was 
employed.  This was selected over the other consensus approaches for a 
number of reasons, as described in chapter 2. These were primarily logistical 
considerations for the researchers (using Internet as medium for data 
collection) and participants (no travel, less time consuming) and cost.  
 
5.2.2 Setting 
This research was conducted within Abu Dhabi, which is the largest city in the 
UAE in terms of geographical size and population numbers, has the highest rate 
of healthcare expenditure and more established governance systems than the 
other zones (National Bureau of Statistics2010). 
 
Stakeholders in this research represented: 
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 all 18 public hospitals in Abu Dhabi which had been authorized by 
Health Authority of Abu Dhabi (HAAD) to conduct research on human 
subjects  
 HAAD 
  Al Ain Medical University 
 
5.2.3 Research Governance 
The research was reviewed and approved by: 
 
i. the ethical review panel of the School of Pharmacy and Life Sciences at 
Robert Gordon University. (see Appendix 5.1) 
 
a. a detailed research protocol was prepared and reviewed by team 
research members. 
b. the protocol was submitted to the ethical review panel and 
approval received four weeks later. 
 
All approvals were in place prior to sampling and recruiting any research 
participants. Throughout the research, all study materials were stored in 
accordance with the Standard Operating Procedures of the School of Pharmacy 
and Life Sciences and the governance policies of Robert Gordon University. 
Signed, informed consent was obtained from all participants. 
 
5.2.4 Delphi statements   
The statements for the Delphi survey instrument were developed from three 
sources: review of narrative and systematic literature reviews related to 
medicines management (Chapter 1); systematic review of the Drug Burden 
Index (Chapter 2); and analysis of data generated from the in-depth interviews 
(Chapter 3). A series of initial statements was developed during several 
meetings of the PI and the research supervisors, as given in Table 5.1. The 
statements were organised into the key elements of the medicines management 
model: 
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1. Guidelines for medicines management in elderly hospitalised patients  
2. Medicines reconciliation  
3. Medicines review 
4. Medicines adherence  
5. Medicines counselling 
6. Health professional training  
7. Evaluation research  
 
Two theoretical frameworks were applied in the design of the Delphi statements 
in this study. Normalization Process Theory was applied in terms of coherence 
(definitions of key elements of medicines management), cognitive participation 
(task allocation of the responsibilities of health professionals), collective action 
(the actual work or skills involved in delivering the tasks relating to medicines 
management) and reflexive monitoring (specialised education and training 
services). The Theoretical Domain Framework and the associated Behaviour 
Change Wheel were applied in terms of changing behaviour via training, SOPs, 
documentation and research. Draft statements were discussed revised 
iteratively at several meetings of the research team.  
 
The statements were tested for face and content validity by a panel of seven 
experts in Scotland and the UAE on aspects of medicines management, 
healthcare processes, behaviour change and research, identified from the 
professional networks of members of the supervisory team. These individuals 
were emailed the statements with instructions to comment on the clarity and 
appropriateness of the statements prior to using it in the UAE. This was 
considered necessary for several reasons: to assess the feasibility of the Delphi 
statements; to assess whether the Delphi statements were realistic and 
workable (Van Teijlingen et al. 2001).  Responses are provided in Table 5.1.  
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Table 5.1: Verbatim responses to the face and content validation of Delphi statements  
 
 
 
Expert Group Comments  
          
                 Professional Title  
 
Statements  
Director 
(psychologist
), Aberdeen 
Centre for 
Trauma 
Research 
Professor of 
Community 
Pharmacy 
Practice 
Academic, 
Researcher  
Academic, 
School of 
Nursing and 
Midwifery 
Professor and 
Director of 
Pharmacy, 
NHS 
Education for 
Scotland  
Lead 
Pharmacist 
Diabetes and 
Advanced 
Pharmacist 
Clinical 
Research 
Head of 
Emergency 
Department 
in Zayed 
Hospital  
 
PI Action 
Background  What is 
meant by 
“medicine-
related 
issues” 
      medicines 
related issues 
(e.g. drug 
selection, 
adverse drug 
reactions, 
adherence) 
1. General Statements Clear      Clear and 
appropriate 
 
1.1 The following definition of 
medicines management should be 
adopted in the UAE - ‘the clinical, 
cost effective and safe use of 
medicines to ensure patients get the 
maximum benefit from the medicines 
they need, while at the same time 
minimizing potential harm’ 
  Clear and 
appropriate 
 I would rate 
‘safe’ before 
‘cost effective 
‘ in the 
statement 
  Reworded 
1.2 Elderly patients with multi-
morbidities are at particular risk of 
medicines related issues 
  Clear and 
appropriate 
  ‘multi-
morbidities’ – 
change to 
multiple co-
morbidities 
  
1.3 Medicines management should 
be a focus of every elderly patient 
admitted to hospital, irrespective of 
the reason for admission or 
presenting complaint 
  Reads as 
though it’s 
the elderly 
patient’s 
focus rather 
than 
healthcare 
professionals. 
Perhaps ‘a 
focus in the 
care of’? 
Otherwise 
clear and 
  Change to 
‘should be a 
focus for’ 
rather than 
‘of’ 
 Reworded 
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appropriate  
1.4 Medicines management should 
be a focus of every elderly patient 
admitted to hospital, irrespective of 
the admitting ward or speciality 
 
  Reads as 
though it’s 
the elderly 
patient’s 
focus rather 
than 
healthcare 
professionals. 
Perhaps ‘a 
focus in the 
care of’? 
Otherwise 
clear and 
appropriate 
  Change to 
‘should be a 
focus for’ 
rather than 
‘of’ 
 Reworded 
1.5 Medicines management should 
be a focus of every elderly patient 
admitted to hospital, irrespective of 
the duration of stay in hospital 
 
  Reads as 
though it’s 
the elderly 
patient’s 
focus rather 
than 
healthcare 
professionals. 
Perhaps ‘a 
focus in the 
care of’? 
Otherwise 
clear and 
appropriate 
  Change to 
‘should be a 
focus for’ 
rather than 
‘of’ 
 Reworded 
1.6 Medicines management should 
only be a focus for those elderly 
patients admitted to hospital with a 
medicines related issue 
  Reads as 
though it’s 
the elderly 
patient’s 
focus rather 
than 
healthcare 
professionals. 
Perhaps ‘a 
focus in the 
care of’? 
Otherwise 
clear and 
appropriate 
 Should the 
word ONLY 
be in bold 
type? 
  Reworded 
1.7 Medicines management is the 
responsibility of all members of the 
healthcare team, specifically nurses, 
  Clear and 
appropriate 
Two different 
things going 
on in this 
Should it 
mention 
Prescribers? 
It should 
either be all 
the 
 Reworded 
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pharmacists and physicians. 
 
statement, 
one general, 
one specific. 
Better to 
separate out 
into two. 
healthcare 
team or 
specifically 
nurses, 
pharmacist 
and 
physicians – 
not both. 
1.8 All health professionals 
(specifically nurses, pharmacists, 
physicians) should be competent in 
medicines management 
  Clear and 
appropriate 
but would 
use commas 
rather than 
brackets as 
per previous 
statement 
As above, 
this doesn’t 
make sense 
to me. 
Define 
competent? 
It should 
either be all 
the 
healthcare 
team or 
specifically 
nurses, 
pharmacist 
and 
physicians – 
not both. 
 Reworded 
1.9 Single disease state evidence 
based recommendations should be 
applied with caution in elderly 
patients with multi-morbidities 
  Clear and 
appropriate 
 Single state 
disease – 
does not read 
well – 
rewords? 
‘multi-
morbidities’ – 
change to 
multiple co-
morbidities 
 Reworded 
2. Guidelines for Medicines 
Management in Elderly 
Hospitalised Patients 
Clear      Clear and 
appropriate 
 
2.1 There is a need to develop 
guidelines for medicines 
management in elderly hospitalised 
patients in the UAE 
  Clear and 
appropriate 
     
2.2 A guideline development group 
should be established, under the 
auspices of Health Authority of Abu 
Dhabi (HAAD)1, with representation 
of experts in medicines in the elderly 
  Clear and 
appropriate 
  ‘representati
on of experts’ 
change to 
‘from’ 
 “of” changed 
to ”from” 
2.3 The guidelines should have a 
focus on medicines reconciliation at 
the point of admitting elderly 
patients to hospital  
  Clear and 
appropriate 
 Also at 
Discharge?? 
  Reworded 
2.4 The guidelines should have a 
focus on the prescribing of medicines 
in the elderly  
  Clear and 
appropriate 
     
2.5 The guidelines should have a 
focus on the monitoring of medicines 
  Clear and 
appropriate 
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in the elderly  
2.6 The guidelines should have a 
focus on managing inappropriate 
polypharmacy (the prescribing of too 
many medicines which are 
inappropriate or no longer indicated) 
in elderly patients with multi-
morbidities 
 
  Appropriate 
but would be 
easier to 
read if re-
worded so 
that the 
definition is 
at the end. 
Also, using 
‘inappropriat
e’ in both the 
term and its 
definition is 
unusual. 
    Reworded 
2.7 The guidelines should have a 
focus on reviewing all medicines in 
elderly patients with multi-
morbidities to promote appropriate 
polypharmacy (prescribing of many 
drugs but which are appropriate) 
  Clear and 
appropriate 
but, again, 
would it be 
possible to 
avoid using 
‘appropriate’ 
in both the 
term and its 
definition? 
 Define 
appropriate 
polypharmec
y?  
Change 
drugs to 
medicines 
 Reworded 
2.8 The guidelines should highlight 
high risk/potentially inappropriate 
medicines in the elderly  
  Clear and 
appropriate 
but would 
use a comma 
rather than 
‘/’ 
 There are 
two 
questions on 
one 
statement 
here? 
  Split into two 
statements  
2.9 Consideration should be given to 
adapting for the UAE context defined 
lists of high risk/potentially 
inappropriate medicines in the 
elderly2, such as: 
i) Beers Criteria (potentially 
inappropriate medicines use in older 
adults) 
ii) STOPP Criteria (screening tool of 
potentially inappropriate prescribing) 
iii) IPET- Improving Prescribing in 
the Elderly Tool (commonly 
encountered drug-disease 
  Appropriate 
but would 
use a comma 
rather than 
‘/’ and also 
move ‘for the 
UAE context’ 
to after 
‘elderly2’ but 
before the 
comma. 
 Too 
lengthy?? 
  Reworded 
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interactions, mostly focusing on 
cardiovascular and psychotropic 
drugs) 
2.10 Consideration should be given 
to adapting for the UAE context 
defined list of commonly omitted 
medicines in the elderly2, such as: 
i) START Criteria (screening tool to 
alert physicians to right treatment) 
 
  Appropriate 
but would 
move ‘for the 
UAE context’ 
to 
after‘elderly’ 
but before 
the comma, 
also add ‘a’ 
before 
‘defined’ and 
‘the’ before 
‘right’. 
    Moved to 2.13 
2.11 The guidelines should have a 
focus on identifying and managing 
adverse drug reactions in the elderly 
  Clear and 
appropriate 
    Moved to 2.12 
2.12 Anticholinergic and sedative 
agents are problematic in the elderly 
  Clear and 
appropriate 
 Too bold a 
statement – 
define more 
of the drugs? 
  Deleted  
2.13 Consideration should be given 
to using the Drug Burden Index3 as a 
tool to quantify exposure to 
anticholinergic and sedative agents 
in the elderly 
  Clear and 
appropriate 
    Moved to 2.11 
2.14 Consideration should be given 
to adopting validated measures of 
adherence4, such as: 
i) Moriskey scale  
ii) Medication adherence 
questionnaire 
iii) Self-Efficacy for Appropriate 
Medication Use Scale 
  For 
consistency 
add ‘for the 
UAE context’ 
after 
‘adherence4’. 
I’m not 
familiar with 
all of these 
but think the 
full name 
(and correct 
spelling) of 
the Morisky 
  Morisky  Morisky  
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Medication 
Adherence 
Scale 
(MMAS-8) 
should be 
listed, 
identify item 
ii more 
clearly and 
add acronym 
for SEAMS 
2.15 The guidelines should have a 
focus on adherence (or non-
adherence) to medicines  
  Clear and 
appropriate 
     
2.16 Consideration should be given 
to adopting in the UAE evidence 
based approaches to guideline 
implementation 
  Appropriate 
but clearer if 
‘in the UAE’ 
is moved to 
the end of 
the 
statement 
    Reworded 
3. Medicines Reconciliation Clear      Clear and 
appropriate 
 
3.1 The following definition of 
‘medicines reconciliation’  should be 
adopted in the UAE - ‘the process of 
identifying the most accurate list of a 
patient’s current medicines – 
including the name, dosage, 
frequency and route – and 
comparing them to the current list in 
use, recognising and discrepancies, 
and documenting any changes, thus 
resulting in a complete list of 
medications, accurately 
communicated’ 
  Clear and 
appropriate 
but would 
delete the 
quotes 
around 
medicines 
reconciliation 
and correct 
typo ‘any 
discrepancies
’. Should this 
be 
referenced? 
    the quotes 
around 
medicines 
review was 
deleted 
3.2 Medicines reconciliation should 
be determined at the point of 
admitting all elderly patients to 
hospital 
  Clear and 
appropriate 
 And also at 
Discharge?? 
  Reworded 
3.3 Determination of medicines 
reconciliation can be undertaken by 
any health professional (nurse, 
pharmacist, physician) 
  If it is ‘any 
health 
professional’ 
shouldn’t be 
followed by a 
Not sure 
about use of 
the word 
“determinatio
n” in these 
 Take out 
examples. 
 Reworded 
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restricted list statements. 
Does it mean 
“deciding 
about” or 
“doing it 
themselves”? 
Could it be 
omitted? 
3.4 Determination of medicines 
reconciliation can be undertaken by 
any nurse 
  Clear and 
appropriate 
     
3.5 Determination of medicines 
reconciliation can be undertaken by 
any pharmacist 
  Clear and 
appropriate 
     
3.6 Determination of medicines 
reconciliation can be undertaken by 
any physician 
  Clear and 
appropriate 
     
3.7 Determination of medicines 
reconciliation should only be 
undertaken by a health professional 
trained in that role 
  Clear and 
appropriate 
     
3.8 Determination of medicines 
reconciliation in an elderly patient 
with dementia or other cognitive 
impairment requires specialist input 
  Clear and 
appropriate 
     
3.9 Any medicines related issues 
resulting from determination of 
medicines reconciliation should be 
recorded in the shared medical 
records 
  Clear and 
appropriate 
     
3.10 There is a need for a standard 
operating procedure to guide the 
determination of medicines 
reconciliation in elderly patients 
  Clear and 
appropriate 
     
3.11 There is a need to develop 
standardised documentation to 
record determination of medicines 
reconciliation in elderly patients 
  Clear and 
appropriate 
 Any 
electronic 
records?? 
   
4. Medicines Review Clear      Clear and 
appropriate 
 
4.1 The following definition of 
‘medicines review’  should be 
adopted in the UAE  - ‘a structured, 
critical examination of the complete 
list of a patient's medicines with the 
  Clear and 
appropriate 
but would 
delete the 
quotes 
    the quotes 
around 
medicines 
review was 
deleted  
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objective of reaching an agreement 
with the patient about treatment, 
optimising the impact of medicines, 
minimising the number of 
medication-related problems and 
reducing waste’ 
around 
medicines 
review. 
Should this 
be 
referenced? 
4.2 All elderly patients with multi-
morbidities should have a full 
medicines review during stay in 
hospital to promote appropriate 
polypharmacy 
  Clear and 
appropriate 
but add 
‘their’ before 
‘stay’ 
    ‘their’ before 
‘stay’ 
4.3 Only elderly patients admitted 
with a medicines related issue should 
have a full medicines review during 
stay in hospital to promote 
appropriate polypharmacy 
  Clear and 
appropriate 
but add 
‘their’ before 
‘stay’ 
    ‘their’ before 
‘stay’ 
4.4 A full medicines review can be 
undertaken by any health 
professional (nurse, pharmacist, 
physician) 
  If it is ‘any 
health 
professional’ 
shouldn’t be 
followed by a 
restricted list 
  Removes 
examples. 
 Reworded 
4.5 A full medicines review can be 
undertaken by any nurse 
  Clear and 
appropriate 
     
4.6 A full medicines review can be 
undertaken by any pharmacist 
  Clear and 
appropriate 
     
4.7 A full medicines review can be 
undertaken by any physician 
  Clear and 
appropriate 
     
4.8 A full medicines review should 
only be undertaken by a health 
professional trained in that role  
  Clear and 
appropriate 
     
4.9 A full medicines review in an 
elderly patient with dementia or 
other cognitive impairment requires 
specialist input 
  Clear and 
appropriate 
     
4.10 Any medicines related issues 
resulting from a full medicines review 
should be recorded in the shared 
medical records 
  Clear and 
appropriate 
     
4.11 There is a need for a standard 
operating procedure to guide the 
conduct of a full medicines review in 
elderly patients 
  Clear and 
appropriate 
     
4.12 There is a need to develop 
standardised documentation to 
  Clear and 
appropriate 
 To include 
any 
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record a full medicines review in 
elderly patients 
electronic 
prescribing? 
4.13 A multi-disciplinary ward team 
(specifically nurses, pharmacists and 
physicians) should review the 
medicines prescribed to elderly 
patients on a regular basis during 
stay in hospital 
  Clear and 
appropriate 
but add 
‘their’ before 
‘stay’ 
 Define 
regular? 
  ‘their’ before 
‘stay’ 
4.14 All medicines prescribed to 
elderly patients during stay in 
hospital should be reviewed prior to 
discharge 
  Clear and 
appropriate 
but add 
‘their’ before 
‘stay’ 
    ‘their’ before 
‘stay’ 
4.15 The standard operating 
procedure should include providing 
information to health professionals 
(family doctor, nurse, pharmacist) 
working in primary care informing 
them of the nature of any changes 
made to medicines during stay and 
any follow-up required  
  Clear and 
appropriate 
     
5. Medicines Adherence Clear      Clear and 
appropriate 
 
5.1 The following definition of 
‘medicines adherence’ should be 
adopted in the UAE - ‘the extent to 
which patients take medications as 
prescribed by their health care 
providers’ 
 
  Clear and 
appropriate 
but would 
delete the 
quotes 
around 
medicines 
adherence. 
Should this 
be 
referenced? 
    the quotes 
around 
medicines 
adherence 
was deleted  
5.2 Adherence (or non-adherence) to 
all medicines should be determined 
at the point of admitting all elderly 
patients to hospital 
  Clear and 
appropriate 
 And also at 
discharge? 
   
5.3 Determination of adherence (or 
non-adherence) can be undertaken 
by any health professional (nurse, 
pharmacist, physician) 
  If it is ‘any 
health 
professional’ 
shouldn’t be 
followed by a 
restricted list 
 Would 
“finding out 
about” be 
better than 
“determinatio
n”? 
Removes 
examples. 
 Reworded 
5.4 Determination of adherence (or   Clear and      
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non-adherence) can be undertaken 
by any nurse 
appropriate 
5.5 Determination of adherence (or 
non-adherence) can be undertaken 
by any pharmacist 
  Clear and 
appropriate 
     
5.6 Determination of adherence (or 
non-adherence) can be undertaken 
by any physician 
  Clear and 
appropriate 
     
5.7 Determination of adherence (or 
non-adherence) should only be 
undertaken by a health professional 
trained in that role  
  Clear and 
appropriate 
     
5.8 Determination of adherence (or 
non-adherence) in an elderly patient 
with dementia or other cognitive 
impairment requires specialist input 
  Clear and 
appropriate 
     
5.9 Any medicines related issues 
resulting from determination of 
adherence should be recorded in the 
shared medical records 
  Clear and 
appropriate 
     
5.10 There is a need for a standard 
operating procedure to guide the 
determination of adherence (or non-
adherence) in elderly patients 
  Clear and 
appropriate 
     
5.11 There is a need to develop 
standardised documentation to 
record determination of adherence 
(or non-adherence) in elderly 
patients 
  Clear and 
appropriate 
     
6. Medicines Counselling Clear        
6.1 The following definition of 
‘medicines counselling’ should be 
adopted in the UAE - ‘provision of 
advice and instruction by a health 
care professional to patients 
regarding the use of their medicines’ 
 
 
 
  Clear and 
appropriate 
but would 
delete the 
quotes 
around 
medicines 
counselling. 
Should this 
be 
referenced? 
A very 
strange 
definition 
indeed. 
Counselling 
first involves 
listening. 
This seems a 
totally health 
professional 
dominated 
agenda. 
What about 
the idea of 
concordance? 
Regarding 
the 
APPROPRIAT
E use of their 
medicines? 
  Reworded 
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6.2 All elderly patients should be 
counselled on their medicines prior to 
discharge 
  Clear and 
appropriate 
 Needs to 
take more 
account of 
therapeutic 
partnerships 
with the 
prescriber 
and the 
patient and 
the 
healthcare 
professionals
? 
   
6.3 Only elderly patients identified as 
non-adherent/ potentially non-
adherent should be targeted for 
counselling on their medicines prior 
to discharge 
  Clear and 
appropriate 
     
6.4 Only elderly patients commenced 
new medicines or having a change in 
medicines should be targeted for 
counselling on their medicines prior 
to discharge 
  Appropriate 
but should it 
be 
‘commenced 
on’ or 
perhaps 
‘started on’? 
     
6.5 Medicines counselling can be 
undertaken by any health 
professional (nurse, pharmacist, 
physician) 
  If it is ‘any 
health 
professional’ 
shouldn’t be 
followed by a 
restricted list 
  Removes 
examples.  
 Reworded 
6.6 Medicines counselling can be 
undertaken by any nurse 
  Clear and 
appropriate 
     
6.7 Medicines counselling can be 
undertaken by any pharmacist 
  Clear and 
appropriate 
     
6.8 Medicines counselling can be 
undertaken by any physician 
  Clear and 
appropriate 
     
6.9 Medicines counselling should only 
be undertaken by a health 
professional trained in that role  
  Clear and 
appropriate 
     
6.10 Medicines counselling in an 
elderly patient with dementia or 
other cognitive impairment requires 
specialist input 
  Clear and 
appropriate 
     
6.11 Medicines counselling should   Think if you  To use where   “where 
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always involve the elderly patient’s 
family/carers/friends where possible 
say ‘always’ 
should delete 
‘where 
possible’ 
appropriate 
instead of 
where 
possible? 
appropriate” 
instead of 
“where 
possible” 
6.12 Counselling should focus on 
elderly patients’ beliefs, intentions, 
and values relating to medicines to 
encourage behavioural and lifestyle 
changes 
  Clear and 
appropriate 
but delete 
comma after 
‘intentions’ 
Probably the 
most 
important of 
all your 
statements 
as far as I 
am 
concerned, 
but why is 
there an 
assumption 
that there is 
something 
wrong that 
they need to 
change? Why 
can’t you 
have a 
statement 
that just 
pledges that 
pharmacists 
will listen to 
what is 
important in 
people’s lives 
that 
influences 
what 
medicines 
they take, 
how and 
why? Until 
you do that I 
don’t think 
you will ever 
understand 
why so many 
people don’t 
behave as 
health 
professionals 
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think they 
should. 
6.13 There is a need for a standard 
operating procedure to guide 
medicines counselling in elderly 
patients 
  Clear and 
appropriate 
     
6.14 The standard operating 
procedure should include providing 
information to health professionals 
(family doctor, nurse, pharmacist) 
working in primary care informing 
them of the nature of any counselling 
provided prior to discharge and any 
follow-up support required  
  Clear and 
appropriate 
     
6.15 There is a need to develop 
standardised documentation to 
record counselling in elderly patients 
  Clear and 
appropriate 
     
6.16 There is potential to include 
medicines counselling programmes 
or group sessions as part of out-
patient care 
  Clear and 
appropriate 
 Not clear – 
needs to be 
reworded? 
  Deleted 
7. Health Professional Training  Clear        
7.1 All health professionals working 
with medicines in the elderly should 
receive regular, ongoing training 
relating to medicines management 
  Clear and 
appropriate 
     
7.2 Training should focus on patient 
involvement in decision making 
  Clear and 
appropriate 
     
7.3 Training should focus on aspects 
of cultural diversity 
  Clear and 
appropriate 
     
8. Evaluation Research          
8.1 Consideration should be given to 
developing a research programme to 
evaluate the implementation of the 
guidelines 
  Clear and 
appropriate 
but add ‘in 
the UAE’ 
 These 
Guidelines? 
  These 
guidelines 
8.2 Evaluation should consider the 
perspectives of all stakeholders, 
including patients 
  Clear and 
appropriate 
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5.2.4.1 Rating of statements  
Each Delphi statement was rated on the following six point rating scale:  
 
 
 
 
 
 
 
 
This Likert Scale had no central or neutral point so that the expert had to rate 
whether he/she was in agreement or disagreement.  
 
5.2.4.2 Determining consensus  
There is no individual approach consistently used for determining the point of 
consensus in Delphi studies, and most use either subjective criteria or 
descriptive statistics. In a review paper, Heiko (2012) describes a number of 
different approaches, which are summarised in Table 5.2. (adapted from 
Heiko  2012).  
 
 
 
 
 
 
 
 
 
 
1. Strongly disagree 
2. Disagree  
3. Somewhat disagree 
4. Somewhat agree 
5. Agree 
6. Strongly agree 
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Table 5.2: Approaches to consensus measurement (adapted from Heiko  2012) 
Measurements of 
consensus 
Criteria 
Stipulated number of 
rounds 
“Research indicated that three iterations are typically 
sufficient to identify points of consensus…Thus, three 
rounds were used in this study.” (Fan and Cheng 2006) 
Subjective analysis “Overall, it was felt that a third round of the study would 
not add to the understanding provided by the first two 
rounds and thus the study was concluded.” (MacCarthy 
and Atthirawong 2003) 
Certain level of 
agreement 
“Consensus was achieved on an item if at least 60% of 
the respondents were in agreement and the composite 
score fell in the “agree” or “disagree” range.” (on a 5 
point Likert scale) (Seagle and Iverson 2001) 
APMO Cut-off Rate 
(average percent of 
majority opinions) 
APMO is based on the sum up of the majority (defined as 
a percentage above 50%) of agreements and 
disagreements divided by the total number of opinions 
expressed.  (Cottam, Roe and Challacombe 2004) 
calculate an APMO Cut-off Rate of 69.7%, thus, questions 
having an agreement level below this rate have not 
reached consensus and are included in the next round. 
Mode, mean/median 
ratings and rankings, 
standard deviation 
“In our case, mode was used as an enumeration of 
respondents who had given 75% or more probability for a 
particular event to happen. If this value was above 50% 
of the total respondents, then consensus was assumed.” 
(Chakravarti et al. 1998) 
Interquartile range 
(IQR) 
“Consensus was obtained, if the IQR was 1 or below on a 
7-point Likert scale” (De Vet et al. 2005) 
Coefficient of variation “A consistent decrease of the coefficients of variation 
between the first and the second round indicated an 
increase in consensus (greater movement toward the 
mean).”  (Buck et al. 1993)  
Post-group consensus “Post-group consensus concerns the extent to which 
individuals – after the Delphi process has been completed 
– individually agree with the final group aggregate, their 
own final round estimates, or the estimates of other 
panelists.”  (Rowe and Wright 1999)  
 
222 
 
The three most widely approaches are: subjective analysis by the researchers; 
average percent of majority opinions cut-off rate; and certain level of 
agreement.  
 
The approach used in this study was ‘certain level of agreement’. While 
Powell (2003) highlights that there is no set standard for the level of 
agreement, Heiko  (2012) notes that a cut off point of 70% agreement is 
commonly employed.  
 
In this study, consensus to an individual statement was deemed to have been 
achieved if 70% or more experts agreed or strongly agreed.  
 
5.2.4.3 Panel of experts 
In any Delphi study, the careful selection of participants as ‘expert panel 
members’ is an essential step to providing high quality, robust and valid data.  
Hanley et al. (2004) define three types of panelists: the stakeholders, the 
experts and the facilitators.  Elwyn et al. (2006) describe four types: decision 
aid developers and researchers, policy makers, health practitioners and 
patients. Delbecq, Van de Ven, Andrew H and Gustafson  (1975) describe in 
detail three roles of panellists which should be represented as  
 
1. top management decision makers who will utilize the outcomes of the 
Delphi study 
2. professional staff together with their support team 
3. the experts to the Delphi questionnaire whose judgments are being 
sought  
 
Defining an ‘expert’  
A dictionary definition of an ‘expert’ is, ‘a person who is very knowledgeable 
about or skilful in a particular area’. (Soanes 2003) Several papers on the use 
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of the Delphi technique have described characteristics which experts should 
possess as being knowledge, experience and ability to influence policy (Cantrill, 
Sibbald and Buetow 1996, Crisp et al. 1999, Keeney, Hasson and McKenna 
2001, Mead and Moseley 2001, Kennedy  2004). Mead and Moseley (2001) 
state that experts can be defined in many ways, for example their public 
acknowledgement or position in a hierarchy or as recommended by other 
participants in a study. Crisp et al. (1999) suggest that the use of the word 
‘expert’ can be changed to ‘informed advocates’, as it is more appropriate. A 
critical review of the Delphi technique by Keeney, Hasson and McKenna (2001) 
quote a variety of definitions of ‘expert’ including ‘informed individual’, 
‘specialist in the field’ or ‘someone who has knowledge about a specific subject’.  
 
1. Knowledge  
There are several approaches to identifying knowledge, such as possessing 
professional qualifications or being registered with professional bodies or 
statutory regulators. Several authors use the term ‘professional qualification’ 
within their definition of ‘expertise’ (Williams and Webb 1994, Hardy et al. 
2004) 
 
Keeney, Hasson and McKenna (2001) however, comment that using knowledge 
alone to define and identify ‘experts’ may be limited, suggesting that knowledge 
does not necessarily equate to expertise. Knowledge can be verified in ways 
other than a professional qualification, for example, possessing a higher degree 
in a specific area may increase the credibility of an expert.  
 
2. Experience  
A predetermined level of experience may reflect a certain level of expertise and 
while this may be connected with a professional qualification (knowledge), the 
two and not necessarily interlinked (Jeffery, Ann Ley, Ian Bennun, Stuart 
McLaren, David  2000, Hardy et al. 2004). 
 
Again, caution is required as Hardy et al. (2004) suggest that it is weak to 
224 
 
consider an individual to be an expert by a certain number of years of 
experience and that consideration still needs to be given to whether the 
individual will posses the required knowledge, attitude and skills. 
 
3. Policy influence 
Several articles recommend the need to consider those holding positions at 
strategic and operational levels within key organisations (Graham, Regehr and 
Wright 2003, Kennedy  2004) 
 
Homogenous or heterogeneous  
Many researchers Mead and Moseley (2001), Mullen  (2003), Powell  (2003), 
Hardy et al. (2004) have all recommended the need for heterogeneity of 
experts, including those from diverse settings, in an attempt to increase the 
validity of the findings. Mead and Moseley (2001) suggest that study findings 
must be meaningful if heterogeneous experts agree. 
 
Number of experts 
There is no clear guidance on the number of panel experts. Delbecq, Van de 
Ven, Andrew H and Gustafson  (1975) recommend that the study population be 
as small as possible, giving reasons of convenience for follow-up. Several 
papers on the use of the Delphi technique have described the most reliable 
samples for Delphi should be small (<20 experts). (Jeffery, Ann Ley, Ian 
Bennun, Stuart McLaren, David  2000, Phillips  2000, Mullen  2003) 
In this study, careful attention was paid to the selection and number of expert 
panel members.  (Sumsion  1998) notes that  ‘… there is no ready answer and 
it becomes the responsibility of each researcher to choose the most appropriate 
group of experts and defend that choice.’ 
 
5.2.4.4 Recruitment of experts 
The key stakeholders in Abu Dhabi in this study were identified as potential 
experts and constituted the sampling frame 
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 senior doctors working within the geriatric speciality,  or those with  
ten years or more experience in managing elderly patients 
 Director or Managers of a hospital department of pharmacy  
 Directors or Managers of a hospital department of nursing  
 chief health professionals (doctors, nurses, pharmacists) holding 
strategic positions within  HAAD  
 chief policy makers working either in hospitals or HAAD  
 chief social workers working either in hospitals or HAAD 
 Senior educators or researchers in Al Ain Medical School working in 
fields relating to medicines management  
 
This sampling frame was estimated to be around 75 health professionals and 25 
other professionals. 
  
INVOLVE (Hanley et al. 2004) is a UK national advisory group, funded by the 
National Institute for Health Research (NIHR), that encourages and supports 
active public involvement in NHS, public health, and social care. INVOLVE 
defines users as “the public,” or “people who use services”. 
While best practice in the UK would be to include expert patients, the position in 
the UAE is very different in terms of patient involvement. Expert patient 
programmes had not yet been established, and the patient’s voice is commonly 
provided from the perspective of healthcare professionals or social workers. 
Patients were therefore not being included as expert panel members for this 
study. 
 
The process of the recruitment of the experts is illustrated in Figure 5.1. This 
involved face to face meetings with key individuals and organisations at distant 
sites in Abu Dhabi.  
 
Informed consent (Appendix 5.2) was obtained from each expert by email once 
they had accepted the invitation to participate in the Delphi method.  
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At the time of study commencement, each expert was sent an email with a link 
to the online survey tool which had been formatted using SNAP 10 (See 
Appendix 5.3). This is an integrated software package used to design surveys 
for either printing or for publishing on the web. Data generated from online 
surveys using SNAP can be transferred directly into SPSS® for data analysis 
(Directorate of Information technology, University of Aberdeen, 2007). 
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Principal Investigator (PI)
Five key stakeholders were 
invited to participate by face to 
face meeting
Head of 
Geriatric 
Department/ 
Hospital
Head of 
Pharmacy 
Department/ 
Hospital
Head of 
Nursing 
Department/ 
Hospital
Manager Clinical 
Reviews and 
Investigation/ 
HAAD
Associate 
Professor/ 
UAE 
University
Invitation email was sent with participant information leaflet
PI asked to pass an invitation 
email to other Geriatricians and 
Family Physicians with  10≥ 
years of experience
PI also pass an invitation 
email to other Chief 
Pharmacists in 4 major 
hospitals
PI asked to pass an 
invitation email to other 
Chief Nurses from different 
hospitals
PI asked to pass an invitation 
email to other Clinical 
Manager, Policy makers, Social 
workers
PI asked to pass an 
invitation email to other 
Academics and Reserchers
Geriatrician
Geriatrician
Family 
Physician(≥10 
years 
experience)
Family 
Physician(≥10 
years 
experience)
Head of Pharmacy 
Department/ 
Hospital
Head of Pharmacy 
Department/ 
Hospital
Head of Pharmacy 
Department/ 
Hospital
Head of Pharmacy 
Department/ 
Hospital
Head of Nursing 
Department/ 
Hospital
Head of Nursing 
Department/ 
Hospital
Head of Nursing 
Department/ 
Hospital
Medical Advisor
Medical Advisor
Director of Public Health
Policy Maker
Policy Maker
Social Worker
Academic at 
Medicine Faculty
Academic at 
Medicine Faculty
Academic at 
Medicine Faculty
Academic at 
Medicine Faculty
Head of Nursing 
Department/ 
Hospital Social Worker
Family 
Physician(≥10 
years 
experience)
 Public Health Advisor
 
Figure 5.1: the process of expert panel member recruitment (n=30)
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5.2.4.5 Delphi round 1  
The round 1 survey was structured into eight sections covering key elements of 
the medicines management, each with several statements. Experts were 
requested to rate their levels of agreement or disagreement with each 
statement on a 6-point Likert scale (strongly disagree, disagree, somewhat 
disagree, somewhat agree, agree, strongly agree). A comments box was 
included for each statements, allowing experts to comment, justify their 
responses and propose new statements. A three week deadline was given for 
completion and return of round 1. 
 
5.2.4.5.1 Analysis of round 1 responses 
Descriptive statistics (frequencies and percentages) were used to analyse 
responses. Content analysis was undertaken for textual responses to identify 
any key emerging themes. 
 
Following analysis, each expert was provided with the summary responses for 
each statement and the verbatim experts’ comments for each statement. 
Comments from the research team were also provided.  
 
5.2.4.6 Delphi round 2 
In addition to providing round 1 responses (see later), the second round 
provided an opportunity to gathering experts’ views and experiences of the 
Delphi approach and its potential uses in the UAE and beyond (the secondary 
research objectives).  
 
A separate survey tool was developed, consisting of a series of statement to be 
rated using a semantic differential scale.  Verhagen, van Den Hooff and Meents 
(2015) stated that this scale requires ‘careful consideration of the research 
context in terms of whether the selected bipolar scales fit the concept being 
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judged (i.e. concept delineation) and the subject group being used (i.e., 
population specification)’. Semantic differential scales had been used to 
measure the meaning of concepts in related areas of I information systems 
planning (Doherty, Marples and Suhaimi 1999), information technology 
(Bhattacherjee and Premkumar 2004), website performance (Huang  2005), 
information systems satisfaction (Xue, Liang and Wu 2011) and perceived 
enjoyment (Luo, Chea and Chen 2011). The scale was devised using opposite-
meaning statements at each pole relating to Delphi participants’ views of their 
involvement in the consensus study  (see table 5.4). The statements were 
reviewed at meetings of the research supervisory team. A three week deadline 
was given to panellists for completion of round 2. 
 
5.2.4.6.1 Analysis of round 2 
Descriptive analysis was used to analyse all responses. Median and interquartile 
range (IQR) were calculated to describe the mid point and range of scores 
(Agresti  2013).  
 
5.2.5 Promoting quality in research: validity and reliability 
Steps were taken to enhance the robustness in terms of the validity and 
reliability of the research at all stages, as described in chapter 2.  
 
 the draft statements of Delphi method was reviewed by academics 
and practitioners independent of the research team  
 heterogeneous members were invited to the study which included 
those from diverse settings (Mead and Moseley 2001) 
 a clearly described sampling strategy was described 
 all participants were given the opportunity to review and comment on 
the statements  
 analysis was independently reviewed by the supervisory team 
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5.3 Results 
5.3.1 Panel of experts 
Out of the original 30 experts invited to participate, 26 consented: three 
geriatricians, two family physicians, five directors of pharmacy departments, 
three directors of nursing departments, five senior academics and eight key 
HAAD professionals (three key medical officers, one director of public health, 
two policy makers and two social workers). The panel composition is 
summarised in Table 5.3 
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Table 5.3: Composition of the panel of experts (n= 26) 
Panel of experts Male Female Total 
Academics  
 Physician 
 Pharmacist 
 Nurse  
 
1 
2 
0 
 
1 
1 
0 
 
2 
3 
0 
Health Professionals  
(working in hospitals) 
 Physician 
 Pharmacist 
 Nurse  
 
 
3 
4 
0 
 
 
2 
1 
3 
 
 
5 
5 
3 
Health Professionals and 
other Professionals 
(working in HAAD) 
 Physician 
 Pharmacist 
 Nurse  
 Others 
 
 
1 
1 
0 
2 
 
 
1 
0 
0 
3 
 
 
2 
1 
0 
5 
Total 14 12 26 
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5.3.2 Round 1 Delphi technique 
This section provides the levels of consensus of experts around each statement, 
separated into eight different sections. Verbatim comments are given for each 
statement; content analysis was not undertaken due to the relatively low 
number of comments. Given the anonymous nature of the Delphi, the responses 
and comments could not be attributed to an individual expert.  
 
5.3.2.1 General Statements 
1. The following definition of medicines management should be adopted in the 
UAE - ‘the clinical, safe and cost effective use of medicines to ensure 
patients get the maximum benefit from the medicines they need, while at 
the same time minimizing potential harm’ 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
4 - - - 6 16 
 
Consensus reached (84%) 
 
 
 
 
 
 
 
 
 
2. Elderly patients with multi-morbidities are at particular risk of medicines   
related issues 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 - - - 7 17 
 
Verbatim comments:  
- a general method is in place but not for above 60 years 
- it covers all the requirements  
- should be adopted because most of the time the availability, 
selection and more specifically administration of medicines to 
elderly affect outcome significantly 
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Consensus reached (92%) 
 
 
 
 
 
 
 
 
 
3. Medicines management should be a focus in the care of every elderly patient 
admitted to hospital, irrespective of the reason for admission or presenting 
complaint 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 - - 1 7 16 
 
Consensus reached (92%) 
 
 
 
 
 
 
4. Medicines management should be a focus in the care of every elderly patient 
admitted to hospital, irrespective of the admitting ward or speciality 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 - - - 8 16 
 
Verbatim comments:  
- drug interactions are high in elderly because of polypharmacy, and 
altered pharmacodynamics in the elderly 
- patients with dementia, A-fibrillation, Heart failure are usually 
candidate for polypharmacy and hence increased risk of medicine 
related issues 
 
 
Verbatim comments:  
- medication reconciliation and review of patient medications for any 
actual and potential side effects should be given high priority in 
causing mental status changes, electrolyte imbalance and renal 
functions deterioration 
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Consensus reached (92%) 
 
5. Medicines management should be a focus in the care of elderly patient 
admitted to hospital, irrespective of the duration of stay in hospital 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 - - 3 7 14 
 
Consensus reached (92%) 
 
 
 
 
6. Medicines management should only be a focus in the care of elderly patients 
admitted to hospital with a medicines related issue 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
10 5 - 2 5 4 
 
Consensus not reached (34%) 
 
 
 
 
 
 
 
7. Medicines management is the responsibility of all nurses, pharmacists and 
physicians 
 
Verbatim comments:  
- but those should be categorise to high risk elderly patients 
 
 
 
Verbatim comments:  
- medication review and management should be applied to every 
elderly admitted to the hospital regardless the diagnosis 
- should focus on elderly in the primary healthcare first 
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - 3 3 19 
 
Consensus reached (84%) 
 
8. All nurses, pharmacists, physicians should be competent in medicines 
management 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - 1 9 15 
 
Consensus reached (92%) 
 
 
 
 
 
 
9. Evidence based recommendations which focus on single disease states 
should be applied with caution in elderly patients with multi-morbidities 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - 1 8 16 
 
Consensus reached (92%) 
 
 
 
Verbatim comments:  
- team work...but not entering the fields of expertise and interfering 
- should be competent in elderly management 
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In summary: 
 
 
 
 
 
 
5.3.2.2 Guidelines for Medicines Management in Elderly Hospitalised Patients 
1. There is a need to develop guidelines for medicines management in elderly 
hospitalised patients in the UAE 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 - - 1 7 16 
 
Consensus reached (88%) 
 
 
 
 
 
 
2. A guideline development group should be established, under the auspices of 
Health Authority of Abu Dhabi (HAAD), with representation from experts in 
medicines in the elderly 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 - 1 1 9 13 
 
Consensus reached (84%) 
 
Section 1: consensus achieved for eight statements.  
  
Consensus not achieved for statement 1.6, that medicines management is a 
focus for those with medicines related issues BUT reached consensus on 1.3, 
that it is a focus for every elderly patient.    
Verbatim comments:  
- currently no guidelines 
- medication errors can arise from lack of such guidelines or not 
applying the existing ones 
- but not leave patient untreated because of guideline  
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3. The guidelines should have a focus on medicines reconciliation at the point of 
admitting and discharging elderly patients to hospital  
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 - - 1 8 15 
 
Consensus reached (88%) 
 
4. The guidelines should have a focus on the prescribing of medicines in the 
elderly  
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 - - - 11 13 
 
Consensus reached (92%) 
 
5. The guidelines should have a focus on the monitoring of medicines in the 
elderly  
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - - 10 15 
 
Consensus reached (96%) 
 
6. The guidelines should have a focus on managing inappropriate polypharmacy 
in elderly patients with multi-morbidities. (Inappropriate polypharmacy is 
Verbatim comments:  
- include: MOH / Dubai health authority 
- i agree with this plan, but I am not sure if HAAD is the only 
regulatory authority 
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defined as ‘the prescribing of too many medicines which are unsuitable or no 
longer indicated’) 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 1 - - 10 14 
 
Consensus reached (92%) 
 
 
 
 
 
 
 
 
 
 
 
7. The guidelines should have a focus on reviewing all medicines in elderly 
patients with multi-morbidities to promote appropriate polypharmacy 
(Appropriate polypharmacy is ‘prescribing of many medicines but which are 
suitable’) 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - - - 9 17 
 
Consensus reached (100%) 
 
8. The guidelines should highlight high risk medicines in the elderly  
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - - 7 18 
 
Consensus reached (96%) 
 
 
 
 
Verbatim comments:  
- check interactions and find suitable solutions always 
-  we noticed many geriatric patients taking more than 15 
medications  
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9. The guidelines should highlight potentially inappropriate medicines in the 
elderly 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 1 - 1 6 16 
 
Consensus reached (84%) 
 
10.Consideration should be given to adapting defined lists of high risk or 
potentially inappropriate medicines in the elderly,2 for the UAE context, such 
as: 
 Beers Criteria (potentially inappropriate medicines use in older adults) 
 STOPP Criteria (screening tool of potentially inappropriate prescribing) 
 IPET- Improving Prescribing in the Elderly Tool (commonly 
encountered drug-disease interactions, mostly focusing on 
cardiovascular and psychotropic drugs) 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 1 - 12 12 
 
Consensus reached (92%) 
 
 
 
 
 
 
11.Consideration should be given to using the Drug Burden Index as a tool to 
quantify exposure to anticholinergic and sedative agents in the elderly  
 
Verbatim comments:  
- especially with medications with narrow therapeutic index and anti-
cholinergic properties as they are troublesome 
 
 
 
Verbatim comments:  
- I have no experience of validity of those criteria! 
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - 2 12 11 
 
Consensus reached (88%) 
 
 
 
 
 
 
 
12.The guidelines should have a focus on identifying and managing adverse 
drug reactions in the elderly 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 1 1 9 14 
 
Consensus reached (88%) 
 
13.Consideration should be given to adapting defined list of commonly omitted 
medicines in the elderly, for the UAE context, such as: 
 START Criteria (screening tool to alert physicians to right treatment) 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 1 - 4 7 13 
 
Consensus reached (76%) 
 
14.Consideration should be given to adopting validated measures of adherence, 
such as: 
 Morisky scale  
 Medication adherence questionnaire 
 Self-Efficacy for Appropriate Medication Use Scale 
 
 
Verbatim comments:  
- not sure of the impact 
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- 1 - 4 7 14 
 
Consensus reached (80%) 
 
 
 
 
 
15.The guidelines should have a focus on adherence (or non-adherence) to 
medicines  
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 1 - 3 10 11 
 
Consensus reached (80%) 
 
16.Consideration should be given to adopting evidence based approaches to 
guideline implementation in the UAE 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - - 2 10 14 
 
Consensus reached (92%) 
 
In summary: 
 
 
 
 
 
 
Verbatim comments:  
- adherence is a major issue in the UAE not only for the elderly 
- I am not familiar with these scales 
 
 
 
 
Section 2: consensus achieved for all statements.  
 
242 
 
5.3.2.3 Medicines Reconciliation 
1. The following definition of medicines reconciliation should be adopted in the 
UAE - ‘the process of identifying the most accurate list of a patient’s current 
medicines – including the name, dosage, frequency and route – and 
comparing them to the current list in use, recognizing and discrepancies, and 
documenting any changes, thus resulting in a complete list of medications, 
accurately communicated’ 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - 2 11 12 
 
Consensus reached (88%) 
 
 
 
 
 
 
 
 
 
 
2. Medicines reconciliation should be determined at the point of admission to 
and discharge from hospital 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - - 9 16 
 
Consensus reached (96%) 
 
 
 
 
 
 
 
 
3. Determination of medicines reconciliation can be undertaken by any nurse, 
pharmacist, physician 
Verbatim comments:  
- the max dose of medications for elderly - the starting dose 
- we find few patients are taking medications from same 
Pharmacological group as brand names are different. So medication 
reconciliation is particularly important 
 
 
 
Verbatim comments:  
- also between services if the patient has been transferred from one 
department to another 
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 5 4 7 5 4 
 
Consensus not reached (34%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Determination of medicines reconciliation can be undertaken by any nurse 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
5 6 6 5 2 2 
 
Consensus not reached (15%) 
 
 
 
 
 
 
 
5. Determination of medicines reconciliation can be undertaken by any 
pharmacist 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 3 3 7 6 6 
 
Consensus not reached (46%) 
 
Verbatim comments:  
- not the nurse - it might be difficult for them to know the drug 
names 
- Physician and Pharmacist should only be involved 
- all together not separately 
- nurses are not prescribers in this country 
- guided by policy and medication reconciliation verified by the 
Clinical Pharmacist 
 
 
Verbatim comments:  
- as long as this is guided by policy 
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6. Determination of medicines reconciliation can be undertaken by any 
physician 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 3 3 4 8 7 
 
Consensus not reached (57%) 
 
7. Determination of medicines reconciliation should only be undertaken by a 
health professional trained in that role 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- 2 3 2 9 10 
 
Consensus reached (73%) 
 
8. Determination of medicines reconciliation in an elderly patient with dementia 
or other cognitive impairment requires specialist input 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- 1 - 1 12 12 
 
Consensus reached (92%) 
 
9. Any medicines related issues resulting from determination of medicines 
reconciliation should be recorded in the shared medical records 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - - 2 9 15 
 
Consensus reached (92%) 
 
10.There is a need for a standard operating procedure to guide the 
determination of medicines reconciliation in elderly patients 
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 1 - 9 15 
 
Consensus reached (92%) 
 
11.There is a need to develop standardised documentation to record 
determination of medicines reconciliation in elderly patients 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- 2 - - 7 17 
 
Consensus reached (92%) 
 
 
In summary: 
 
 
 
 
 
 
 
 
 
 
5.3.2.4 Medicines Review 
1. The following definition of medicines review should be adopted in the UAE  - 
‘a structured, critical examination of the complete list of a patient's 
medicines with the objective of reaching an agreement with the patient 
about treatment, optimising the impact of medicines, minimising the number 
of medication-related problems and reducing waste’ 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - 1 1 16 8 
Section 3: consensus achieved for seven statements.  
 
Consensus not achieved for statements 3.3, 3.4, 3.5 and 3.6, that 
determination of medicines reconciliation can be undertaken by any 
nurse or any pharmacist or any physician BUT reached consensus on 3.7, 
that it should only be undertaken by a health professional trained in that 
role. 
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Consensus reached (92%) 
 
2. All elderly patients with multi-morbidities should have a full medicines review 
during their stay in hospital to promote appropriate polypharmacy 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- 1 - 2 8 15 
 
Consensus reached (88%) 
 
3. Only elderly patients admitted with a medicines related issue should have a 
full medicines review during their stay in hospital to promote appropriate 
polypharmacy 
 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
6 5 5 2 6 2 
 
Consensus not reached (30%) 
 
4. A full medicines review can be undertaken by any nurse, pharmacist, 
physician 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
3 8 5 1 6 3 
 
Consensus not reached (34%) 
 
5. A full medicines review can be undertaken by any nurse 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
10 3 10 - 3 - 
 
Consensus not reached (11%) 
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6. A full medicines review can be undertaken by any pharmacist 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 5 2 5 4 8 
 
Consensus not reached (46%) 
 
 
 
 
 
 
 
 
7. A full medicines review can be undertaken by any physician 
 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 3 3 4 9 5 
 
Consensus not reached (54%) 
 
8. A full medicines review should only be undertaken by a health professional 
trained in that role  
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 1 1 3 7 12 
 
Consensus reached (73%) 
 
9. A full medicines review in an elderly patient with dementia or other cognitive 
impairment requires specialist input 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 1 1 - 9 14 
 
Consensus reached (88%) 
Verbatim comments:  
- In elderly, you need expert clinical pharmacist 
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10.Any medicines related issues resulting from a full medicines review should be 
recorded in the shared medical records 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- 1 1 - 8 16 
 
Consensus reached (92%) 
 
 
 
 
 
 
 
 
11.There is a need for a standard operating procedure to guide the conduct of a 
full medicines review in elderly patients 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - 1 - 10 15 
 
Consensus reached (96%) 
 
12.There is a need to develop standardised documentation to record a full 
medicines review in elderly patients 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - 1 1 8 16 
 
Consensus reached (92%) 
 
13.A multi-disciplinary ward team (specifically nurses, pharmacists and 
physicians) should review the medicines prescribed to elderly patients on a 
regular basis during their stay in hospital 
 
Verbatim comments:  
- should be discussed during multidisciplinary meeting for the patients 
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - 1 3 6 16 
 
Consensus reached (84%) 
 
14.All medicines prescribed to elderly patients during stay in hospital should be 
reviewed prior to their discharge 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - 1 - 9 16 
 
Consensus reached (96%) 
 
15.The standard operating procedure should include providing information to 
health professionals (family doctor, nurse, pharmacist) working in primary 
care informing them of the nature of any changes made to medicines during 
stay and any follow-up required  
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - 1 - 9 16 
 
Consensus reached (96%) 
 
 
 
 
 
 
 
In summary: 
Verbatim comments:  
- this is mostly not applied and lead to repetition of the problem 
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5.3.2.5 Medicines Adherence 
1. The following definition of medicines adherence should be adopted in the 
UAE - ‘the extent to which patients take medicines as prescribed by their 
health care providers’ 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - 1 13 11 
 
Consensus reached (92%) 
 
2. Adherence (or non-adherence) to all medicines should be determined at   the 
point of admitting all elderly patients to hospital 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 1 - 4 9 10 
 
Consensus reached (73%) 
 
 
 
Section 4: consensus achieved for 10 statements.  
 
Consensus not achieved for statement 4.3, that only elderly patients 
admitted with a medicines related issue should have a full medicines 
review BUT reached consensus on 4.2, that all elderly patients with 
multi-morbidities should have a full medicines review. 
 
Consensus not achieved for statements 4.4, 4.5, 4.6 and 4.7, that a full 
medicines review can be undertaken by any nurse or any pharmacist or 
any physician BUT reached consensus on 4.8, that It should only be 
undertaken by a health professional trained in that role. 
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3. Determination of adherence (or non-adherence) can be undertaken by any 
nurse, pharmacist, physician 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 4 3 8 6 4 
 
Consensus not reached (38%) 
 
 
 
 
 
 
 
 
4. Determination of adherence (or non-adherence) can be undertaken by any 
nurse 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
3 5 1 10 6 1 
 
Consensus not reached (27%) 
 
5. Determination of adherence (or non-adherence) can be undertaken by any 
pharmacist 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 2 2 5 9 7 
 
Consensus not reached (62%) 
 
Verbatim comments:  
- during each visit to the clinic  
- may not be possible to determine this on admission  
-  
Verbatim comments:  
- pharmacist is the best to do it  
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6. Determination of adherence (or non-adherence) can be undertaken by any 
physician 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 2 1 5 11 5 
 
Consensus not reached (62%) 
 
7. Determination of adherence (or non-adherence) should only be undertaken 
by a health professional trained in that role 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 1 1 1 14 7 
 
Consensus reached (80%) 
 
8. Determination of adherence (or non-adherence) in an elderly patient with 
dementia or other cognitive impairment requires specialist input 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 2 3 9 11 
 
Consensus reached (76%) 
 
9. Any medicines related issues resulting from determination of adherence 
should be recorded in the shared medical records 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - 1 - 11 14 
 
Consensus reached (96%) 
 
10.There is a need for a standard operating procedure to guide the 
determination of adherence (or non-adherence) in elderly patients 
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 3 1 6 15 
 
Consensus reached (80%) 
 
11.There is a need to develop standardised documentation to record 
determination of adherence (or non-adherence) in elderly patients 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 2 - 7 16 
 
 
Consensus reached (88%) 
 
 
In summary: 
 
 
 
 
 
 
 
 
 
 
 
5.3.2.6 Medicines Counselling 
 
1. The following definition of medicines counselling should be adopted in the 
UAE - ‘provision of advice and instruction by a health care professional to 
patients regarding the appropriate use of their medicines’ 
 
 
 
 
Section 5: consensus achieved for seven statements.  
 
Consensus not achieved for statements 5.3, 5.4, 5.5 and 5.6, that 
determination of adherence can be undertaken by any nurse or any 
pharmacist or any physician BUT reached consensus on 5.7, that It should 
only be undertaken by a health professional trained in that role. 
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 1 1 8 15 
 
Consensus reached (88%) 
 
2. All elderly patients should be counselled on their medicines prior to discharge 
 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - 1 - 8 17 
 
Consensus reached (96%) 
 
3. Only elderly patients identified as non-adherent/ potentially non-adherent 
should be targeted for counselling on their medicines prior to discharge 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
4 7 4 1 5 5 
 
Consensus not reached (38%) 
 
 
 
 
 
 
 
4. Only elderly patients commenced new medicines or having a change in 
medicines should be targeted for counselling on their medicines prior to 
discharge 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
5 8 2 2 8 1 
 
Verbatim comments:  
- every single patient of any age or case must have counselling prior 
to discharge  
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Consensus not reached (34%) 
 
 
 
 
 
 
 
 
5. Medicines counselling can be undertaken by any nurse, pharmacist, 
physician 
 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
5 6 4 4 5 2 
 
Consensus not reached (26%) 
 
6. Medicines counselling can be undertaken by any nurse 
 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
6 8 7 3 1 1 
 
Consensus not reached (7%) 
 
7. Medicines counselling can be undertaken by any pharmacist 
 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 2 2 5 6 9 
 
Consensus not reached (57%) 
 
8. Medicines counselling can be undertaken by any physician 
 
 
Verbatim comments:  
- all elderly should be targeted   
- all patient and sometimes reinforcement needed  
- medication counselling should be done on regular basis  
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 6 1 5 8 4 
 
Consensus not reached (46%) 
 
 
9. Medicines counselling should only be undertaken by a health professional 
trained in that role 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
2 1 1 3 9 10 
 
Consensus reached (73%) 
 
 
 
 
 
 
 
 
10.Medicines counselling in an elderly patient with dementia or other cognitive 
impairment requires specialist input 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - 1 2 11 12 
 
Consensus reached (88%) 
 
11.Medicines counselling should always involve the elderly patient’s 
family/carers/friends where appropriate 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 1 1 7 16 
 
Consensus reached (88%) 
Verbatim comments:  
- only pharmacist who is an expert in that field 
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12.Counselling should focus on elderly patients’ beliefs, intentions and values 
relating to medicines to encourage behavioural and lifestyle changes 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 1 3 9 12 
 
Consensus reached (80%) 
 
 
 
 
 
 
13.There is a need for a standard operating procedure to guide medicines 
counselling in elderly patients 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 2 1 6 16 
 
Consensus reached (84%) 
 
14.The standard operating procedure should include providing information to 
health professionals (family doctor, nurse, pharmacist) working in primary 
care informing them of the nature of any counselling provided prior to 
discharge and any follow-up support required 
 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
- - - 1 10 15 
 
Consensus reached (96%) 
 
15.There is a need to develop standardised documentation to record counselling 
in elderly patients 
Verbatim comments:  
- not applicable here 
258 
 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - 1 9 15 
 
Consensus reached (92%) 
 
In summary:  
 
 
 
 
 
 
 
 
 
 
 
 
5.3.2.7 Health Professional Training 
1. All health professionals working with medicines in the elderly should receive 
regular, ongoing training relating to medicines management 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 1 - 7 17 
 
Consensus reached (92%) 
 
2. Training should focus on patient involvement in decision making 
 
 
Section 6: consensus achieved for nine statements.  
 
Consensus not achieved for statement 6.3 and 6.4, that only elderly 
patients identified as non-adherent/ potentially non-adherent or 
commenced new medicines should be targeted for counselling on their 
medicines prior to discharge BUT reached consensus on 6.2, that all 
elderly patients should be counselled on their medicines prior to 
discharge. 
 
Consensus not achieved for statements 6.5, 6.6, 6.7 and 6.8, that 
medicines counselling can be undertaken by any nurse or any 
pharmacist or any physician BUT reached consensus on 6.9, that It 
should only be undertaken by a health professional trained in that role. 
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 1 2 9 13 
 
Consensus reached (84%) 
 
3. Training should focus on aspects of cultural diversity 
 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - 2 - 10 13 
 
Consensus reached (88%) 
 
In summary: 
 
 
 
 
 
 
5.3.2.8 Evaluation Research 
1. Consideration should be given to developing a research program to evaluate 
the implementation of the these guidelines in the UAE 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - 1 10 14 
 
Consensus reached (92%) 
 
2. Evaluation should consider the perspectives of all stakeholders, including 
patients 
 
 
 
Section 7: consensus achieved for all statements.  
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Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1 - - - 10 15 
 
Consensus reached (96%) 
 
In summary:   
 
 
 
 
5.3.3 Round 2 Delphi technique 
During round 2, experts were provided with the detailed results of round 1, 
highlighting most of statements achieving consensus agreement (≥70%). While 
20 statements did not reach consensus, the decision was taken to not repeat a 
further round attempting to gain consensus for these 20. It was considered that 
the responses to those statements achieving consensus themselves explained 
those not achieving consensus. For example, while consensus was achieved that 
all elderly patients should be a focus for medicines management, it was not 
achieved for only targeted patients.  
 
The second round therefore focused on the secondary research objectives, 
gathering expert’ views and experiences of the Delphi approach and its potential 
uses in the UAE and beyond.  
 
Out of the original 30 key stakeholders invited to participate, the response rate 
was 83% (n=25). Eighty-four percent (n=21) of panellists were not aware of 
consensus research methods and only 8% (n=2) had prior experience of being 
involved in a consensus study. Table 5.4 gives detailed responses.  
 
 
 
 
Section 8: consensus achieved for all statements.  
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Table 5.4: Delphi participants’ views of their involvement in the consensus study (n=25) 
Statements Anchor 
1 
%(n) 
 
2 
%(n) 
 
3 
%(n) 
 
4 
%(n) 
Anchor 
5 
%(n) 
Statements Median 
(M) 
& 
IQR 
The information provided was sufficient to 
complete the tasks  
 
68  
(17) 
16  
(4) 
8 
(2) 
 
4 
(1) 
4 
(1) 
 
The information provided was insufficient to 
complete the tasks 
M    = 1 
IQR = 1 
I had sufficient knowledge and understanding 
of the subject to participate  
32  
(8) 
52 
(13) 
8 
(2) 
4 
(1) 
4 
(1) 
I had insufficient knowledge and understanding 
of the subject to participate 
M    = 2 
IQR = 1 
Completing the survey was time consuming   
0 
12 
 (3) 
60 
(15) 
16 
 (4) 
12 
 (3) 
Completing the survey was not time consuming M    = 3 
IQR = 1 
The survey was easy to complete 12 
 (3) 
64 
(16) 
12  
(3) 
8 
(2) 
4 
(1) 
The survey was difficult to complete 
 
M    = 2 
IQR = 0.5 
Statements were not at all threatening 68 
 (17) 
8 
(2) 
12 
(3) 
 
0 
12 
 (3) 
Statements were extremely threatening M    = 1 
IQR = 1.5 
I gained new knowledge from completing the 
survey 
20 
 (5) 
52 
(13) 
12 
 (3) 
12  
(3) 
4 
(1) 
I did not gain new knowledge from completing 
the survey 
 
M    = 2 
IQR = 1 
I was under no pressure to agree with the 
other panel members  
68 
 (17) 
16 
 (4) 
4 
(1) 
4 
(1) 
8 
(2) 
I felt under great pressure to agree with the 
other panel members 
M    = 1 
IQR = 1 
The Delphi was a very useful approach to 
obtaining consensus  
36 
 (9) 
48 
(12) 
8 
(2) 
 
0 
8 
(2) 
The Delphi was not very useful approach to 
obtaining consensus 
M    = 2 
IQR = 1 
The Delphi process met my expectations  48 
 (12) 
28 
 (7) 
16 
 (4) 
4 
(1) 
4 
(1) 
The Delphi process did not meet my 
expectations 
M    = 2 
IQR = 1.5 
Using the Delphi approach in developing 
medicines management guidelines was 
effective  
24 
 (6) 
60 
(15) 
8 
(2) 
4 
(1) 
4 
(1) 
Using the Delphi approach in developing 
medicines management guidelines was not 
effective 
M    = 2 
IQR = 0.5 
Using the Delphi approach promoted 
multidisciplinary working 
40 
 (10) 
44 
(11) 
12 (3) 4 
(1) 
 
0 
Using the Delphi approach did not promote 
multidisciplinary working 
M    = 2 
IQR = 1 
I will consider adopting the Delphi approach 
to future practice developments  
28 
 (7) 
52 
(13) 
8 
(2) 
12 
 (3) 
0 I will not consider adopting the Delphi 
approach to future practice developments 
M    = 2 
IQR = 1 
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5.4 Discussion  
 
5.4.1 Key findings  
The aim of this phase of the research was to determine consensus in relation to 
strategic and operational approaches around medicines management for elderly 
hospitalised patients. 
 
A high level of expert participation was achieved with consensus agreement for 
almost all statements on structures and processes of medicines management at 
round one. Twenty statements did not reach consensus and the reasons for not 
undertaking a further round as follows  
 
Statement 6 (section 1):  
Only 34% of the panellists voiced an agreement, stated that ‘medicines 
management should only be a focus in the care of elderly patients admitted to 
hospital with a medicines related issue.’ In contrast, there was 84% agreement 
regarding the statement that ‘medicines management should be a focus in the 
care of every elderly patient admitted to hospital, irrespective of the reason for 
admission or presenting complaint’.  
 
Statements 3, 4, 5 and 6 (section 3):  
Consensus was not achieved on the matter of the specific professionals who 
should undertaken medicines reconciliation. However, consensus was achieved 
(73%) for that ‘medicines reconciliation should only be undertaken by a health 
professional trained in that role’.  
 
Statements 3, 4, 5, 6 and 7 (section 4):  
Consensus was achieved on all elderly patients with multi-morbidities should 
have a full medicines review hence not for only those with a medicines related 
issue. Continuing the trend from previous section, there was no agreement over 
which specific professionals should undertake medicines reviews but consensus 
that this could be undertaken by those trained for that role.  This was also 
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observed in relation to determining medicines adherence (statements 3, 4, 5 
and 6 (section 5)) and counselling (statements 3, 4, 5, 6, 7 and 8 (section 6)).   
 
The second round involved gathering experts’ views and experiences of the 
Delphi approach. Panellists responded positively to all aspects of the process 
(other than the time commitment) and the potential for Delphi to be employed 
in future studies and professional development.  
 
5.4.2 Study strengths and limitations  
There are a number of strengths to this study. The current study provided 
quantitative information regarding aspects of the structures and processes of 
medicines management of elderly hospitalised patients. The statements for 
Delphi survey instrument were developed from three sources: review of 
narrative and systematic literature reviews related to medicines management 
(Chapter 1); systematic review of the Drug Burden Index (Chapter 3); and 
analysis of data generated from the in-depth interviews (Chapter 4). It was also 
grounded in theory with NPT being applied as a theoretical lens in terms of 
coherence (definitions of key elements of medicines management), cognitive 
participation (task allocation of the responsibilities of health professionals), 
collective action (the actual work or skills involved in delivering the tasks 
relating to medicines management) and reflexive monitoring (specialised 
education and training services). The TDF and BCW were also lenses applied in 
terms of changing behaviour via training, SOPs, documentation and research. In 
addition, these statements were tested for face and content validity by a panel 
of seven experts on medicines management and related areas in Scotland and 
the UAE.  
 
The expert panel members came from diverse settings of different healthcare 
professionals and other key professions. This increases the likelihood of having 
generated valid responses, addressing all the key elements of medicines 
management for elderly, hospitalised patients in the UAE.  
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The different expertise and professions among panel members allowed for more 
generalisable (externally valid) research findings. The importance of 
heterogeneity in healthcare decision-making has been highlighted recently by 
Kanoute, Faye and Bourgeois (2014) and is clearly a feature of NPT. Indeed, 
when several different professions are represented in a decision-making team, 
the Delphi method may be the most effective tool for reaching a decision which 
is suggested by Elwyn et al. (2006).  
 
This study produced a high response rate of 87% which meant that the 
likelihood of response bias is low and the data are therefore more likely to be 
internally valid and generalisable. 
 
Throughout this Delphi study, attention was paid to aspects of the robustness of 
research. Validity and reliability are found to decrease in Delphi studies due to 
subject or situation bias. (Kastein et al. 1993) In this study, validity was 
supported and maximised by selecting expert panel members, the use of 
multiple iterations, a structured response analysis, statistical consensus and a 
feedback loop to expert panel members. Delphi studies are considered reliable if 
the same results can be obtained from similar panellists under similar contexts 
and conditions. (Kastein et al. 1993) 
  
The research design attempted to avoid issues around sampling bias but the 
exact sampling frame was difficult to access and therefore unknown (roles and 
numbers). However the Delphi sample size does not depend on statistical 
power; it depends on group dynamics for arriving at consensus among experts. 
(Delbecq, Van de Ven, Andrew H and Gustafson  1975) 
 
However, there are study limitations and hence the findings should be 
interpreted with caution. There was a ‘snowballing’ element to the sampling 
process where certain individuals were requested to pass study invites to 
others. While instructions were given on the criteria of the individuals to be 
invited, the actual approach to identifying and selecting these individuals was 
outwith the control of the PI and hence largely unknown. In Delphi studies, 
snowballing is used to recruit participants who are difficult to find or not easily 
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accessible to researchers through other sampling strategies. A study by Cohen 
and Arieli (2011) describes that snowball sampling contradicts many 
conventional assumptions of statistical sampling, though it does hold several 
advantages in allowing access to certain segments of the population that may 
not be otherwise easily accessed.  
 
Another limitation is that the cut off value for determining consensus of 
agreement was rather arbitrary with no set of standard, although this is one of 
the most widely used approaches. (Powell  2003 and Heiko  2012) It was not 
possible to identify individual respondents and hence there could be unidentified 
skewing of the findings. For example, while 84% of experts agreed with the 
proposed definition of medicines management, four experts strongly disagreed. 
It is possible that these four may all be from the same profession, which could 
reduce the validity of the conclusion and generalisability of the data. It is 
notable that for almost all those statements where consensus was achieved, 
one or more experts strongly disagreed but provided little comment to justify 
their responses.  Future studies could build in a process to identify individual 
experts but this may reduce the participation and hence response rate.  
 
Another limitation is that there were no expert patients included in this study, 
for reasons described previously.  
 
Moreover, though the study was unique in its focus on a Middle Eastern area 
(UAE), its generalisability may be questionable due to cultural and conceptual 
differences. (Lages, Pfajfar and Shoham 2015)  Nair, Aggarwal, et al. (2011) 
state that one of the weaknesses of Delphi study is generalisability of the study 
findings hence while these findings have been generated for Abu Dhabi, they 
may not be applicable to the entire emirate, the UAE, the Middle East and 
beyond. While this is a limitation, the funding for the research was provided by 
the UAE Embassy to provide data relevant to that country. However, experts 
without the UAE were involved in statement validation, which may increase 
generalisability.  
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5.4.3 Interpretation of findings  
The responses to the statements are in line with the concept of clinical 
governance, defined as ‘a system through which organisations are accountable 
for continuously improving the quality of their services and safeguarding high 
standards of care by creating an environment in which excellence in clinical care 
will flourish’. (Scally and Donaldson 1998) A policy manual issued by HAAD 
(2012) indicated the purpose of clinical governance, which is to ensure, as far 
as possible, the provision of safe, effective, ethical and high quality healthcare 
in the Emirate of Abu Dhabi. Responses highlight the need for trained staff to 
deliver high quality service supported by standard operating procedures and 
clearly documented audit trails. 
 
This remainder of this section is informed by a comprehensive literature search 
of Medline, CINAHL, and International Pharmaceutical Abstracts (see Appendix 
5.4 for search strategy) of consensus method research in relation to strategic 
and operational approaches around medicines management for elderly patients, 
from the health professional perspective. Four relevant studies were identified 
which are described in Table 5.5.  
 
The four studies focused on general elements of medicines management 
structures and processes.  
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Table 5.5: Data extraction for four relevant consensus studies 
Reference Specified 
Aim/objective 
Setting 
(country, 
institution) 
Design Participants Outcome 
measures 
Key Findings Conclusion 
(Esmaily et 
al. 2008) 
To obtain experts' 
consensus about 
appropriate educational 
outcomes of rational 
prescribing for general 
physicians in CME and 
developing curricular 
contents for this 
education. 
Tabriz (Iran)  A two-round 
Delphi 
consensus 
process to 
identify the 
outcome-
based 
educational 
indicators 
regarding 
rational 
prescribing for 
general 
physicians in 
primary care  
21 stakeholders: 
7 experienced 
GPs, 4 CME 
decision makers, 
3 pharmacists, 3 
pharmacologists 
and 4 medical 
specialists 
 
Potential outcome 
for rational 
prescribing 
identified from a 
range of sources. 
21 learning outcomes were 
identified through a modified 
Delphi process. The indicators 
were used by the panels of 
experts and six educational 
topics were determined for 
the CME programme and the 
curricular content of each was 
defined. The topics were 1) 
Principles of prescription 
writing, 2) Adverse drug 
reactions, 3) Drug 
interactions, 4) Injections, 5) 
Antibiotic therapy, and 6) 
Anti-inflammatory agents 
therapy. 
Consensus on learning 
outcomes was achieved 
and an educational 
guideline was 
designed. Before 
suggesting widespread 
use in the country the 
educational package 
should be tested in the 
CME context. 
(Greenwald 
et al. 
2010) 
To identify barriers to 
meaningful 
implementation of 
medication 
reconciliation and 
developing a feasible 
plan toward its 
effective 
implementation in the 
hospital setting 
 
Chicago (US) 
 
Consensus 
method by 
invitation-only 
meeting held 
on the 
Northwestern 
Medical 
Campus in 
Chicago 
 
 
Stakeholders 
representing 
professional, 
clinical, health 
care quality, 
consumer, 
regulatory, and 
accreditation 
organizations 
 
 
The outcome 
measure was four 
key relevant 
domains: 
(1) how to 
measure success 
in medication 
reconciliation, (2) 
key elements of 
successful 
strategies, (3) 
leveraging 
partnerships 
outside the 
hospital setting to 
support 
medication 
reconciliation, and 
4) the roles of the 
patient and 
family/caregivers 
and health 
literacy 
 
The participants identified 10 
key areas requiring further 
attention in order to move 
medication reconciliation 
toward this focus:  
1. There is need for a 
uniformly acceptable and 
accepted definition of what 
constitutes a medication and 
what processes are 
encompassed by 
reconciliation. 
2. The varying roles of the 
multidisciplinary participants 
in the reconciliation process 
must be clearly defined. 
3. Measures of the 
reconciliation processes must 
be clinically meaningful (that 
is, of defined benefit to the 
patient) and derived through 
consultation with stakeholder 
groups. 
4. While a comprehensive 
Medication 
reconciliation is 
complex and made 
more complicated by 
the disjointed nature of 
the American health 
care system. 
Addressing these 10 
points with an 
overarching goal of 
focusing on patient 
safety rather than only 
accreditation should 
result in improvements 
in medication 
reconciliation and the 
health of patients 
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 reconciliation system is 
needed across the continuum 
of care, a phased approach to 
implementation, allowing it to 
start slowly and be tailored to 
local organizational structures 
and workflows, will increase 
the chances of successful 
organizational uptake. 
5. Developing mechanisms for 
prospectively and proactively 
identifying patients at risk for 
medication-related adverse 
events and failed 
reconciliation is needed 
6. Given the diversity in 
medication reconciliation 
practices, research aimed at 
identifying effective processes 
is important and should be 
funded with national 
resources. 
7. Strategies for medication 
reconciliation-both successes 
and key lessons learned from 
unsuccessful efforts-should be 
widely disseminated. 
8. A personal health record 
that is integrated and easily 
transferable between sites of 
care is needed. 
9. Partnerships between 
health care organizations and 
community-based 
organizations create 
opportunities to reinforce 
medication safety principles 
outside the traditional 
clinician- patient relationship. 
10. Aligning health care 
payment structures with 
medication safety goals is 
critical to ensure allocation of 
adequate resources to design 
and implement effective 
medication reconciliation 
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processes. 
 
 
(Clyne, 
White and 
McLachlan 
2012) 
To develop practical 
consensus-based policy 
solutions to address 
medicines non-
adherence for Europe 
Europe A four-round 
Delphi study 
was conducted 
The Delphi Expert 
Panel comprised 
50 participants 
from 14 countries 
and was 
representative of: 
patient/carers 
organisations; 
healthcare 
providers and 
professionals; 
commissioners 
and policy 
makers; 
academics; and 
industry 
representatives 
experience 
Participants were 
invited to respond 
to open questions 
about the causes, 
consequences and 
solutions to 
medicines non-
adherence 
43 separate policy solutions to 
medication non-adherence 
were agreed by the Panel. 25 
policy solutions were 
prioritised based on composite 
scores for importance, and 
operational and political 
feasibility. Prioritised policy 
solutions focused on 
interventions for patients, 
training for healthcare 
professionals, and actions to 
support partnership between 
patients and healthcare 
professionals. Few solutions 
concerned actions by 
governments, healthcare 
commissioners, or 
interventions at the system 
level 
Consensus about 
practical actions 
necessary to address 
non-adherence to 
medicines has been 
developed for Europe. 
These actions are also 
applicable to other 
regions. Prioritised 
policy solutions for 
medicines non-
adherence offer a 
benefit to policymakers 
and healthcare 
providers seeking to 
address this 
multifaceted, complex 
problem 
(O'Mahony 
et al. 
2015) 
Aims of this study: 
screening tool of older 
people's prescriptions 
(STOPP) and screening 
tool to alert to right 
treatment (START) 
criteria were first 
published in 2008. Due 
to an expanding 
therapeutics evidence 
base, updating of the 
criteria was required 
European 
countries 
Delphi 
consensus 
methodology 
Nineteen experts 
from 13 European 
countries 
reviewed a new 
draft of STOPP & 
START criteria 
including 
proposed new 
criteria 
To propose 
additional criteria 
they considered 
important to 
include in the 
revised STOPP & 
START criteria 
and to highlight 
any criteria from 
the 2008 list they 
considered less 
important or 
lacking an 
evidence base. 
The expert panel agreed a 
final list of 114 criteria after 
two Delphi validation rounds, 
i.e. 80 STOPP criteria and 34 
START criteria. This 
represents an overall 31% 
increase in STOPP/START 
criteria compared with version 
1 
STOPP/START version 
2 criteria have been 
expanded and updated 
for the purpose of 
minimizing 
inappropriate 
prescribing in older 
people. These criteria 
are based on an up-to-
date literature review 
and consensus 
validation among a 
European panel of 
experts 
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Esmaily et al., in a two round Delphi study of 21 stakeholders in Iran, 
highlighted 21 learning outcomes to achieve an educational approach regarding 
rational prescribing for general physicians in primary care (Esmaily et al. 2008). 
These findings relate to the seventh section which comprised three statements 
regarding health professional training. 
 
Greenwald et al., in employing consensus methods with key stakeholders in 
Chicago, highlighted 10 key areas requiring attention to improve medicines 
reconciliation and the health of patients (Greenwald et al. 2010). These findings 
relate to 11 statements regarding medicines reconciliation in this doctoral 
research.  
 
Clyne, White and Mclachian in a four round Delphi study of 50 participants from 
14 European countries, indicated that the causes, consequences and solutions 
to medicines non-adherence (Clyne, White and McLachlan 2012). These findings 
relate to the fifth set of statements consisted of 11 statements relating to 
medicines adherence.  
 
A Delphi study of 19 experts from 13 European countries conducted by 
(O'Mahony et al. 2015) generated an updated criteria for the purpose of 
minimizing potentially inappropriate prescribing in older people. While the 
STOPP/START criteria have been used widely in Europe to aid the identification 
of potentially inappropriate prescribing no studies have focused on the Middle 
East. (Hill-Taylor et al. 2013)  In this doctoral research, 92% of the panellists 
agreed that ‘consideration should be given to adapting defined lists of high risk 
or potentially inappropriate medicines in the elderly, for the UAE context such as 
STOPP/START’. 
 
Chapter 1 outlines the issue of potentially inappropriate prescribing in the 
elderly, describing a systematic review of criteria to aid the identification of 
potentially inappropriate prescribing. (Hill‐Taylor et al. 2013) Notably, 92% 
agreement was reached among the experts around adopting lists of high risk or 
potentially inappropriate medicines in the elderly such as Beers and 
STOPP/START. Furthermore, 88% consensus reached to consider using the Drug 
Burden Index to determine anticholinergic burden. This is an area which 
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requires further attention and research. Notably there are no published papers 
which report the use of such criteria within the Middle East. While it may be 
necessary to review these criteria for their appropriateness to Middle Eastern 
practice (medicines available, commonly used etc.) and culture, these provide a 
useful starting point.  
 
In a recent systematic review of the literature on interventions (alone or in 
combination) to improve appropriate polypharmacy for older people, Patterson 
et al. highlighted the lack of clarity around the impact of interventions to 
improve appropriate polypharmacy, such as pharmaceutical care, on health 
outcomes despite the impact relating to reducing potentially inappropriate 
prescribing. (Patterson et al. 2014) The findings of this research demonstrate 
complete agreement (100%) that medicines management guidelines should 
focus on reviewing all medicines in elderly patients with multi-morbidities to 
promote appropriate polypharmacy.  
 
A very recent systematic review of 26 studies (10 RCTs, 3 non-RCTs and 13 
pre-post design) of the determinants of medicines reconciliation identified three 
possible interventions to reduce risk of medicines discrepancies. (Mueller et al. 
2012) Notably, 88% agreement was achieved to adopting this definition of 
medicines reconciliation in the UAE ‘the process of identifying the most accurate 
list of a patient’s current medicines – including the name, dosage, frequency 
and route – and comparing them to the current list in use, recognizing and 
discrepancies, and documenting any changes, thus resulting in a complete list of 
medications, accurately communicated’. Also consensus was reached (73%) for 
the statement authorising a ‘health professional trained in that role’ to 
undertake medicines reconciliation. 
 
One further finding of this research is the very high level of agreement to 
adopting the following definition of medicines adherence in the UAE, ‘the extent 
to which patients take medications as prescribed by their health care providers’. 
Furthermore, 80% consensus was reached that determination of adherence 
should be undertaken by a health professional trained in that role and 80% 
agreed to develop a standardised operating procedure to guide the 
determination of adherence (or non-adherence) in elderly patients. The review 
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of systematic reviews in the field of medicines adherence described in chapter 1 
(Kardas, Lewek and Matyjaszczyk 2013) and a recent systematic review of 109 
RCTs published since 2007 Nieuwlaat et al. (2014) highlight that the vast 
majority of the primary literature is of poor quality (high potential for bias, few 
studies of clinical outcomes) and that improving adherence is complex and may 
be multifactorial.  
 
Experts’ responses to round two are encouraging in terms of the future use of 
consensus approaches within the UAE for both development of policy and 
practice, and research. To date, few published studies from the Middle East 
have reported the use of consensus approaches. Consensus research, involving 
a group of tobacco cessation experts in Africa and the Middle East who 
participated in a series of four meetings held in Cairo, Cape Town, and Dubai in 
to develop a draft guideline tailored to their region. (Ali et al. 2012) A 
multidisciplinary expert panel critically reviewed available evidence to provide 
consensus recommendations for the management of invasive Candida infections 
in the Middle East. (Alothman et al. 2014) This doctoral research therefore 
extends the available literature on the of consensus approaches in the Middle 
East. 
 
5.4.4 Conclusion  
The current study sought to determine the consensus of experts in regards to 
various aspects of medicines management for elderly hospitalised patients. The 
results of the Delphi study have identified very high levels of agreement around 
structures and processes of medicines management for elderly, hospitalised 
patients and will form the basis for further work. Grounding the research in 
theoretical frameworks of NPT and TDF offer a unique insight into aspects of 
medicines management and will form the basis for further discussion and 
research.  
 
5.4.5 Summary  
This phase of the research has resulted in a set of statements around medicines 
management in guidelines, medicines reconciliation, medicines review, 
medicines adherence, medicines counselling, health professional training and 
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evaluation research where consensus has been achieved by a panel of experts 
in the UAE. 
 
The following chapter will consider the all findings of the doctoral research, their 
implications and potential impact. 
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CHAPTER 6: Discussion 
 
This chapter commences with restating the overall aim of the doctoral research, 
the aim of each phase and the key findings. The originality of the research is 
highlighted and there is further interpretation of the results. The chapter ends 
with further work related to the on development, implementation and 
sustainability of the guidelines to impact practice, patient care and outcomes.  
 
6.1 Overall aim and aim of each phase   
The overall aim of the doctoral research was to explore the structures and 
processes of medicines management in elderly hospitalised patients in the UAE.  
 
This would form part of the initial phase of developing and implementing 
guidelines to support medicines management. The research was conducted in 
three phases, each of which was sequential, and building on the findings of the 
previous phases. 
 
Phase 1 
The review of the literature in chapter 1 identified a wealth of evidence around 
aspects of medicines management in terms of medicines reconciliation, 
medicines adherence and potentially inappropriate prescribing. Generic tools 
and criteria to support medicines selection and identify potentially inappropriate 
prescribing in the elderly were described in terms of their development and use, 
noting the lack of evidence around specific tools which relate to anticholinergic 
agents. 
 
The aim of this phase was to critically appraise, synthesize and present 
evidence of the use of the Drug Burden Index (DBI) to identify potentially 
inappropriate prescribing of anticholinergic and sedative agents in elderly 
patients, focusing on institutionalised care (in line with the doctoral research 
setting). 
 
 
   
275 
Phase 2 
The aim of this phase of the research was to explore the views, experiences and 
perceptions of health professionals in Abu Dhabi in terms of the medicine 
management healthcare structures, processes and outcomes for elderly, 
hospitalised patients.  
 
Phase 3 
The aim of the final phase of the research was to determine consensus in 
relation to strategic and operational approaches around medicines management 
for elderly, hospitalised patients in the UAE. 
 
6.2 Key findings 
Chapter 1 provided a narrative overview of systematic reviews on medicines 
reconciliation, medicines adherence and potentially inappropriate prescribing. 
 
One key finding of phase 1 (systematic review) was that there was a lack of 
studies which had focused on any aspect of the use of the DBI in 
institutionalised care, with only seven studies (three cohort studies, three mixed 
cohort and cross-sectional studies and one cross-sectional study) identified. DBI 
scores (or categories) were found to be associated with an array of outcomes, 
including activities of daily living, length of hospital stay, falls and quality of life. 
None of the studies used the DBI prospectively as a tool to identify the need to 
alter potentially inappropriate prescribing; one used it retrospectively to check if 
the pharmacists’ interventions, as part of a medicines review service, had 
resulted in decreased DBI scores, and identified statistically significant 
reductions in scores.  
 
The key findings of phase 2 (qualitative exploration of structures, processes and 
outcomes around medicines management for elderly, hospitalised patients) 
highlighted health professionals’ perceptions of the need for: appropriate 
polypharmacy in elderly patients with multimorbidities; a systematic approach 
to medicines history taking; improved communication and documentation; 
improved patients’ adherence to medicines; guidelines and policies to support 
medicines selection; and an educated and trained multidisciplinary team. These 
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findings were underpinned by two theoretical frameworks. The TDF was used in 
relation to domains of determinants of behaviour at the individual practitioner 
level. The domains which were most dominant were: professional role and 
identity; beliefs about capabilities; beliefs about consequences; environmental 
context and resources; knowledge; and goals. NPT was used at the 
organisational level with little evidence of coherence, cognitive participation, 
collective action and reflexive monitoring. 
 
Key findings of phase 3 demonstrated the achievement of a high level of 
consensus (≥70% strongly agree/agree) from expert panel members for most 
statements relating to the structures and processes of medicines management 
for elderly hospitalised patients. 
 
Expert panel members did not support targeting medicines management 
processes to those with medicines related issues but to all elderly patients. They 
did not support which professions (nursing, pharmacy, physcian) were most 
suited to roles (e.g. medicines reconciliation, review etc.) but were in high 
agreement that those delivering the roles should be trained. 
 
Strengths and weaknesses of each phase were discussed in the individual 
chapters; one key strength is that each phase was designed to build on the 
methodologies, methods and findings of the previous phase(s).   
 
6.3 Originality of the research 
This doctoral research is a novel and original contribution to knowledge in 
several regards. Firstly, it focuses on the structures and processes (as defined 
by Donabedian  1990) of medicines management across the entire patient 
journey (from admission to hospital to the point of discharge back to the 
patient’s home or other care setting). Figure 6.1 illustrates how the findings of 
each phase relate to each other, in terms of the medicines management model 
proposed in Figure 1.1 
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Figure 6.1: An illustration of the overall research findings 
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Secondly, there is extensive application of behavioural and organisational theory 
underpinning the research conducted in phases 2 and 3. Thirdly, there is a 
paucity of published research in the UAE (and the Middle East more generally) 
which used consensus based approaches. Findings have been presented at 
several international conferences and via peer reviewed publications, with 
further dissemination planned. 
 
The findings of the Delphi study identified very high levels of agreement around 
structures and processes of medicines management for elderly, hospitalised 
patients. This work will form the basis for further research focusing on 
developing the guidelines to support medicines management of elderly, 
hospitalised patients, followed by pilot testing and with evaluation from the 
perspectives of health professionals, managers, leaders and patients, prior to 
full scale implementation. 
 
While this research has focused on elderly, hospitalised patients where issues of 
medicines management may be more complex, the findings are relevant to the 
care of all patients.  
 
6.4 Development, Implementation, Evaluation of guidelines  
Guidelines have been a feature of clinical practice for decades. The practice 
guidelines are defined as ‘systematically developed statements to assist 
practitioner and patient decisions about appropriate health care for specific 
clinical circumstances’. These guidelines ‘should identify recommendations for 
appropriate and cost effective management of clinical conditions or the 
appropriate use of clinical procedures with principal aim of promoting good 
performance’.   (Field and Lohr  1990)  
 
There are many steps in developing guidelines, summarised in table 6.1. 
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Table 6.1: Summary steps in the guideline development process (adapted from 
Kish and Infectious Diseases Society of America 2001) 
Step Description Recommended time to 
completion 
1 Selection of panel 2-4 weeks 
2 Introductory meeting of panel members (via 
conference call or in person, as determined 
by the panel chair); if the guideline so lends 
itself, the chair could divide and distribute the 
assignments among individual panel 
members; steps 3-5 can done at the same 
time 
1-2 months 
3 Determine the scope of the guideline Concurrent with step 2 
4 Determine the target audience and the target 
population 
Concurrent with step 2 
5 Determine how the evidence will be selected 
(e.g., by means of a MEDLINE search); 
review the plan with the chair of the Practice 
Guidelines Committee 
Concurrent with step 2 
6 Select and review the evidence to be used in 
writing the guideline (this step should be 
divided among panel members); set a date 
for completion  
2-3 months 
7 Grade the evidence and determine what will 
be used and what will be discarded 
Concurrent with step 6 
8 Write the guideline, including an executive 
summary; if algorithms are used, be sure 
that they are presented in the proper format; 
tables and graphs, which are useful for 
guideline readers, should be provided 
3 months 
9 Submit the guideline for outside review  Within 9-10 months of 
the start of the project 
10 Modify the guideline on the basis of the 
outside review 
1-2 months 
11 Submit the guideline to Infectious Diseases 
Society of America (IDSA) Practice Guidelines 
Committee for review and publication 
Preferably within 12 
months of the start of 
the project 
12 Review and update the guideline as 
appropriate 
Every 2 years 
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Findings of this research relate to: 
 
 Step 1-4, the Delphi panel of experts and the statements reaching 
consensus 
 Steps 5-8, based on the findings of the systematic reviews presented in 
chapter 1, the DBI systematic review, the interviews and the Delphi. 
 
While developing guidelines is an extremely important step, many have noted 
that great attention must be given to guideline implementation, and there is a 
wealth of evidence to support implementation. A literature search of identified 
many systematic reviews relating to guideline implementation. (Davis and 
Taylor-Vaisey 1997, Grimshaw et al. 2004, Kawamoto et al. 2005, Francke et 
al. 2008, Hakkennes and Dodd 2008) Three of these focus specifically on health 
care and are described in the data extraction table (Table 6.2).  
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Table 6.2: Data extraction from systematic reviews relating to guideline implementation  
 
Authors/year 
published 
Review aim Databases/years Hits Number of 
papers 
reviewed 
Findings 
(Davis and Taylor-
Vaisey 1997) 
To recommend 
effective 
strategies for 
implementing 
clinical practice 
guidelines 
Medline 1990-1996 Not 
specified 
Not specified Findings from the review stated that the variables affecting 
the adoption of guidelines include: 
 qualities of the guidelines 
 characteristics of the health care professional 
 characteristics of the practice setting 
 incentives  
 regulation and patient factors  
 
Specific strategies fell into 2 categories:  
 primary strategies involving mailing or publication of 
the actual guidelines  
 secondary interventional strategies to reinforce the 
guidelines 
 
The interventions were shown to be: 
 weak (didactic, traditional continuing medical 
education and mailings)  
 moderately effective (audit and feedback, especially 
concurrent, targeted to specific providers and 
delivered by peers or opinion leaders)  
 relatively strong (reminder systems, academic 
detailing and multiple interventions) 
 
(Francke et al. 
2008) 
To gain a better 
understanding of 
which factors 
affect the 
implementation 
of guidelines, and 
to provide insight 
into the "state-
of-the-art" 
regarding 
research within 
this field 
PubMed (2006) 
 
CINAHL (2006) 
 
Cochrane Library 
(2006) 
 
Embase (2006) 
 
NIVEL catalogues 
(2006) 
1359 12 Findings from the review were that  effective strategies often 
have multiple components and that the use of one single 
strategy, such as reminders only or an educational 
intervention, is less effective. 
Various factors could influence the implementation such as: 
 characteristics of the guidelines themselves; e.g. 
guidelines that are easy to understand, can easily be 
tried out, and do not require specific resources, have 
a greater chance of implementation 
 characteristics of professionals – e.g. awareness of 
the existence of the guideline and familiarity with its 
content  
 patient characteristics appear to exert influence- for 
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instance, co-morbidity reduces the chance that 
guidelines are followed 
 environmental characteristics may influence guideline 
implementation; e.g. a lack of support from peers or 
superiors, as well as insufficient staff and time, 
appear to be the main impediments 
 
The authors concluded that future research comparing 
combinations of implementation strategies versus single 
strategies was needed  
(Hakkennes and 
Dodd 2008) 
To evaluate the 
effects of the 
introduction of 
clinical guidelines 
for allied health 
professionals, 
and to estimate 
the effectiveness 
of the guideline 
dissemination 
and 
implementation 
strategies used 
Medline (1966-
2006) 
 
CINHAL (1988-
2006) 
 
Embase (1988-
2006) 
 
PsychINFO (1985–
2006) 
 
AMED (1985– 2006) 
 
Cochrane Controlled 
Trials Register  
(2006)  
 
DARE  (2006) 
4569 14 Of the 14 included studies, intervention categories were 7 on 
distribution of educational material, 5 on educational 
meetings, 3 on reminders, 3 on guideline care, 2 on 
educational outreach visit and one each for audit and 
feedback, local opinion leaders, revision of professional roles 
and provider incentive. Also findings from 14 studies stated 
that 6 used a single intervention strategy, 7 used a 
multifaceted implementation strategy and one study 
compared both single and multifaceted strategies. The review 
showed that multifaceted interventions were no more 
effective than single intervention strategies and effects of the 
same strategy varied across trials. Authors concluded that 
implementing clinical guidelines required first to identify 
specific barriers to change using theoretical frameworks of 
behaviour change and after that apply strategies that deal 
with these barriers 
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There is some overlap to the findings of these three systematic reviews. 
Guidelines are may be more likely to be effective if educational strategies 
(interventions that aim to influence targeted professionals’ attitudes, awareness 
and understanding of guidelines) implementation strategies (interventions that 
aim to translate knowledge into changes in practice) are considered. 
 
6.5 Use of theory 
The development and implementation of guidelines to support medicines 
management of elderly, hospitalised patients in the UAE is considered a 
complex intervention. Complex interventions are described by MRC framework 
(as discussed in Chapter 1) as ‘interventions that contain several interacting 
components’.(Craig et al. 2008) 
 
Hakkennes and Dodd (2008) (see table 6.2) concluded in their systematic 
review that ‘When implementing clinical guidelines it is important to first 
identify specific barriers to change using theoretical frameworks of behaviour 
change and then develop strategies that deal with these barriers’.   (Hakkennes 
and Dodd 2008)   
 
There is a consensus in the literature that behaviour change is key to increasing 
the uptake of evidence into healthcare practice (Francis, O'Connor and Curran 
2012) and this is reiterated within the MRC guidelines. (Craig et al. 2008) 
Implementing behaviour-change interventions commences with problem 
analysis, which would ideally be informed by theory. The NPT (May and Finch 
2009) mechanisms and the TDF (Michie et al. 2005) behavioural determinants 
utilised in this study have provided a theoretical approach to identifying the 
determinants in relation to medicines management, specific to the UAE, which 
require consideration and attention. It should be noted, however, that these 
were studied using a qualitative approach and hence are not necessarily 
transferable to all health professionals in the UAE.   
 
NPT was used at the organisational level with findings related to the four 
mechanisms of coherence, cognitive participation, collective action and reflexive 
monitoring. 
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The following is a brief description of the initial conceptualisation of how the 
four mechanisms of NPT might apply to the implementation of medicines 
management for elderly hospitalised patients. 
 
 coherence: one key element of coherence is a shared understanding of 
the overall aim of medicines management, its structures, processes and 
intended outcomes. If the processes of the medicines management 
model (e.g. medicines reconciliation) are to be ‘normalized’, there needs 
to be effective engagement throughout the organisation from policy 
makers, managers, leaders and health professionals. 
 
 cognitive participation: the organisational division of staff is a key 
element of cognitive participation and relates to who (i.e. the structures) 
performs the specific tasks (i.e. the processes). For medicines 
management processes to be normalized in the organisation there would 
need to be clear task allocation and definition of responsibilities. For 
example, it needs to be very clear who is responsible for medicines 
reconciliation, and in what circumstances. While there is insufficient 
evidence to support allocating this task to a specific health profession, it 
is clear from the Delphi that the main consideration is training and 
competence. Consideration also needs to be given to the number and 
types of staff available at any given time. It could be that this is a task 
undertaken by trained, competent nurses and that patients are referred 
to pharmacists in situations (clearly defined) where more extensive 
expertise in areas of medicines is required.  
 
 collective action: is a construct that relates to specific task definition (the 
actual process) of the different elements on the medicines management 
model. These medicines management processes could become 
normalized if the specific tasks are clearly defined. Using the medicines 
reconciliation example, there should be standard operating procedures 
which clearly outline how the task will be performed, documented and 
communicated to the relevant members of the healthcare team. This is 
in line with the findings of the Delphi around the need for standard 
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operating procedures, consistent documentation and channels of 
communication.  
 
 reflexive monitoring: is a construct which describes or discusses of how 
the patient outcomes of the processes of medicines management are 
assessed. The approaches to reflexive monitoring should be clearly 
defined, communicated and agreed (coherence) by all. Furthermore, 
these should be normalized within daily practice so that data are 
routinely gathered, analysed and used to inform that practice.  
 
Consideration of the structures and processes of medicines management 
relating to theses mechanisms should result in more effective and efficient use 
of health professionals, resulting in enhanced care and patient outcomes. 
  
The doctoral research used two theoretical frameworks as underpinning. The 
TDF was used in relation to domains of determinants of behaviour at the 
individual practitioner level. Paying attention to these determinants at level of 
the practitioners, in combination with the NPT organisational focus, should 
result in more effective and efficient guideline implementation. The use of the 
Behaviour Change Wheel to identify these change strategies has been discussed 
in Chapter 4.The following is a consideration of the TDF determinants might 
apply to the implementation of guidelines for medicines management. 
 
 Professional role and identity: very much in line with NPT cognitive 
participation, for guidelines to be implemented effectively clearly defined 
roles and responsibilities in the different processes of medicines 
management are required. Throughout the implementation, attention 
should be paid to encouraging, supporting and mentoring health 
professionals.  
 
 beliefs about consequences: health professionals need to have shared 
beliefs (coherence) around the consequences of the specific elements of 
the medicines management model. Intervention is required at the 
individual practitioner levels to highlight the need for processes. For 
example, in terms of determining medicines adherence at the point of 
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admission to hospital, if practitioners are not fully aware of the benefits of 
undertaking this assessment and how it can contribute to decision 
making around diagnosis, medicines selection, support following 
discharge, need for family and carer involvement etc. then they are less 
likely to perform the task to the best of their abilities and hence be less 
likely to realise the implications of any findings. As above, support 
involving persuasive communication could assist in implementation.  
 
 beliefs about capabilities: similarly, practitioners who are fully educated 
and trained should be supported so that they are confident in the 
processes being undertaken.  
 
 knowledge: this is fundamental and interviewees expressed clearly their 
lack of knowledge around tools to support medicines selection and 
identifying potentially inappropriate prescribing in the elderly.  
 
 goals: again, aligned to coherence, all health professionals need to be 
aware of, understand and engage with the overall goals of medicines 
management and the goals of the specific processes. Education, training, 
support, persuasion and agreed guidelines could all assist in 
implementation. 
 
 environmental context and resources: the actual guidelines themselves 
should be a key resource to improving medicines management. Lack of 
time to deliver care may be alleviated through clearly defined roles, 
responsibilities and tasks (i.e. cognitive participation and collective 
action) avoiding duplication of tasks. 
 
6.6 Future work 
Further work now must focus on development, implementation and 
sustainability of the guidelines to impact practice, patient care and outcomes. 
The work involved should not be underestimated and while changing behaviours 
at the organisational or individual level is complex and difficult.  
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The following outlines key, prioritised research questions which emerge from 
the doctoral research.  
6.6.1 Exploring the impact of medicines management guidelines implementation 
from health professionals’ perspectives  
Research Question: 
What are the health professionals’ perspectives of the impact of the 
implementation of medicines management guidelines on healthcare structures 
and processes and outcomes?  
 
Research philosophy: 
This study will adopt a pragmatic approach, both quantifying and exploring the 
impact of the implementation of medicines management guidelines.  
 
Methodology and method: 
A mixed methodology (an explanatory sequential approach) combining cross-
sectional survey and phenomenology, perhaps with focus groups or interviews, 
will be employed to determine the impact in terms of healthcare structures and 
processes and outcomes. The quantitative element will take the form of a 
questionnaire using stratified sampling across the UAE to determine their self-
reported perspectives. Questionnaire items will be developed from the findings 
of this research, with aspects of TDF and NPT. Following analysis of 
questionnaire data, qualitative interviews or focus groups of purposive samples 
would explore and triangulate the findings of the cross-sectional survey. 
 
Outcome measures: 
Quantitative measures would include their perceptions of: 
 coherence,  
 goals and intentions, 
 task allocation,  
 involvement in processes,  
 professional role and identity and 
 beliefs of consequences 
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Qualitative measures would focus on their experiences of and behaviours 
relating to the implementation and sustainability of the guidelines. 
 
6.6.2 The impact of medicines management guidelines implementation on 
elements of medicines management. For example this could be related to the 
determination of medicines adherence at the point of admission to hospital. 
Research Question: 
What is the impact of medicines management guidelines implementation on 
medicines adherence determination at the point of admission?  
This study would be based on the guideline part which relates to medicines 
adherence and any SOPs contained within the guideline.  
 
Research philosophy: 
This study would adopt a positivist approach in which it quantifies medicines 
adherence determination at the point of admission. 
 
Methodology and method: 
The SOP would identify which profession should conduct medicines adherence 
determination, the tools to be employed and how the results of the process 
would be documented.  
 
Outcome measures: 
The key outcome measures would include: 
 
 adherence scores, measured using the Arabic translation of the Morisky 
questionnaire (Nguyen, Caze and Cottrell 2013), 
 the proportions fully adherence, poorly adherent etc. and 
 actions documented in relation to the scores and actions. 
 
6.7 Impact of research  
Research Councils UK (RCUK is ‘committed to research excellence with impact’) 
defines research impact as ‘the demonstrable contribution that excellent 
research makes to society and the economy through fostering global economic 
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performance, increasing effectiveness of public services and policy and 
enhancing quality of life, health and creative output’. (Hughes et al. 2013) 
 
RCUK suggests that research impact is considered in terms of its: 
 
 academic impact, 
 economic impact and 
 societal impact. 
 
This has been used as a template to consider the doctoral research impact, 
which is summarised in Figure 6.2.  
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Figure 6.2: Doctoral research impact 
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This doctoral research has impacted: 
 
 the principal researcher in terms of the overall training in a range of 
health services related research paradigms, methodologies and methods 
 the research team, specifically around the use of the TDF and NPT in 
research 
 the participants in the research, particularly those involved in the Delphi 
study 
 practitioners in the UAE in terms of collecting, generating original data 
and presenting and publishing that data may also impact a wider 
audience 
 the likelihood of the development and implementation of medicines 
management guidelines for elderly, hospitalised patients in the UAE which 
in turn should impact the structures, processes and outcomes. 
 
The ‘pathway to impact’ outlined by RCUK is given in Figure 6.3. In terms of this 
doctoral research, the pathway is:  
 
 presentation of findings at international conferences 
 publication in peer reviewed journals 
 feedback of research findings to participants 
 
Further feedback is planned within the UAE and specifically the hospitals in 
which the research was conducted. 
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Figure 6.3: Pathways to Impact (adapted from Hughes et al. 2013) 
 
6.8 Conclusion  
This doctoral research has generated original findings which contribute to 
knowledge. While the DBI is an emerging tool to quantify anticholinergic and 
sedative burden, there is a limited literature base on its use in elderly, 
hospitalised patients. The potential link between higher DBI scores and several 
outcomes around the risk of functional impairment requires further research, as 
does its role alongside explicit tools of potentially inappropriate prescribing. 
 
There is a lack of published studies which research the entire process of 
medicines management in patients while in the hospital. The primary research 
conducted is therefore highly original and has identified a clear need and 
consensus agreement for well defined approaches to medicines management in 
elderly, hospitalised patients in the UAE. In particular, this research has 
identified the need to more clearly define, refine and agree on healthcare 
structures and processes across the entire patient journey from admission to 
the point of discharge. The findings of the consensus study will contribute to the 
future development and implementation of guidelines within the UAE. The use 
of the NPT and TDF has highlighted those individual practitioners and 
organisational issues which require consideration through interventions such as 
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policy development, education and training, health professional engagement, 
support and mentoring. These findings have the potential to impact greatly on 
healthcare practice and patient care. While the research was conducted within 
the UAE, there is potential for wider impact and this will be facilitated by 
ongoing dissemination of the research.  
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Appendix 3.1: the JBI Meta Analysis of Statistics Assessment and 
Review Instrument (JBI-MAStARI) 
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Appendix 3.2: JBI-MAStARI data extraction instrument 
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Appendix 3.3: The list of excluded articles and the reason for exclusions 
 
I searched Medline, IPA, CINAHL, PsycArticles using “Drug Burden Index” resulted in Title 
screening for 41 articles. The system automatically reduced to 32 articles following review of 
duplicates.  
From abstract screening  (32 articles) were reduced to (18 articles). The reason for excluding (14 
articles) = 11 (Duplicate), 1 (Narrative Study), 1 (Comparison study), 1 (Construction study). 
Table 1: illustrate all studies in search strategies (Database: Medline, IPA, CINAHL, PsycArticles) 
Date of search:  29 August 2013 
Key word search: (Drug Burden Index) ALL TEXT, Limit (English Language and Time line 2007 to 
2013) 
Title Setting  Describe the Use 
of DBI 
Describe the 
Construction of 
DBI  
1. A standard 
international version 
of the drug burden 
index for cross-
national comparison of 
the functional burden 
of medications in older 
people 
Hospital  No (Excluded) Yes 
2. Drug burden index, 
physical function, and 
adverse outcomes in 
older hospitalized 
patients. 
Hospital  Yes No  
3. Drug Burden Index 
and hospitalization 
among community-
dwelling older people. 
Community  Yes No  
4. Drug Burden Index 
associated with 
function in 
community-dwelling 
older people in 
Finland: a cross-
sectional study. 
Community  Yes No  
5. Effects of drug burden 
index on cognitive 
function in older men. 
Community  Yes No 
6. Associations between 
drug burden index and 
mortality in older 
people in residential 
aged care facilities. 
Residential 
aged care  
Yes No 
7. Drug Burden Index 
and physical function 
in older Australian 
men. 
Community  Yes No 
8. Associations between 
drug burden index and 
falls in older people in 
residential aged care. 
Residential 
Aged Care  
Yes No 
9. A drug burden index 
to define the 
functional burden of 
medications in older 
people. 
Community  Yes No 
10. Drug Burden Index 
and Beers Criteria: 
Impact on Functional 
Self Care 
Retirement 
Village 
Yes No 
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Outcomes in Older 
People Living in Self-
Care Retirement 
Villages. 
11. A pilot randomized 
clinical trial utilizing 
the drug burden index 
to reduce exposure to 
anticholinergic and 
sedative medications 
in older people. 
Self care 
Retirement 
Village  
Yes  No 
12. Drug Burden Index 
and potentially 
inappropriate 
medications in 
community-dwelling 
older people: the 
impact of Home 
Medicines Review. 
Community  Yes No 
13. Drug burden index 
score and functional 
decline in older 
people. 
Community  Yes No 
14. Associations between 
drug burden index and 
physical function in 
older people in 
residential aged care 
facilities. 
Residential 
Aged Care  
Yes No 
15. Impact of residential 
medication 
management reviews 
on drug burden index 
in aged-care homes: a 
retrospective analysis. 
Hospital  Yes  No 
16. Measures of 
Anticholinergic Drug 
Exposure, Serum 
Anticholinergic 
Activity, and All-cause 
Postdischarge 
Mortality in Older 
Hospitalized Patients 
With Hip Fractures. 
Hospital Yes Yes 
17. High risk prescribing 
in older adults: 
prevalence, clinical 
and economic 
implications and 
potential for 
intervention at the 
population level. 
Hospital  Yes Yes 
18. A comparison of four 
methods to quantify 
the cumulative effect 
of taking multiple 
drugs with sedative 
properties. 
Comparison 
Study 
No No 
19. Medication use and 
functional status 
decline in older adults: 
a narrative review. 
Narrative 
Review  
Yes No 
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20. Use of Potentially 
Harmful Medications 
and Health-Related 
Quality of Life among 
People with Dementia 
Living in Residential 
Aged Care Facilities. 
Residential 
Aged Care 
Yes No 
21. High-risk prescribing 
and incidence of frailty 
among older 
community-dwelling 
men. 
Community  Yes No 
 
To Summarize in Histogram:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
321 
Appendix 4.1: The ethical review panel of the School of Pharmacy and Life Sciences at Robert Gordon 
University- Phase 2 
 
 
 ROBERT GORDON UNIVERSITY 
SCHOOL OF PHARMACY AND LIFE SCIENCES 
ETHICAL APPROVAL FORM FOR UNDERGRADUATE, TAUGHT MSc, PhD AND EXTERNAL PROJECTS 
 
SECTION 1 – to be completed  
Research Student Name Saeed Al Shemeili 
Study Coordinator Professor Derek Stewart 
Research Project Title 
Exploring medicines management in elderly, hospitalized patients in the United Arab Emirates: health 
professionals’ views, experiences and perceptions of associated healthcare structures, processes and outcomes 
 
 
SECTION 2 – to be completed by the School Research Ethics Committee                   Date submitted to panel: 2013 
Indicate Yes or No to 
each question and 
comment as appropriate. 
 Panel member 1 Panel member 2 Panel member 3 
 
Student Response 
Is the research question 
clear?  
Partially – doesn’t fully 
tie to research – could 
do with some rethinking 
and mapping to 
method. 
Partially – agree with 
PM1’s comments 
Yes 
      
Is the project scientifically 
robust? 
yes yes Yes 
      
Are the procedures for 
obtaining informed consent 
clear and appropriate? If an 
audit does the student have 
approved access to 
information? 
yes yes yes 
      
Is the extent of participant 
involvement clear? 
yes yes yes 
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Are the recruitment 
procedures ethical and 
appropriate? 
yes yes yes 
 
Are the inclusion and 
exclusion criteria relevant 
and appropriate? 
yes yes yes 
 
Is the extent and type of 
participant involvement 
ethical? 
(consider issues of 
unnecessary invasiveness, 
exposure, undue stress, 
anxiety and concern, 
inappropriate time 
commitments) 
yes yes yes 
      
Are there clear procedures 
for ensuring compliance 
with the Data Protection 
Act? 
yes yes yes 
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Please check the boxes below 
with your decision 
Panel member 1 Panel member 2 Panel member 3 
1.  Approved – submit to 
LREC / MREC as appropriate 
and provide copy of approval 
letter to supervisor OR 
provide supervisor with 
evidence that submission not 
necessary 
   
2.  NOT Approved – MINOR 
ISSUES approval subject to 
submitting a response, to 
ethics review panel via 
supervisor, addressing minor 
issues outlined above 
   
3.  NOT approved – MAJOR 
ISSUES serious issues of 
concern to be addressed and 
whole proposal to be 
resubmitted via supervisor 
for further ethical review. 
   
4.  NOT approved – 
UNETHICAL the study is 
unethical and a re-
submission will not be 
considered. 
   
Comments:    
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SECTION 3  - OVERALL ETHICAL DECISION to be completed by Chair of School Research Ethics Committee 
1.  Approved – submit to LREC / MREC as appropriate and provide copy of approval letter to supervisor OR  
      provide supervisor with evidence that submission to LREC / MREC not necessary   
2.  NOT Approved – MINOR ISSUES: subject to submitting a response, to ethics review panel via supervisor, addressing 
minor issues outlined above  
3. NOT approved – MAJOR ISSUES: there are serious issues of concern to be addressed and whole proposal to be 
resubmitted via supervisor for further ethics panel review.  
4. NOT approved – UNETHICAL: the study is completely unethical and a re-submission will not be considered.   
 
Signed (on behalf of the School Research Ethics Committee)  Dr Lesley Diack    Date:  9th July 2013 
    
Membership: Dr Stuart Cruickshank, Dr Lesley Diack (Chair), Dr Marie Goua, Dr Graeme Kay, Dr Morag McFadyen, Mrs Katie Maclure, Dr 
Stephen Macmanus, Dr Colin Thompson, Dr Anita Weidmann, Dr Wendy Wrieden. 
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 Appendix 4.2: Ethics and Research Committee in Al Mafraq Hospital 
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 Appendix 4.3: Al Ain Hospital Ethics Committee 
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 Appendix 4.4: Institutional Review Board/Research Ethics Committee in 
SKMC 
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Appendix 4.5: Al Ain Medical District Human Research Ethics Committee in 
Tawam Hospital 
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Appendix 4.6: Ethic and Research Committee in Zayed Hospital 
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 Appendix 4.7: Email Invitation- Phase 2 
 
 
 
 
Dear Colleagues, 
I am a hospital pharmacist from Abu Dhabi who is 
studying for a PhD at Robert Gordon University 
(RGU) in Scotland. My research focuses on medicines 
management in elderly hospitalized patients in 
AbuDhabi. I am keen to obtain the views and 
experiences of health professionals such as you in 
respect of this key aspect of healthcare delivery and 
support. 
The study has been approved by RGU and HAAD. It is 
being conducted under the supervision of Professors 
Derek Stewart, Susan Klein and Alison Strath in 
Aberdeen and Dr Saleh Fares (Consultant, 
Emergency Department, Zayed Military Hospital) in 
Abu Dhabi. 
I would be grateful if you could click on the following 
link or cut and paste the entire URL into your browser 
to get information about the study: 
https://www.surveymonkey.com/s/HospitalProfession
al 
If you are willing to take part, please complete the 
short questionnaire, and I will be in touch with you to 
conduct the next stage of this research. 
Yours faithfully 
Saeed Al Shemeili 
00971505526562 
0303462@rgu.ac.uk 
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 Appendix 4.8: Participant information leaflet-Phase 2 
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PARTICIPANT INFORMATION  
  
Research Team  
Robert Gordon University (RGU): Saeed Al Shemeli 
Professor Derek Stewart 
Professor Susan Klein 
Professor Alison Strath 
 
United Arab Emirates (UAE):  Dr Saleh Fares 
 
Title of Project 
Exploring medicines management in elderly, hospitalized patients in the United 
Arab Emirates (UAE): health professionals’ views, experiences and perceptions of 
associated healthcare structures and processes. 
 
You are being invited to take part in a research study.  Before you decide if you 
wish to take part, it is important for you to understand why the research is being 
undertaken and what it will involve.  Please take time to read the following 
information carefully. Talk to others about the study if you wish.  
 
Ask me if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
The aim of the research is to explore the views, experiences and perceptions of 
doctors, nurses and pharmacists in the UAE relating to medicines management for 
the elderly, hospitalized patients. While there is no standardized, universally 
accepted definition of ‘medicines management’, this basically refers to ‘getting the 
best from medicines’.  
 
 
Institute for Health & Welfare 
Research                                                   
Graduate School 
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Study aim 
This research aims to explore the role of the health professional in medicines 
management for the elderly, hospitalized patients in the United Arab Emirates. It 
also takes into consideration the views of health professionals, their experiences 
and perceptions of healthcare structures and processes. 
 
A researcher (Saeed Al Shemeili) from the UAE and former employee at Zayed 
hospital will carry out the study. I am currently studying at Robert Gordon 
University and this work will form part of a submission towards a Doctor of 
Philosophy qualification from Robert Gordon University. 
 
Why have I been chosen? 
You have been chosen because you are a doctor, nurse or pharmacist working in 
hospital practice in the UAE. You therefore have experience of medicines related 
issues and belong to one of the health professional groups involved with medicines 
management in elderly, hospitalized patients and you are familiar with the current 
healthcare structure and process in the UAE. 
 
Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  If you do, you will be 
given this information sheet to keep and be asked to sign an informed consent 
form. You are still free to withdraw at any time and without giving a reason.  A 
decision to withdraw at any time, or a decision not to take part, will not affect any 
way your employment with Health Authority of Abu Dhabi (HAAD). 
 
What will happen to me if I take part? 
If you interested, you should complete the short questionnaire. You may then be 
invited to take part in an interview of approximately 30 to 45 minutes with the 
researcher at either a private room in the hospital or your office, whichever is more 
convenient. You will be asked to provide your views and experiences relating to 
medicines management in elderly hospitalized patients. The interview will be audio 
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recorded with your permission. The recording will be transcribed into a qualitative 
data software system to aid analysis. You will be provided with a transcript of the 
audio recording if requested and allowed to make any required amendments to the 
transcript. 
 
Any information provided during the interview will be anonymous and confidential. 
Your name will not appear on the transcript or any report of the research. This 
information may be used anonymously in any publication or presentation of the 
study results.  
 
What do I have to do? 
If you decide to take part in the study, you will be asked to sign an informed 
consent form and to take part in the interview as described above. 
 
What are the possible benefits of taking part? 
There are no direct benefits to you by taking part in the study.  
There may be benefits to the organisation in term of learning from your views and 
experiences of medicines management for elderly. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study will be 
addressed. If you have any complaints or would like further information about the 
study please contact: 
 
Professor Derek Stewart 
School of Pharmacy & Life Sciences 
Robert Gordon University 
Aberdeen 
AB10 7QJ 
Scotland  
+44 (0)1224 262432 
d.stewart@rgu.ac.uk 
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Will my taking part in the study be kept confidential?  
Yes.  All the information about your participation in this study will be kept 
confidential.  Any data relating to your participation will be stored securely at all 
times and can only be accessed by the researcher. 
 
You will be given a copy of the information sheet and a signed consent 
form to keep. 
Thank you for taking time to read the information sheet and for considering taking 
part in this study. 
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 Appendix 4.9: Online sampling questionnaire 
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ONLINE QUESTIONNAIRE 
 
1. Your profession is 
 
 □ Doctor   □ Nurse   □ Pharmacist 
 
 
2. Your main place of work is 
 
 □ Government services/ Public sector   □ Private Sector 
 
 
3. You manage elderly patients (60 years or older) in your day to day work 
 
 □ Yes                 □ No  
 
4. You have been practising in your profession for  
 
 □ 5 years or less  □ 6-10 years   □ 11-15 years 
  
 □ 16-20 years  □ 21-25 years  □ 26-30 years 
 
 □ 31-35 years  □ >35 years 
 
 
5. You completed your undergraduate training in  
 
 □ UAE    □ Other, please specify______________ 
 
 
6. You have also practised as a health professional in countries other than UAE 
 
 □ No    □ Yes, please specify country_________  
 
7. Are you willing to take part in the interview, as described in the participant information leaflet?  
 
 □ Yes                 □ No  
 
If yes, please give the following details so that you can be contacted to arrange the 
interview 
 
Name______________________________________________ 
Email ______________________________________________ 
Institute for Health & Welfare 
Research                                                   
Graduate School 
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 Appendix 4.10: Interview participant consent form 
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CONSENT FORM  
Title of Project 
Exploring medicines management in elderly, hospitalized patients in the United 
Arab Emirates (UAE): health professionals’ views, experiences and perceptions of 
associated healthcare structures and processes. 
 
Researcher 
Saeed Al Shemeili 
PhD Student 
Robert Gordon University 
UK 
E-mail: 0303462@rgu.ac.uk 
 
 
Participant Study Number................. 
 
 
 Please INITIAL 
box 
 
I confirm that I have read and understand the information sheet 
for the above study and have had the opportunity to ask 
questions. 
 
  
 
I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving reason. 
 
 
 
I agree to take part in the above study. 
 
 
I agree to the interview being audio recorded. 
 
 
I agree to the use of anonymised quotes in publications. 
 
 
________________                   ____              _____________ 
Name of Participant                    Date               Signature 
 
 
________________                   ____              _____________ 
Name of Researcher                   Date               Signature 
  
 
 
 
 
 
 
Institute for Health & Welfare 
Research                                                   
Graduate School 
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 Appendix 4.11: Draft semi-structured interview schedule 
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SEMI-STRUCTURED INTERVIEW SCHEDULE 
 
Title of Project 
Exploring medicines management in elderly, hospitalized patients in the United 
Arab Emirates (UAE): health professionals’ views, experiences and perceptions of 
associated healthcare structures and processes. 
 
 
Participant Number 
  
Date  
/   / 
Start time  
: 
 
Introduction 
 
Hello, thanks for agreeing to be interviewed for this project.  Please, can I check you have 
read the participant information sheet? 
If not, here is a copy to read before we begin. 
 
The main purpose of this interview is to find out your views, experiences and perceptions of 
medicines management for elderly, hospitalised patients in the United Arab Emirates (UAE). 
 
Your participation is voluntary and you may withdraw at any point.  
If you do not want to answer a specific question, then please let me know.  
There are no right or wrong answers and I am interested in your personal opinions.  
 
Your identity will remain strictly confidential and it will not be possible to identify individuals 
from the study results.  
 
The interview should take approximately 30 to 45 minutes. Are you ok to go ahead? 
 
 
 
IF NO: That’s okay.  When would be 
more convenient?  
 
Thanks I’ll see you on day/date/time 
at ..............location. Bye. 
 
 
Write the new day/date/time here and in 
the diary chart: 
 
IF YES continue:  That’s great, thank you. 
 
 
 
 
 
Institute for Health & Welfare 
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Housekeeping 
As you are aware from the information sheet and consent form, this conversation is being 
audio recorded but I would emphasise that it is confidential.   
 
Please do not use names of patients or hospital staff during this interview. It is ok to refer 
to “a patient”, “another doctor”, “ a nurse”, “a pharmacist” etc 
 
Are you still OK with that?   
 
 
IF NO:  
That’s fine. I’ll need a bit more time to 
write down notes as we go through the 
sections and I may ask you to repeat 
some answers so I don’t miss anything. 
 
Reminders 
 Take time to write detailed notes 
 If in doubt, ask the interviewee 
for clarification before you move 
on to the next section 
 
If you decide after the interview you no longer wish to be a part of the research, please let 
me know.  The contact details are on the information sheet. 
 
Do you have any questions before we begin? 
 
Technical problem? Keep calm! Explain, apologise and rearrange interview 
day/date/time   
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Can I start off by asking if you have had any specific training around medicines in 
the elderly? 
 can you please describe the training, where you received it, when, 
duration etc. 
 what did you think of the training? 
 would you recommend it to others?  
 
I am interested in issues/problems/difficulties relating to medicines in elderly 
patients and how you handle these. 
 
 
 
 
  
 
 
 
What issues do you routinely encounter in your 
day to day practice? 
 
 
 
 
 
 
How do you handle these? 
 
 
 
 
 
 
Why in that way? 
 
 
 
 
 
 
 
 Note answers here for 
backup and reference 
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I am now going to ask you about different stages of the patient journey or patient 
stay while in hospital. I am really interested in your routine day to day 
practice and care given to every patient  
 
These first questions are about how you are routinely involved at the point of 
patient admission to hospital 
 
 
  
 
 
 
Are you routinely involved with patients and 
medicines that were taking before they admitted to 
hospital  
What do you do in relation to  
 
 Finding out medicines patients take,  
 Finding out how and when they take them, 
 Finding out how long,  
 Finding out any side effects they are having, 
 Finding out issues related to poor adherence 
 
Do you have sufficient time and resources to do 
this for every patient or do you target certain 
patient. 
 If target, how do decide which patient  
 
How and where do you document your actions? 
 
Do you share this information with other health 
professionals?  
 
 Probe on how etc. 
 
Why do you do what you do? 
 
 Probe around learnt from others, experience 
etc 
 
Do you think that it works well? 
 
 Probe around how do you know, measure 
that it works well etc 
 
Why does it work well or not work well? 
 
 
  
 Note answers here for 
backup and reference 
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Now moving from the point of admission to in-patient stay in hospital. 
 
 
 
 
  
 
 
 
Are you routinely involved with patients and 
medicines prescribed in hospital 
 
What do you do in relation to  
 
 Probe around issues relating to medicine 
choice,  
 ADRs, 
 interactions,  
 continuous review and monitoring  
 
Do you do this for every patient or do you target 
certain patient 
 If target, how do decide which patient  
 
How and where do you document your actions? 
 
Do you share this information with other health 
professionals?  
 
 Probe on how etc.  
 
Why do you do what you do? 
 
 Probe around learnt from others, 
experience etc 
 
Do you think that it works well? 
 
 Probe around how do you know, measure 
that it works well etc 
 
Why does it work well or not work well? 
 
 
 
 Note answers here for 
backup and reference 
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Now moving to the point of patient discharge from hospital. 
 
 
 
 
 
 
 
Are you routinely involved with patients and 
medicines as they discharged from the hospital 
 
What do you do in relation to  
 
 Probe around issues relating to review of 
medicines, medicine choice etc  
 Probe around patient/carer education 
 Probe around passing care to other 
professionals 
 
Do you do this for every patient or do you target 
certain patient. 
 If target, how do decide which patient  
 
How and where do you document your actions? 
 
Do you share this information with other health 
professionals?  
 
 Probe on how etc.  
 
Why do you do what you do? 
 
 Probe around learnt from others, 
experience etc 
 
Do you think that it works well? 
 
 Probe around how do you know, measure 
that it works well etc 
 
Why does it work well or not work well? 
  
 Note answers here for 
backup and reference 
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Now some more general questions. 
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In your experience are ADRs  a common cause of 
admission for elderly patients? Or during stay? 
 Probe for examples, reasons 
 
In your experience are there issues related to poor 
adherence to medicine regimens? And educating 
patients and carers 
 Probe for examples, reasons 
 
 
In your experience are there issues around 
prescribing/drug selection? 
 Probe for examples, reasons 
 
Do you use any guidelines or policies to help you 
in drug selection? 
 
Are you aware of any list of high risk medicines in 
the elderly  
 STOPP/START, 
 BEERS,  
 Medication Appropriateness Index (MAI)  
 DBI 
 Probe how heard, what are their opinions? 
 
 
Have you heard of the term ‘polypharmacy’? What 
does it mean to you? Are there implications for 
your practice?  
 
 
What is your experience around issues of 
communication between health professionals 
related to medicines in the elderly? 
 
Can you tell me about the main influences on your 
practice around medicines in the elderly 
 Probe on the role of peers and significant 
others, personal experiences, professional 
experiences, their profession, the 
organisation  
 
Do you think there is any need for specialist 
education and training around medicines in the 
elderly? 
 Probe on what, how  
 
Do we think that we optimise medicines 
management of elderly patients? 
 Probe on how can we do it better - 
prescribing/drug selection/appropriate 
polypharmacy – you, profession, 
organisation 
 Note answers here for 
backup and reference 
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Is there anything that prevents us better 
optimising their medicines? 
 Probe them, peers, organisation etc 
 Resources and time  
 
Do you think that there would be any barriers to 
change? 
 
What would help with change? 
 
 
How ready are you for any change? 
 Probe on reasons for response, factors 
influencing readiness, do you like change  
 
 
 
Lastly, do you think that patients are satisfied and 
that they think we optimise their medicines? 
 Probe on why and how 
 
 Note answers here for 
backup and reference 
4. Is there anything else you would like to add on medicines 
and elderly patients? Note answers here for backup and reference 
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Well that’s all of my questions.  You’ve been very helpful and I 
appreciate you taking the time to speak to me.  If you think of 
anything else you would like to add, please get in touch.  
If you would like to see a copy of the transcript from the interview, 
please let me know and I will arrange for this to be supplied to you. 
Thank you very much.   
Transcript 
Y/N 
 
Interview  
concluded at: 
: 
   
351 
Appendix 4.12: Search Strategy - Phase 2 
 
Database: MEDLINE, CINAHL, INTERNATIONAL PHARMACEUTICAL ABSTRACTS 
Date of search: 24 Jan 2015 
Key words Search: TEXT, Limit (English Language and Time line 2000 to 2015)  
 
 Medicines Hits 
1 medic* 5,354,648 
2 drug* 2,907,261 
3 pharmaceutical* 373,247 
A 1 or 2 or 3 6,925,758 
 Management Hits 
4 prescrib* 200,833 
5 management* 1,517,507 
6 process* 2,689,679 
7 activit* 2,889,399 
8 adherence* 145,129 
9 counselling 50,668 
10 reconcil* 24,639 
11 train* 712,882 
B 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 6,813,783 
 Qualitative Hits 
C Qualitative 260,122 
Final search A and B and C 
Abstract- A and B and C 
Title- A and B and C 
81,668 
0 
0 
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Appendix 5.1: The ethical review panel of the School of Pharmacy- Phase 3 
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 Appendix 5.2: Participant consent form- Delphi Study 
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CONSENT FORM  
Title of Project 
Determination of the United Arab Emirates stakeholder consensus in relation to 
strategic and operational approaches around medicines management in the elderly. 
 
Researcher 
Saeed Al Shemeili 
PhD Student 
Robert Gordon University 
UK 
E-mail: 0303462@rgu.ac.uk 
 
Participant Study Number................. 
 
 Please INITIAL 
box 
 
I confirm that I have read and understand the information sheet 
for the above study and have had the opportunity to ask 
questions. 
 
  
 
I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving reason. 
 
 
 
I agree to take part in the above study. 
 
 
 
I agree to the use of anonymised quotes in publications. 
 
_______________                   ____              _____________ 
Name of Participant                    Date               Signature 
 
 
________________                   ____              _____________ 
Name of Researcher                    Date              Signature 
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 Appendix 5.3: SNAP 10- Online survey tool 
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 Appendix 5.4: Search strategy - Phase 3 
 
Database: MEDLINE, CINAHL, INTERNATIONAL PHARMACEUTICAL ABSTRACTS 
Date of search: 12 April 2015 
Key words Search: Title, Limit (English Language and Time line 2000 to 2015)  
 
 Medicines Hits 
1 medic* 586,816 
2 drug* 413,590 
3 pharmaceutical* 38,835 
A 1 or 2 or 3 1,023,463 
 Management Hits 
4 prescrib* 23,186 
5 management* 369,493 
6 process* 196,210 
7 activit* 586,490 
8 adherence* 26,429 
9 counselling 5,910 
10 reconcil* 2,688 
11 train* 130,165 
B 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 1,326,528 
 Delphi Hits 
12 Delphi 2,143 
13 Consensus 19,040 
C  12 or 13  20,846 
Final search A and B and C 
A and B and Delphi 
194 
21 
 
 
 
 
 
